Protocol  I5T-MC-AACG(d)  
 
Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s 
Disease  
 
 [STUDY_ID_REMOVED] 
 
Approval Date: 09- Oct-2018 
 
 
I5T-MC-AACG(d)Clinical Protocol Page 1
LY3002813Protocol I5T -MC-AACG(d)
Assessment of Safety , Tolerability ,and Efficacy  of 
LY3002813 i n Early Symptomatic A lzheimer’s Disease
Confidential Information
The information contained in this document is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY3002813, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.
Note to Regulatory Authorities:   This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure.  Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release.  In 
the United States, this document is subject to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwis e disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.
LY3002813
Multicenter, randomized, double -blind, placebo -controlled, Phase 2 study comparing up to 
1400 mg of LY3002813 with placebo over 76weeks in approximately 250 patients with 
early symptomatic AD.
Eli Lilly and Company
Indianapolis, Indiana USA 46285
Protocol Electronically Signed and Approved by Lilly:  30 August 2017   
Amendm ent (a) Electronically Signed and Approved by Lilly:  30 October 2017
Amendm ent (b) Electronically Signed and Approved by Lilly:  12 December 2017
Amendm ent (c) Electronically Signed and Approved by Lilly : 21 May 2018
Amendm ent (d) Electronically Signed and Approved by Lilly
on approval date provided below.
Approval Date: 09-Oct-2018 GMT
Please note that strikethroughs used in Appendix 7 do not indicate redacted content
but instead describe content removed during a protocol amendment.
I5T-MC-AACG(d)Clinical Protocol Page 2
LY3002813Table of Conte nts
Section Page
Protocol I5T-MC-AACG(d) Assessment of Safet y, Tolerability, and 
Efficacy of LY3002813 in Early  Symptom atic Alzheimer’s Disease ................................... 1
Table of Contents ........................................................................................................................ 2
1.Synopsis............................................................................................................................. 9
2.Schedule of Act ivities....................................................................................................... 14
3.Introduction ...................................................................................................................... 25
3.1.Study Rationale............................................................................................................ 25
3.2.Background .................................................................................................................. 26
3.2.1. LY3002813 Nonclinical Studies ........................................................................... 26
3.2.2. LY3002813 Phase 1 Studies ................................................................................. 27
3.3.Benefit/Risk Assessment .............................................................................................. 28
3.3.1. Benefit................................................................................................................. 28
3.3.2. Risks.................................................................................................................... 28
3.3.3. Benefit/Risk Assessment Summary ...................................................................... 30
4.Objectives and Endpo ints.................................................................................................. 32
5.Study Design..................................................................................................................... 34
5.1.Overall Design ............................................................................................................. 34
5.1.1. Screening Period (Visit 1) .................................................................................... 36
5.1.1.1. Screening Procedures ..................................................................................... 37
5.1.1.1.1. Modified Hachinski Ischemic Scale (MHIS) ............................................. 37
5.1.1.1.2. Mini-Mental State Examinat ion (MMSE) ................................................. 37
5.1.1.1.3. CogState Brief Battery .............................................................................. 37
5.1.1.1.4. Columbia Suici de Severity Rating Scal e –Adult 
Version..................................................................................................... 38
5.1.1.1.5. Screening Positron Emissio n Tomography and 
Magnetic Resonance Imaging ................................................................... 38
5.1.1.1.5.1. Screening Flortaucipir F18 PET Scan .................................................. 38
5.1.1.1.5.2. Screening MRI .................................................................................... 39
5.1.1.1.5.3. Screening Florbetapir F18 PET Scan ................................................... 39
5.1.2. Double-Blind Peri od (Visit 2 through Visit 21) .................................................... 39
5.1.3. Immunogenicity and Safet y Follow-up Visits (Visits 801 
through 804) ........................................................................................................ 40
5.2.Number of Participant s.................................................................................................40
5.3.End of Study  Definition............................................................................................... 40
5.4.Scientific Rationale for Study  Design........................................................................... 40
I5T-MC-AACG(d)Clinical Protocol Page 3
LY30028135.5.Justification for Dose ................................................................................................... 41
6.Study Population............................................................................................................... 42
6.1.Inclusion Criteria.......................................................................................................... 42
6.2.Exclusion Criteria........................................................................................................ 44
6.2.1. Rationale for Excl usion of Certain Study  Candidates ........................................... 47
6.3.Lifestyle Restrict ions.................................................................................................... 47
6.4.Screen Failures ............................................................................................................. 48
7.Treatments ........................................................................................................................ 49
7.1.Treatments Administered ............................................................................................. 49
7.1.1. Packaging and Labelling ...................................................................................... 49
7.1.1.1. LY3002813 Packaging and Labelling ............................................................. 50
7.2.Method of Treatment Assignment ................................................................................ 50
7.2.1. Selection and Timing o f Doses............................................................................. 50
7.2.1.1. LY3002813:  Select ion and Timing of Doses .................................................. 50
7.3.Blinding....................................................................................................................... 51
7.4.Dosage Modification .................................................................................................... 51
7.4.1.LY3002813 Dosage Modificat ion for ARIA-E..................................................... 51
7.4.2. LY3002813 Dosage Modificat ion for ARIA-H.................................................... 52
7.5.Preparation/Handling/Storage/Accountabilit y............................................................... 52
7.6.Treatment Compliance .................................................................................................53
7.6.1.LY3002813 Treatment Compliance ...................................................................... 53
7.7.Concomitant Therapy ................................................................................................... 53
7.8.Treatment after the End of the Study ............................................................................ 54
7.8.1. Treatment after Study  Completion........................................................................ 54
8.Discontinuati on Criteria.................................................................................................... 55
8.1.Discontinuati on from Study Treatment......................................................................... 55
8.1.1. Temporary Discontinuation from Study Treatment............................................... 56
8.1.1.1. Temporary Discontinuation from LY3002813 Study  
Treatment Due to ARIA -E.............................................................................. 56
8.1.1.2. Temporary Discontinuation from LY3002813 Study  
Treatment for Reasons Other than ARIA-E ..................................................... 57
8.1.2. Discontinuati on of Inadvertent ly Enrolled Subjects .............................................. 57
8.2.Discontinuati on from the Study .................................................................................... 57
8.3.Lost to Follow -Up........................................................................................................ 58
9.Study Assessments and Procedures ................................................................................... 59
9.1.Efficacy Assessments ................................................................................................... 59
9.1.1.Primary Efficacy  Assessments ............................................................................. 59
9.1.2. Secondary  Efficacy Assessments .......................................................................... 60
I5T-MC-AACG(d)Clinical Protocol Page 4
LY30028139.1.2.1. Alzheimer’s Disease Assessment Scale —Cognitive 
subscale (ADAS -Cog13)................................................................................ 60
9.1.2.2. Alzheimer’s Disease Cooperative Study —Activities of 
Daily Living Inventory  (ADCS-ADL)............................................................ 60
9.1.2.3. Clinical Dement ia Rating Scale (CDR -SB)..................................................... 61
9.1.2.4. Mini-Mental State Examinat ion (MMSE) ....................................................... 61
9.1.3. Biomarker Efficacy  Measures (Doubl e-Blind Peri od)........................................... 61
9.1.4. Appropriateness of Efficacy  Assessments ............................................................ 61
9.2.Adverse Events ............................................................................................................ 62
9.2.1. S erious Adverse Events ........................................................................................ 63
9.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 64
9.2.1.2. Adverse Events of Special Interest .................................................................. 64
9.2.2. Complaint Handling ............................................................................................. 64
9.3.Treatment of Overdose .................................................................................................64
9.4.Safety........................................................................................................................... 65
9.4.1. Physical and Neurological Examinat ions.............................................................. 65
9.4.2. Electrocardiograms .............................................................................................. 65
9.4.3. Vital Signs........................................................................................................... 66
9.4.3.1. Blood Pressure ................................................................................................ 66
9.4.3.2.Height, Weight, and Body  Temperature.......................................................... 66
9.4.4. Laboratory  Tests.................................................................................................. 67
9.4.5. Immunogenicity Assessments .............................................................................. 67
9.4.6. Other Tests ........................................................................................................... 67
9.4.6.1. Columbia Suici de Severity Rating Scal e –Adult Versi on............................... 67
9.4.6.2. Magnetic Resonance Imaging ......................................................................... 68
9.4.6.3. Ophthalmo logical Examinat ion....................................................................... 68
9.4.6.4. Dermatological Examinat ion.......................................................................... 69
9.4.7. Safety Monitoring................................................................................................ 70
9.4.7.1. LY3002813 Hy persensitivity (Immediate and Non -
immediate), Including Infusio n-Related Reactions .......................................... 70
9.4.7.1.1. Premedication for Infusions...................................................................... 70
9.4.7.1.2. Management of Infusio n Reactions ........................................................... 70
9.4.7.2. LY3002813 Immunogenic ity.......................................................................... 71
9.4.7.3. Hepatic Safety Monitoring.............................................................................. 72
9.4.7.4. Amyloid-Related Im aging Abnorm alities (ARIA -E and 
ARIA-H)........................................................................................................ 72
9.4.8. Appropriateness of Safet y Assessments ................................................................ 73
9.5.Pharmacokinet ics......................................................................................................... 73
9.6.Pharmacodynamics ...................................................................................................... 74
I5T-MC-AACG(d)Clinical Protocol Page 5
LY30028139.6.1. Clearance of Amylo id Deposits ............................................................................ 74
9.6.2. Accumulat ion of Tau Deposits ............................................................................. 74
9.7.Pharmacogeno mics [OR] Genetics ............................................................................... 75
9.7.1. Apolipoprotein E Genotyping ............................................................................... 75
9.7.2. Whole Blood Samples for Pharmacogenet ic Research .......................................... 75
9.8.Biomarkers................................................................................................................... 75
9.9.Medical Resource Utilizat ion and Healt h Economics ................................................... 76
10.Statistical Considerations .................................................................................................. 77
10.1.Sample Size Determinat ion.......................................................................................... 77
10.2.Populations for Analyses .............................................................................................. 77
10.3.Statistical Analyses ...................................................................................................... 78
10.3.1. General Statist ical Considerat ions........................................................................ 78
10.3.1.1. Handling of Missing Items for Scales ............................................................. 78
10.3.2. Treatment Group Comparabilit y........................................................................... 79
10.3.2.1. Subject Disposit ion......................................................................................... 79
10.3.2.2. Subject Characterist ics.................................................................................... 79
10.3.2.3. Prior and Concomi tant Therapy ...................................................................... 80
10.3.2.4. Treatment Compliance .................................................................................... 80
10.3.3. Efficacy Analyses ................................................................................................ 80
10.3.3.1. Primary Analyses ........................................................................................... 80
10.3.3.2. Secondary  Efficacy Analyses .......................................................................... 81
10.3.4. Safety Analyses.................................................................................................... 81
10.3.4.1. Adverse Events ............................................................................................... 81
10.3.4.2. Vital Signs and Weight ................................................................................... 82
10.3.4.3. Laboratory  Analyses ....................................................................................... 82
10.3.4.4. Electrocardiograms ......................................................................................... 83
10.3.4.5. ARIA-E and ARIA -H..................................................................................... 85
10.3.4.6. Evaluation of Immunogenicit y........................................................................ 85
10.3.4.7. Suicidal Ideation and Behavior ....................................................................... 85
10.3.5. Pharmacokinet ic/Pharmacodynamic Analyses ...................................................... 86
10.3.6. Interim Analyses .................................................................................................. 86
11.References ........................................................................................................................ 87
12.Appendices ....................................................................................................................... 92
I5T-MC-AACG(d)Clinical Protocol Page 6
LY3002813List of Tables
Table Page
Table AACG.4.1. Objectives and Endpo ints............................................................................... 32
Table AACG.7.1. Treatment Regimens, Double -Blind Peri od.................................................... 49
Table AACG.7.2. LY3002813 Dosage Modificat ions for First Occurrence of ARIA -E..............52
Table AACG.10.1. Criteria for Abnorm al Vital Signs....................................................... 82
Table AACG.10.2. Criteria for Abnorm al ECG Parameters ............................................... 84
Table AACG.10.3. Criteria for Prolonged ECG QTcF Interval .......................................... 84
I5T-MC-AACG(d)Clinical Protocol Page 7
LY3002813List of Figures
Figure Page
Figure AACG.5.1. Illustration of study design for Clinical Protocol I5T -MC-
AACG........................................................................................................... 35
I5T-MC-AACG(d)Clinical Protocol Page 8
LY3002813List of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definitions........................................................................ 93
Appendix 2. Clinical Laboratory  Tests............................................................................... 98
Appendix 3. Study Governance Considerat ions................................................................ 100
Appendix 4. Hepatic Monitoring Tests for Treatment -Emergent Abnormalit y.................. 105
Appendix 5. Flortaucipir F18 Tau PET Im aging.............................................................. 106
Appendix 6. Florbetapir F18 Amyl oid PET Im aging........................................................ 109
Appendix 7. Protocol Amendment [I5T- MC-AACG(c)] Summary  [Assessment of 
Safety, Tolerability, and Efficacy  of LY3002813 in Early  Symptom atic 
Alzheimer’s Disease] ................................................................................... 111
I5T-MC-AACG(d)Clinical Protocol Page 9
LY30028131.Synopsis
Title of Study:
Protocol I5T-MC-AACG(d).  Assessment of Safety , Tolerabili ty,and Efficacy  of LY3002813 i n 
Early Symptomat ic Alzheimer’s Disease .
Rationale:
LY3002813 is an ant ibody directed at the py roglutamate modification of the third amino acid of 
amyloid beta (N3pG Aβ) epitope that is present only in brain amylo id plaques.  It i s being 
studied for the treatm ent of Alzheimer’s disease (AD).  The mechanism of action of LY3002813 
is considered to be the targeting and removal of exist ing amylo id plaque, which is a key 
pathological hallmark of AD.  The clinical strategy for LY3002813 targets the N3pG Aβ specific 
to amyloid plaque in the populat ion of early  symptomatic AD patients with existing brain 
amyloid load, as measured using the amylo id plaque biomarker, florbetapir F18 positron 
emission tomography (PET) imaging.  This rationale is based on the amyloid hypothesis of AD,
which states that the production and deposition of Aβ is an early and necessary  event in the 
pathogenesis of AD (Selkoe 2000).  Clinical support for this hypothesis co mes from the 
demonstration that parenchymal Aβ levels are elevated before the appearance of symptoms of 
AD, and supported by  genetic variants of AD that overproduce brain Aβ and genetic variants that 
protect against Aβ production (Jonsson et al. 2012; Fleisher et al. 2015).  Furthermore, early  in 
the disease, the presence of brain amylo id appears to increase the risk of conversi on from mild 
cognitive impairment ( MCI) to AD dement ia (Doraiswamy et al. 2012).  This suggests that 
enhanced clearance of Aβ will lead to slowing of AD progression.
Study I5T-MC-AACG (AACG) is a Phase 2, double -blind, placebo -controlled, study  to evaluate
the safety and efficacy of N3pG antibody  (LY3002813 ) in patients wi th early symptom atic AD 
(prodrom al AD and mild dement ia due to AD).  StudyAACG will assess whether removal of 
existing amylo id plaque can slow the progressi on of disease as assessed by cl inical measures and 
biomarkers of disease pathology  and neurodegenerati on over up to 72weeks of treatment.
Multiple biomarkers of disease progress will also be evaluated.  The bio marker florbetapir F18 is 
a PET ligand that binds to fibrillar amylo id plaque.  This bio marker can provide a qualitat ive and 
quantitative measurement of brain plaque load in patients with prodromal AD ormild AD 
dementia.  The absence of significant florbetapir F18 signal on a visual read indicates that those 
patients clinically  manifesting cognit ive impairment have sparse to no amylo id plaques.  As 
such, implementation o f florbetapir F18 will  provide a screening tool for entry  into the clinical 
trial and provi de a confirmat ion of amylo id pathology.  Florbetapir F18 PET al so provides 
quantitative assessment of fibrillar amylo id plaque in the brain and can assess amylo id plaque 
reductions from the brain by LY3002813.
Alzheimer’s disease progression is also associated with cerebral tauopathy , which will be 
assessed by  flortaucipir F18 PET scans, a cortical marker of paired helical filaments.  Brain 
atrophy, as an indicator of neurodegenerat ion, will be assessed by  volumetric resonance imag ing 
(vMRI).
I5T-MC-AACG(d)Clinical Protocol Page 10
LY3002813The patient populat ion for the clinical trial is selected to be AD patients with early symptomatic 
disease defined both clinically  (prodrom al to mild AD dement ia) and by bio markers (low to 
medium tau burden, plus amylo id plaque presence).  The 2018 NIA -AA draft AD research 
framework (Alzheimer’s Associat ion 2017a) proposes that AD is defined by  its underlying 
pathophysio logic processes which can be documented in vivo by bio markers (such as tau and 
amyloid PET) or by  post-mortem examinat ion.  This framework will enable a more precise 
approach to therapeutic intervent ion trials where specific pathways can be targeted at specific 
points in the disease process and to the appropriate people (Alzheimer’s Associat ion 2017b).  
Clinical-pathological correlations also strongly  suggest that baseline imaging that allows staging 
on the basis of neurofibrillary tangles could substant ially improve the power of clinical trials 
aimed at changing the rate of progression o f the disease (Qian et al. 2017).  An early AD 
population defined clinically and patho logically is anticipated to be more homogeneous than 
populations defined without tau PET, and will be sufficient ly early to respond to treatments prior 
to more advanced irreversible neuronal lo ss.
I5T-MC-AACG(d)Clinical Protocol Page 11
LY3002813Objective(s)/En dpoints:
Primary Objective Primary Endpoint
To test the hypothesis that LY300281 3 
administered for up to 72weeks will decrease 
the cognitive and/or functional decline in 
patients with early symptomatic ADChange in cognition and function as measured by the 
change in integrated Alzheimer’s Disease Rating Scale 
(iADRS) score from baseline to 18 months
Secondary Objectives Secondary Endpoints
To assess the effect of LY300281 3 vs. placebo 
on clinical progress ion in patients with early 
symptomatic ADChange in cognition from baseline to 18 months as 
measured by:
the change in Alzheimer’s Disease Assessment 
Scale—Cognitive subscale (ADAS -Cog13) 
score
the change in Clinical Dementia Rating Scale 
Sum of Boxes (CDR-SB) score
the change in Mini -Mental State Examination 
(MMSE) score
the change in Alzheimer’s Disease Cooperative 
Study-instrumental Activities of Daily Living 
scale (ADCS -iADL) score 
To assess the effect of LY300281 3 vs. placebo 
on brain amyloid depositionChange in brain amyloid plaque deposition from 
baseline through 18 months as measured by florbetapir
F18 PET scan  
To assess the effect of LY300281 3 vs. placebo 
on brain tau depositionChange in brain tau deposition from baseline to 18 
months as measured by flortaucipir F18 PET scan  
To assess the effect of LY300281 3 vs. placebo 
on brain volume measuresChange in volumetric MRI measures from baseline to 
18 months.
Safety Objective Safety Endpoints
To evaluate safety and tolerability of 
LY300281 3Standard safety assessments:
ospontaneously reported adverse events 
(AEs)
oclinical laboratory tests
ovital sign and body weight 
measurements
o12-lead electrocardiograms (ECGs)
ophysical and neurological 
examinations
MRI (amyloid-related imaging abnor malities 
[ARIAs]and emergent radiological findings )
Columbia Suicide Severity Rating Scale
(C-SSRS)
Summary of Study Design:
Study AACG is a m ulticenter, randomized, double- blind, placebo -controlled, Phase 2 study of 
LY300281 3 in subjects with early symptomat ic AD.  The 133-week study  includes a screening 
I5T-MC-AACG(d)Clinical Protocol Page 12
LY3002813period of up to 9weeks, a treatment period of up to 72weekswith final evaluat ions occurring 
4weeks later at Week 76, and a 48-week immunogenicit y and safet y follow-up period.
Treatment Arms and Duration:
Patients will receive the following treatments for up to 72weeks:
LY300281 3:  intravenous LY3002813 (700 mg Q4WK for the first 3 doses, then 1400 
mg Q4WK)for up to 72 weeksor
Placebo:  intravenous placebo Q4WKfor up to 72weeks.
Approximate Number of Patients:
Screened – 1497
Randomized – 266
Statistical Analysis:
All efficacy analyses will fo llow the intent -to-treat (ITT) principle unless otherwise specified. 
An ITT analysis is an analysis of data by  the groups to which subjectsare assigned by rando m 
allocation, even if the subjectdoes not take the assigned treatment, does not receive the correct 
treatment, or otherwi se does not fo llow the protocol .Unless otherwise noted, all pairwise tests 
of treatment effects will be conducted at a 2 -sided alpha level of0.05; 2-sided confidence 
intervals (CIs) will be displayed wit h a 95% confidence level.
Efficacy:
The primary  objective of this study  is to test the hypothesis that intravenous infusion o f 
LY300281 3 will slow the cognitive and/or funct ional decline of AD as measured by the 
composite measure iADRS co mpared with placebo in pat ients with early symptom atic AD.  The 
change from baseline score on the iADRS at each scheduled postbaseline visit during the 
treatment period will be analyzed using an MMRM model ,which includes the fo llowing term s:  
baseline score, pooled invest igator, treatment, visit , treatment-by-visit interaction, baseline -by-
visit interaction, conco mitant AChEI and/or memant ine use at baseline (yes/no) , and age at 
baseline.  The primary  time point for treatment comparison will be at the end of the double blind 
treatment period (Week 76).  The treatment group contrast in least- squares mean progression and 
its associated p-value and 95% CI will be calcula ted for thetreatment comparisonof LY3002813 
vs. placebo.  In addition, Bayesian posterior probabilit y of theactive treatment arm being 
superior to placebo by at least a margin of interest (25% slowing of placebo progression) will 
also be calculated .
Change from baseline at each scheduled postbaseline visit during the treatment period in 
secondary  efficacy outcom es, including ADAS -Cog13,ADCS-iADL,CDR-SB, and MMSE, will 
be analyzed using the same MMRM model described for the primary analysis.
Safety:
Safety will be assessed by summarizing and analyzing AEs, laboratory  analytes, vi tal signs, MRI 
scans, ECGs, immunogenicit y during the double -blind treatment period.
I5T-MC-AACG(d)Clinical Protocol Page 13
LY3002813Pharmacokinetics/Pharmacodynamics :
Compartmental modeling of LY3002813 P K data using nonlinea r mixed effects modeling or 
other appropriate software may be explored, and populat ion estimates for clearance and central 
volume of distribut ion may be reported.  Depending on the model selected, other PK parameters 
may also be reported.  Exploratory  graphical analyses of the effect of dose level or demographic 
factors on PK parameters may be conducted.  If appropriate, data from other studies of 
LY300281 3 may beused in this analysis.
Pharmacokinet ic/pharmacodynamic ( PK/PD) rel ationships between plasma LY3002813 
concentration and SUVr, cognit ive endpoints, ARIA incidence rate or other markers o f PD 
activity may be explored graphically .  The relati onship between the presence of ant ibodies to 
LY3002813 and PK, PD, safet y and/or efficacy  may be assessed gra phically.  If warranted, 
additional analysis may be explored to evaluate potential interact ions for ADA, PD and other 
endpoints (PET scan, ARIA- E, etc.).  Additional modeling may  be perform ed based on the 
results of the graphical analyses.
I5T-MC-AACG(d)Clinical Protocol Page 14
LY30028132.Schedule of A ctivities
I5T-MC-AACG(d)Clinical Protocol Page 15
LY3002813Schedule of Activities Protocol -I5T-MC-AACG Visit 1 (Screening Period)
Period:
Procedure
Visit No.: V1
End of Week Relative to Study Medication StartaWk -9through Wk -1
Tolerance Interval for Visit (days)a,b63
PRELIMINARY SCREENING
Entry and Administrative 
Abbreviated (or full) Informed Consent –participant and study partnercX
  Patient number assigned via IWRS X
  Demographics and habits X
Entry Diagnostics 
  MMSEc,d,sX
  CBBcX
SCREENING
Full Informed Consent –participant and study partnerdX
  Inclusion/exclusion review X
  Physical/neurological examinationeX
  Previous/concomitant medications X
  Preexisting conditions X
Entry Diagnostics
  MHIS X
Safety Assessments
   Vital signsfX
   Height and weightgX
   ECG in triplicatehX
   C-SSRS/SHSF/SHFUi,jX
Laboratory Specimens
  Human chorionic gonadotropin (HCG) (if applicable)k,l,mXb
  Clinical chemistry, hematology Xb
  High sensitivity C -reactive protein X
  HBsAgnX
  HCV RNA PCRoX
  Urinalysis X
Screening PET Scans and MRI
   Flortaucipir F18 PET scanl,pX
   MRIqX
   Florbetapir F18 PET scanb,m,rX
I5T-MC-AACG(d)Clinical Protocol Page 16
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 1 (Screening Period) Abbreviations and Footnotes
Abbreviations:  A = amyloid ; CBB = CogState Brief Battery; C-SSRS = Columbia Suicide Severity Rating 
Scale; ECG = electrocardiogram; ED = early discontinuation visit; HBsAg = h epatitis B surface antigen ;
HCG=human chorionic gonadotropin; HCV= hepatitis C virus ;IWRS=interactive web response system; 
MHIS = Modified Hachinski Ischemia Scale; Examination; MMSE = Mini -Mental State Examination; 
MRI=magnetic resonance imaging; No. = number; PCR = polymerase chain reaction ; PET = positron emission 
tomography ; SHSF = Self -Harm Supplement form;SHFU = Self-Harm Follow -Up;V = visit; Wk = week.
aThe interval between V1 and V2 may be up to 63days to allow for completion of V1 screening procedures, 
assessments, and evaluation of results from laboratory tests and ECGs.  V1 is not considered complete until all 
screening procedures have been completed and results reviewed by the investigator to determine patient 
eligibility.  V1 may be conducted over more than 1 day. Subjects in screening at the timescreening was paused 
are allowed to continue screening beyond the 63 days to allow for completion of V1 screening procedures ;this 
will not be a protocol deviation. Additional details are provided in Section 5.1.1.Subjects who had completed 
screening but were not yet randomized at the time randomization was paused are allowed to be randomized 
beyond63 days; this will not be a protocol deviation.  Additional details are provided in Section 5.1.1.
bA florbetapir F18 PET scan is the final screening criterion for establishing patient eligibility , although theMRI 
may be performed after the florbetapir F18 PET scan. Patients whose screening florbetapir F18 PET scan results 
are not available within the 63day screening window will remain eligible within V1 until these results become 
available if all other eligibility criteria have been met.  Note:  If a patient’s screening florbetapir F18 PET scan 
result confirming eligibility for the study has not been received by the site by Day 63of the screening period, 
then repeat the following lab oratory tests:  blood hematology, chemistry, and serum pregnancy test (HCG) for 
women of childbearing potential (WOCBP) .  Results of the repeated labs are to be reviewed by the investigator 
or qualified designee for assessment of the patient’s continued el igibility.  Repeat screening for MMSE,CBB, 
C-SSRS, ECG , flortaucipir F18 PET, MRI, and laboratory testing for HBsAg and HCV RNA PCR is not 
required.  V1 is not considered complete until all screening procedures have been completed and results reviewed 
by the investigator or qualified designee to determine patient eligibility.
cA preliminary screening informed consent may be obtained to conduct initial screening to collect demographics 
data and administer the MMSE and CBB.  Patients w ho do not meet the MMSE screening criteria are not to have 
any other screening procedures performed with the exception of the CBB.  The CBB should be administered to 
all patients at the screening visit, regardless of the MMSE score.  They may be rescreened for the MMSE 8 
weeks after the first screen. Study partners are not required to complete the preliminary screening informed 
consent.
dPatients who meet the MMSE screening criteria may proceed to the remaining screening procedures once they 
have given signed/dated inf ormed consent for the full study and their study partner has given signed/dated 
informed consented to participate as a study partner.
eA complete physical and neurological exam is to be performed at this visit.  Additional details are provided in 
Section 9.4.1.
fSitting bloodpressure and pulse will be measured after 5 minutes in the sitting position only.  Temperature will 
be collected with sitting vital signs.
gHeight and weight will be measured with shoes removed.
hECGs should be taken in triplicate at approximately 1 -minute intervals.  ECGs should be collected at 
approximately the same time of day, as much as possible, to minimize diurnal vari ation.
iThe baseline version of the C -SSRS is to be administered at V1.  Patients at imminent risk of suicide (positive 
response to question 4 or 5 on the C -SSRS) will be excluded from participating in the study.
I5T-MC-AACG(d)Clinical Protocol Page 17
LY3002813jThe SHSFis completed after each C -SSRS administration to enter the number of discrete events of suicidal 
behavior identified.  If, based on administration of the C -SSRS, it is determined that suicide -related behaviors 
have occurred, then the SHFU form will be use d to collect additional information to allow for a more complete 
assessment of these behaviors.
kFemales of childbearing potential are to have a serum pregnancy test (HCG) at V1 (if applicable).
lFemales of childbearing potential are to have a urine preg nancy test (HCG) on the day  of flortaucipir F18 PET 
imaging before the flortaucipir F18 dose is administered.
mFemales of childbearing potential are to have a urine pregnancy test (HCG) on the day  of florbetapir F18 PET 
imaging before the florbetapir F18 dose is administered.
nPatients with a past history of Hepatitis B are to have a serum HBsAg test at screening V1and are excluded if the 
HBsAg test is positive.
oPatients with a past history of Hepatitis C are to have a HCV RNA PCR test at screening V1and are excluded if 
the HCV RNA PCR test is positive.
pA screening flortaucipir F18 PET scan will be performed as part of the study eligibility criteria at all sites to 
determine patient eligibility for participation in Study AACG (see Appendix 5 ).  With the exception of an MRI
andaflorbetapir F18 PET scan, apatientshould meet all other V1 eligibility criteria before having a screening 
flortaucipir F18 PET scan.  Theflortaucipir F18 PET scan will be submitted to a centralized PET imaging vendor 
designated by Lilly for an assessment of patient’s eligibility.  A historical flortaucipir F18 PET scan may be 
submitted to be considered for el igibility if performed within 6 months of V1.
qA local screening MRI will be performed at V1as part of the study eligibility criteria.  With the exception of the 
evidence of amyloid pathology by florbetapir F18 PET scan , apatient should meet all other V1eligibility criteria 
before having an MRI scan.  The MRI scans will be reviewed by the investigator or qualified designee for 
immediate patient management.  After the MRI scan is read locally, the scan is to besubmitted to the centralized 
MRI vendor des ignated by Lilly for final determination of MRI eligibility.  Results of centrally read MRIs will 
be used for data analysis and repo rt-writing purposes and patient safety and eligibility will be reported back to 
sites.
rA screening florbetapir F18 PET scan will be performed as part of the study eligibility criteria to determine 
patient eligibility for participation in Study AACG (see Appendix 6 ).  With the exception of an MR I,a patient 
should meet all other V1 eligibility criteria before having a screening florbetapir F18 PET scan.  The PET scan 
will be submitted to a centralized PET imaging vendor designated by Li lly for assessment of patient’s eligibility .  
The florbetapir F18 PET screening criteria must be met (scan results consistent with the presence of amyloid 
pathology) in order for the patient to proceed to V2 and be randomized to treatment assignment.
sAssessment is to include the audio voice recording of the rater’s questions and the patient and caregiver 
responses to assessment questions.
I5T-MC-AACG(d)Clinical Protocol Page 18
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 14 (Double -Blind Period)
Period:
ProcedureRand
Visit No.: V2a,bV3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14
End of Week Relative to Study Medication Start0 4 8 12 16 20 24 28 32 36 40 44 48
Tolerance Interval for Visit (days) 0777777777777
   Inclusion/exclusion review X X X X X X X X X X X X X
   Contact IWRS –dispensation of study medicatio n
   (LY3002813)X X X X X X X X X X X X X
   Physical/neurological examinationeXfXfXfXg
   Ophthalmological examinationh jXhXh
   Dermatological examinationi jXiXi
   Previous/concomitant medications X X X X X X X X X X X X X
   Preexisting conditions/adverse eventseX X X X X X X X X X X X X
   LY3002813 studymedication administeredkX X X X X X X X X X X X X
Efficacy Measures
   ADAS-Cog 13l,ffX X X X
   ADCS-ADLl,ffX X X X
   CDR-SBl,ffX X X X
   MMSEl,ffX X X
Safety Assessment
   C-SSRS/ SHSF/SHFUm,n mX X X X X X X X X X X X
I5T-MC-AACG(d)Clinical Protocol Page 19
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 14 (Double -Blind Period)
Period:
ProcedureRand
Visit No.: V2a,bV3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14
End of Week Relative to Study Medication Start 0 4 8 12 16 20 24 28 32 36 40 44 48
Tolerance Interval for Visit (days) 0777777777777
Laboratory Specimenso
   Clinical chemistry, hematologypX X X X X X
   High sensitivity C -reactive proteinpX X X X X X
   UrinalysispX
   Serum for anti -LY3002813 antibodypX X X X X X X
   Serum LY3002813q,rXqXrXrXqXrXqXr
   Blood for assessment of APOE genotypep,sX
Whole blood, plasma and serum for biomarker 
storagep,tXX X X
   Blood for pharmacogenomicsp,t,uX
Other Safety Measures
   Weight X X X X
   Vital signs and temperaturev,wXwX X XwX X XwX X XwX X X
   ECG in triplicatexX X X X X X
   MRIy zX XaaX X X
Additional Efficacy Measures
  Flortaucipir F18 PET scanbb,cc z
  Florbetapir F18 PET scanbb,dd zXbb,dd
I5T-MC-AACG(d)Clinical Protocol Page 20
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 15 through Visit 21(Double-Blind Period) and Follow-Up
Period:
Procedure
Visit No.:V15 V16 V17 V18 V19 V20 V21 EDcV801-
V804d,ee
End of Week Relative to Study Medication Start 52 56 60 64 68 72 76 88-124
Tolerance Interval for Visit (days) 7777777 14
   Inclusion/exclusion review X X X X X X
   Contact IWRS –dispensation of study medications
   (LY3002813 )X X X X X X   
   Physical/neurological examinationeXfXgXfXf
   Ophthalmological examinationh,jXh
   Dermatological examinationi,jXi
   Previous/concomitant medications X X X X X X X X X
   Preexisting conditions/adverse eventseX X X X X X X X X
   LY3002813 studymedication administeredkX X X X X X
Efficacy Measures
   ADAS-Cog 13l,ffX X X X
   ADCS-ADLl,ffX X X X
   CDR-SBl,ffX X X X
   MMSEl,ffX X X X
Safety Assessment
   C-SSRS/SHSF/SHFUm,nX X X X X X X X X
I5T-MC-AACG(d)Clinical Protocol Page 21
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 15 through Visit 21(Double-Blind Period) and Follow-Up
Period:
Procedure
Visit No.:V15 V16 V17 V18 V19 V20 V21 EDcV801-
V804d,ee
End of Week Relative to Study Medication Start 52 56 60 64 68 72 76 88-124
Tolerance Interval for Visit (days)7777777 14
Laboratory Specimenso
   Clinical chemistry, hematologypX X X X
   High sensitivity C -reactive proteinpX X X X
   UrinalysispX X X X
   Serum for anti -LY3002813 antibodypX X X X
   Serum LY3002813q,rXqXrXqXrXrXr
   Blood for assessment of APOE genotypep,s
   Whole blood, plasma and serum for biomarker storagep,tX X X X
   Blood for pharmacogenomicsp,t,u
Other Safety Measures
   Weight X X X X
   Vital signs and temperaturev,wXwX X XwX X XwXwX 
   ECG in triplicate X X X X
   MRIyX X X
Additional Efficacy Measures
   Flortaucipir F18 PET Scanbb,ccXbb,ccXbb,cc
   Florbetapir F18 PET scanbb,ddXbb,ddXbb,ddXbb,dd
I5T-MC-AACG(d)Clinical Protocol Page 22
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 21(Double-Blind Period) and 
Follow-Up Abbreviations and Footnotes
Abbreviations:  A = amyloid ; ADA = anti -drug antibodies; ADAS -Cog13= 13-item Alzheimer’s Disease 
Assessment Scale -Cognitive subscore; ADCS -ADL = Alzheimer’s Disease Cooperative Study Activities of 
Daily Living Inventory; APOE = apolipoprotein subtype E ; ARIA-E = amyloid related imaging abnormalities –
edema/effusions ;CDR-SB = Clinical Dementia Rating -Sum of Boxes; CRF = case report form; C-SSRS = 
Columbia Suicide Severity Rating Scale; ECG=electrocardiogram; ED = early discontinuation visit; 
HCG=human chorionic gonadotropin; IWRS =interactive web response system; MMSE = Mini -Mental State 
Examination; MRI = magnetic resonance imaging; No. = number; PET = positron emission tomography; SHFU 
= Self-Harm Follow -Up form; SHSF = Self -Harm Supplement form; TE = treatment -emergent; V = visit.
aConfirm that the patient has met all V1 eligibility criteria before proceeding with V2 procedures.
bAt V2, appointments should be made for all remaining visits and should be scheduled as close as possible to the 
targetdate, relative to V2.  Procedures for some visits may take more than 1 day.
cIf a patient discontinues before the double -blind period endpoint (V 21at Week 76), complete the Early 
Discontinuation CRFs.  The patient should be encouraged to return to the s ite beginning 12 weeks after the ED 
visit for an immunogenicity follow -up visit ( V801through V804).
dPatients are to return to the site for collection of blood samples and safety assessments for assessment of 
immunogenicity status at V801(Week 88).  Fol low-up for patients experiencing clinically significant events 
associated with TEADAstatus is described in Section 9.4.7.2.
eAny clinically  significant changes from baseline on follow -up physical/neurological examinations should be 
noted on the AE page.
fA complete physical and neurological exam is to be performed at this visit.  Additional details are provided in 
Section 9.4.1.
gA brief physical and neurological exam is to be performed at this visit.  Additional details are provided in Section 
9.4.1.
hOphthalmological examinations will be performed only in patients who previously received LY3202626/oral 
placeboin this study .  The final examination for each patient will be the next sc heduled ophthalmological
examination after the final administration of LY3202626/oral placebo . It will not be considered a protocol 
deviation if this examination is scheduled sooner than indicated above in order to accommodate patient and/or 
site preference .  Patients w ho received LY3202626/oral placebo after their V9 ophthalmological examination are 
to have an unscheduled ophthalmological examination at the next ava ilable opportunity.  These examinations
must be conducted by an ophthalmologist or optometrist (where permitted by law).  Additional details are 
provided in Section 9.4.6.3.
iDermatological examinations will be performed only in patients who previously received LY3202626 /oral 
placeboin this study.  The final examination for each patient will be the next scheduled dermatological 
evaluation after the final administration of LY3202626/oral placebo.  It will not be considered a protocol 
deviation if this examination is scheduled sooner than indicated above in order to accommodate patient and/or 
site preference.  Patients w ho received LY3202626/oral placebo after their V8 dermatological examination are to 
have an unscheduled dermatological examination at the nex t available opportunity.  These examinations must be 
conducted by a dermatologist.  Additional details are provided in Section 9.4.6.4.
jFor subjects randomized prior to amendment (d), theophthalmological and dermatological examination 
performed at screening will serve as the baseline ophthalmological and dermatological examination.
kStudy drug will be administered by intravenous administration at investigative study site. Patients should be 
observed for approximately 2 hours following each infusion of LY3002813 for the first 6 infusions.  After the 
first six doses, a minimal post -infusion observation time of 60 minutes will be required for all subsequent 
infusions.  However , patients w ho have had dosing restarted after ARIA -E are required to be monitored for 2 
hours following infusion for a minimum of 3 subsequent infusions, and a minimum of 60 minutes post -infusion 
observation thereafter .
I5T-MC-AACG(d)Clinical Protocol Page 23
LY3002813lWhen administered, cognitive and functional assessments (ADAS -Cog13, ADCS-ADL, CDR, and MMSE) 
should be performed first, before medical procedures that could be stressful for the patient ( e.g., blood draws).
mThe C-SSRS administered at screening will serve as the baseline C -SSRS.
nThe ‘since last visit’ version of the C-SSRS will be administered at visits after V2 (Week 0) to the patient with 
the study partner/study informant present, after the cognitive and functional assessments.  The SHSF is 
completed after each C -SSRS administration to enter the number of discrete events of suicidal behavior 
identified.  If, based on administration of the C -SSRS, it is determined that suicide -related behaviors have 
occurred, then the SHFU form will be used to collect additional information to allow fo r a more complete 
assessment of these behaviors
oUnscheduled laboratory tests may be performed at the discretion of the investigator.
pLabs are to be collected prior to administration of the intravenous study medication (LY3002813 or IVplacebo).  
Recordthe date and times of sample collection on the Lab Requisition Form.
qPre-dose(before beginning the infusion )samples for intravenous study medication (LY3002813) may be 
collected from the intravenous site prior to beginning the infusion .Post-dose(within 30 minutes of completion 
of the infusion) samples for intravenous study medication (LY3002813) should be collected from the arm that 
did not receive the infusion at V2 (Week 0), V5 (Week 12), V8 (Week 24), V15 (Week 52), and V20 (Week 72).
rA single pre-dose LY3002813 sample should be collected before beginning the infusion at V3 (Week 4), V4 
(Week 8), V6 (Week 16), V11 (Week 36), and V18 (Week 64).  In addition, a single sample for serum 
LY3002813 should be collected at V21 (Week 76), or ED , and V801(visits at which the patient may not receive 
a study drug infusion). If LY3002813 infusion is permanentlydiscontinued but the patient remains in the study, 
one PK sample should be collected at the soonest scheduled visit regardless if serum LY300281 3 is on the 
Schedule of Activities at that visit . Subsequent PK sample collection should follow the protocol Schedule of 
Activities for serum LY3002813 collection unless the scheduled visit exceeds6 months since discontinuation of 
infusions. No additional serum collection for LY3002813 isrequired oncethe patient exceeds6 months since 
discontinuation of LY3002813 infusions.Record the actual date and times of sample collection on the Lab 
Requisition Form.
sA blood sample will be collected to determine APOE genotype.  The APOE genotype sample may be collected at 
an alternative visit if it cannot be collected at V2.
tBlood for biomarker storage, and blood for pharmacogenomic samples are to be collected unless not allowed or 
unfeasible due to local regulations prohibiting sample transport outside of the country.
uPharmacogenomic samples may be collected at an alternative visit if they cannot be collected at V2.  It will not 
be a protocol deviation if a biomark er storage sample cannot be collected for technical reasons ( e.g., if the site is 
unable to collect enough blood via venipuncture).
vSitting blood pressure and pulse will be measured after 5 minutes in the sitting position at allvisits.  Temperature 
willbe collected with sitting vital signs.
wIn addition, orthostatic blood pressure and pulse will be measured at V2 (Week 0), V5 (Week 12), V8 (Week 24), 
V11 (Week 36), V15 (Week 52), V18 (Week 64), V21 (Week 76) , or ED, and at unscheduled visits after 5 
minutes in the supine position and after 3 minutes standing.
xElectrocardiograms should be taken in triplicate at approximately 1 -minute intervals.  ECGs should be collected 
at approximately the same time of day, as much as possible, to minimize diurnal var iation.  ECGs are to be 
performed prior to the administration of intravenous study medication (LY3002813 and IV placebo).
yIf MRI is done on the same day as cognitive and functional assessments, then it should be done after cognitive 
and functional tests.   MRI may be done before other visit procedures, including cognitive and functional tests, 
but in that case must be done at least 1 day before other visit procedures.
zThe screening flortaucipir F18 PET scan, MRI ,and florbetapir F18 PET scan done at V1 s erve as the baseline 
flortaucipir F18 PET scan, MRI ,and florbetapir F18 PET scan , respectively .
aaThe V5 MRI is to be performed 2 weeks prior to the V5 (Week 12) LY3002813 infusion to allow for receipt and 
review of the central vendor MRI report prior to a possible LY3002813 dose change at V5 (Week 12).
I5T-MC-AACG(d)Clinical Protocol Page 24
LY3002813bbFemales of childbearing potential are to have a urine pregnancy test (HCG) performed on the day of florbetapir 
F18PET and flortaucipir F18 PET imaging before the florbetapir F18 dose or flortaucipir F1 8dose is 
administered to confirm that they are not pregnant.
ccAll patients will have a flortaucipir F18 PET scan done at V21 (Week 76) or ED (if ED occurs more than 36
weeks after randomization ) (see Appendix 5 ).  Before the flortaucipir F18 PET scan, the investigator should 
review the patient’s medical history and concomitant medications to verify there is no risk factor for torsadesde 
pointesand review the most recent ECG. If clinically meaningful abnormalities are noted on the ECG, the 
advisability of the flortaucipir scan should be considered by the investigator in consultation with the 
Lilly-designated medical monitor. The study investigat or and site clinical study team will not have access to 
the flortaucipir F18 follow-up scans, as the site clinical study team must remain blinded to any potential 
changes in tau deposition .
ddAll patients will have double -blind period florbetapir F18 PET scansdone at V8 (Week 24), V15 (Week 52), and 
V21 (Week 76) or ED (if ED occurs more than 8weeks after a florbetapir F18 PET scan has been performed at a 
previous visit ) (see Appendix 6 ).  The study investigator and site clinical study team will not have access to any 
florbetapir F18 follow-up scans, as the site clinical study team must remain blinded to any potential change s 
in amyloid deposition.
eePatients are to return to the site for an immunogenicity and safety follow -up visit ( V801) at Week 88 (or 
12weeks after the ED visit) for collection of blood samples for anti -drug antibody (ADA) measurements and 
assessment of a dverse events and concomitant medications.  The need for additional study visits after V801 will 
be determined by results of the ADA sample taken at V801. A patient will stop immunogenicity follow -up visits 
when they either complete 3 additional quarterly visits (Week 100, Week 112, and Week 124) or complete a visit 
at which their ADA returns to baseline (2 -fold titer from baseline), whichever occurs first.  See Section 5.1.3and 
Section 9.4.7.2for details.
ffAssessment is to include the audio voice recording of the rater’s questions and the patient and caregiver 
responses to assessment questions.
I5T-MC-AACG(d)Clinical Protocol Page 25
LY30028133.Introduction
3.1.Study Rationale
LY3002813 is an ant ibody directed at the py roglutamate modification of the third amino acid of 
amyloid beta (N3pG Aβ) epitope that is present only in brain amylo id plaques.  It i s being 
studied for the treatm ent of Alzheimer’s disease (AD).  The mechanism of action of LY3002813 
is considered to be the targeting and removal of exist ing amylo id plaque, which is a key 
pathological hallmark of AD.  The clinical strategy for LY3002813 targets the N3pG Aβ specific 
to amyloid plaque in the populat ion of early  symptomatic AD patients with exist ing brain 
amyloid load, as measured using the amylo id plaque biomarker, florbetapir F18positron 
emission tomography (PET) imaging. This rationale is based on the amyloid hypothesis of AD,
which states that the production and deposition of Aβ is an early and necessary  event in the 
pathogenesis of AD (Selkoe 2000).  Clinical support for this hypothesis co mes from the 
demonstration that parenchymal Aβ levels are elevated before the appearance of symptoms of 
AD, and supported by  genetic variants of AD that overproduce brain Aβ and genetic variants that 
protect against Aβ production (Jonsson et al. 2012; Fleisher et al. 2015).  Furthermore, early  in 
the disease, the presence of brain amylo id appears to increase the risk of conversi on from mild 
cognitive impairment ( MCI) to AD dement ia (Doraiswamy et al. 2012).  This suggests that 
enhanced clearance of Aβ will lead to slowing of AD progression.
Study I5T-MC-AACG (AACG) is a Phase 2, double -blind, placebo -controlled study  to evaluate 
the safety and efficacy of N3pG antibody  (LY3002813 ) in patients wi th early symptom atic AD 
(prodrom al AD and mild dement ia due to AD).  StudyAACG will assess whether removal of 
existing amylo id plaque can slow the progressi on of disease as assessed by cli nical measures and 
biomarkers of disease pathology  and neurodegenerati on over up to 72weeks of treatment.
Multiple biomarkers of disease progress will also be evaluated.  The bio marker florbetapir F18 is 
a PET ligand that binds to fibrillar amyloid plaque .  This bio marker can provide a qualitat ive and 
quantitative measurement of brain plaque load in patients with prodromal AD ormild AD 
dementia.  The absence of significant florbetapir F18 signal on a visual read indicates that those 
patients clinically  manifesting cognit ive impairment have sparse to no amylo id plaques.  As 
such, implementation o f florbetapir F18 will  provide a screening tool for entry  into the clinical 
trialand provi de a confirmat ion of amylo id pathology.  Florbetapir F18 PET al so provides 
quantitative assessment of fibrillar amylo id plaque in the brain and can assess amylo id plaque 
reductions from the brain by LY3002813.
Alzheimer’s disease progression is also associated with cerebral tauopathy , which will be 
assessed by  flortaucipir F18 PET scan, a cortical marker of paired helical filaments.  Brain 
atrophy, as an indicator of neurodegenerat ion, will be assessed by  volumetric resonance imaging 
(vMRI).
The patient populat ion for the clinical trial is selected to be AD patients with early symptomatic 
disease defined both clinically  (prodrom al to mild AD dement ia) and by bio markers (low to 
medium tau burden, plus amylo id plaque presence).  The 2018 NIA -AA draft AD research 
I5T-MC-AACG(d)Clinical Protocol Page 26
LY3002813framework (Alzheimer’s Associat ion 2017a) proposes that AD is define d by its underlying 
pathophysio logic processes which can be documented in vivo by bio markers (such as tau and 
amyloid PET) or by  post-mortem examinat ion.  This framework will enable a more precise 
approach to therapeutic intervent ion trials where specific pathways can be targeted at specific 
points in the disease process and to the appropriate people (Alzheimer’s Associat ion 2017b).  
Clinical-pathological correlations also strongly  suggest that baseline imaging that allows staging 
on the basis of neurofibri llary tangles could substant ially improve the power of clinical trials 
aimed at changing the rate of progression o f the disease (Qian et al. 2017).  An early AD 
population defined clinically and patho logically is anticipated to be more homogeneous than 
populations defined without tau PET, and will be sufficient ly early to respond to treatments prior 
to more advanced irreversible neuronal lo ss.
3.2.Background
Alzheimer’s disease is an age -related neurodegenerative disorder characterized by progressive 
decline in cognitive function and the abilit y to perform activities of daily living, ult imately
resulting in dement ia, typically with fatal complications.  The amylo id hypothesis of AD 
postulates that the accum ulation of amylo id-β peptide (Aβ) i s an early and necess ary event in the 
pathogenesis of AD.  This hypothesis suggests that treatments that slow the accumulation o f Aβ 
plaque in the brain or increase clearance of Aβ may  be able to sl ow the progression of the AD 
clinical syndro me.  The other hallmark neuropathol ogical lesi on of AD, intraneuronal 
neurofibrillary  tangles consist ing of tau proteins, is thought to be another marker for disease 
progression (Braak and Braak 1996).  The relat ionship between these 2 pathologies is st ill 
unclear, although the presence of both is necessary for the diagnosis of definite A D.
Converging evidence fro m both genet ic at-risk and age at -risk cohorts suggests that the 
pathophysio logical process of AD begins well more than a decade before the clinical stage now 
recognized as AD demen tia, and that neurodegeneration is already apparent on magnet ic 
resonance imaging (MRI) by the stage of MCI.  Like many  disorders, AD occurs on a con tinuum 
from asymptom atic (preclinical) to MCI, then to dement ia in mild, moderate, and severe stages.  
Recent clinical trial results in mild -to-moderate AD dem entia, as well as evidence fro m 
transgenic animal experiments, suggest that treating AD during the earlier stages could have the 
greatest potential benefit on the disease and its progressio n, particularly when considering 
therapies targeted at Aβ reduction (Doody  et al. 2014; Fleisher et al. 2015; Siemers et al. 2016).
3.2.1.LY3002813 Nonclinical Studies
The safety of LY3002813, a plaque-specific m onoclonal antibody, was assessed in a 6 -week 
toxicity study in cynomolgus monkeys, including evaluat ions of safety pharmacol ogy and 
toxicokinetics.  The administration of LY3002813 in mo nkeys of up to a maximum dose of 100 
mg/kg/week (bo lus intravenous [IV]) for 6 weeks resulted in no drug- related findings.  Repeat -
dosehazard ident ification studies of up to 6 months’ duration were conducted in the aged 
PDAPP (APPV717F) transgenic mouse model o f Aβ deposi tion to invest igate potential effects 
related to clearance of Aβ from the brain.  In addit ion, a specialized 3 -month study to investigate 
the potential for cerebral  amyloid angiopathy (CAA)-associated microhemorrhage was 
I5T-MC-AACG(d)Clinical Protocol Page 27
LY3002813conducted in aged PDAPP transgenic mice.  These studies in the PDAPP mouse were conducted 
with mE8c (LSN3026818), a m urine analog ant ibody of LY3002813, to avoid limitations due to 
potential immunogenici ty from repeated administration of the humanized ant ibody to the mouse.  
No drug-related findings occurred in the hazard ident ification studies in PDAPP mice at mE8c 
doses of up to 100 mg/kg/week (the highe st dose tested).  Treatment of PDAPP mice wit h mE8c 
at 12.5 mg/kg/week for 3 months did not exacerbate CAA -associated microhem orrhage at a dose 
that produced a maximum pharmaco logical response (reduction in deposited brain Aβ) in these 
animals.  See the In vestigator’s Brochure (IB) for details regarding nonclinical LY3002813 
studies.
3.2.2.LY3002813 Phase 1 Studies
The first human dose study  of LY3002813 was I5T -MC-AACC (Study  AACC).  Study  AACC 
was a Phase 1, patient -and invest igator-blind, randomized wit hin cohort, placebo-controlled, 
parallel-group, single -dose followed by multiple-dose, dose -escalation study in patients with 
MCI due to AD or mild- to-moderate AD to assess the safet y, tolerability, pharmacodynamics 
(PD), and pharmacokinet ics (PK) of single and multiple IV doses of LY3002813.  The study  
included Japanese and non -Japanese patients.  Patients with AD were enrolled into the 
single-ascending dose (SAD) phase and were each administered a single IV dose of LY3002813 
(5dosing cohorts from 0.1 mg/kg IV to 10 mg/kg IV) or pl acebo foll owed by a 12-week 
follow-up period for each dose level.  After the fo llow-up period, the sam e patients proceeded 
into the multiple-ascending dose (MAD) phase (5 cohorts) and were administered IV doses of 
LY3002813 (0.3 mg/kg IV to 10 mg/kg IV; subjects in the 0.1 mg/kg SAD cohort received 
0.3mg/kg in the MAD phase) or placebo approximately once per month for up to 4 doses, 
depending on the init ial dose level.  This phase concluded wit h a 12-week follow-up period.  The 
relative exposure assessment of an unblinded single subcutaneous (SC) dose of 3 mg/kg 
LY3002813 in AD patients was also performed, followed by a 12 -week follow-up assessment.  
The PK of an unblinded single IV dose of 1 mg/kg LY3002813 in young, healt hy male subje cts 
was assessed to determine whether the absence of the amyloid target affected the PK as 
compared with amyloid-positive AD pat ients.
After single -dose administrati on from 0.1 mg/kg to 3.0 mg/kg, the mean terminal eliminat ion 
half-life was approximately 4 days, increasing to approximately  10 days (243 hours) at the 
10-mg/kg dose level.  The PK of a single dose of 1.0 mg/kg IV LY3002813 in young, healt hy 
subjects was indist inguishable fro m the PK in AD pati ents at the sam e dose level.
In AACC, florbetapir F18scans were performed at baseline and after the last MAD, separated by  
approximately  7 months, to assess the PD effects of LY3002813.  The change from baseline in 
grey matter standardi zed uptake value ratio (SUVr) with cerebellum as a reference region wa s 
compared across dose cohorts.  There was a highly significant reduction from baseline in 
cerebral amylo id by PET at the highest dose, 10 mg/kg (p<.0002).  The analysis showed 
consistent reduction in cortical amylo id among these patients who received 3 to 5 doses of 
10mg/kg LY3002813.  The mean observed reductio n in florbetapirF18PET signal corresponds 
to a mean 50% reducti on in total  brain fibrillar amylo id.  Meaningful target engagement 
(amyloid reduction) was likely not achieved at doses smaller than or equal to 3 mg/kg IV every  
I5T-MC-AACG(d)Clinical Protocol Page 28
LY30028134weeks (Q4W) because of the rapid eliminat ion of LY3002813 and the lack of sustained 
exposure.
I5T-MC-AACD (Study  AACD) i s an ongoing Phase1b single-and multiple-dose study  to assess 
the safety, tolerability, PK, and PD of single and mul tiple IV doses of LY3002813 in pat ients 
with mild cognit ive impairment due to AD or mild to moderate Alzheimer’s dement ia.  It is 
evaluatingup to 150 pati ents in 6different dosing cohorts receiving single, every 2 weeks, or 
every 4 weeks dosing of either 10 mg/kg, 20 mg/kg or 40 mg/kg of LY3002813.  Treatment 
durationsbeing assessed include single dose, six month dosing every  two weeks, or up to 72 
weeks of every  4 week dosing.  Safet y, PK and PD data from this ongo ing study are used to 
inform further development of LY3002813.  See Section 3.3and the IB for detailed safet y and 
PK information regarding LY3002813.
3.3.Benefit/Risk Assessm ent
3.3.1.Benefit
There is a large unmet medical need for disease -modifying treatments for AD. Data from the 
completed Phase 1a Study  AACC and from  the ongoing Phase 1b Study  AACD indicate a 
dramatic reduction in cerebral amylo id (as assessed by  florbetapir F18PET imaging) in 
individuals who received repeated doses of at least 10 mg/kg (IB; Fleisher et al. 2018).   Along 
withassessment of safet y and tolerability of LY3002813, thi s study will assess whether removal 
of existing amylo id plaquewill show evidence o f slowed clinical  decline and change in 
biomarkers of disease progression relat ive to placebo treatment.
Although there are currently no available disease -modifying agents for the treatment of AD, 
there are several medicat ions approved by  the Food and Drug Administration ( FDA)and Health 
Canada for the treatment of symptoms of AD; these include acet ylcholinesterase inhibitors (e.g., 
donepezil, galantamine, and rivast igmine) and the N-methyl D-aspartate receptor antagonist 
memantine. Because these medic ations are considered standard of care for the treatment of AD, 
participants in thi s trial will be permitted to take these medications during the course of the 
study, provided that they have been on a stable dose at the time of rando mization and rem ain on
a stable dose throughout the study .
3.3.2.Risks
Potential risks (discussed below) for LY3002813 include, but are not limited to , formation of 
anti-drug antibodies (ADA), hypersensit ivity (immediate and non -immediate, including infusio n-
related reacti ons), and amyloid-related imaging abnormalit ies(ARIA).
Anti-Drug Antibodies :  High incidences of treatment -emergent anti -drug antibodies (TEADAs) 
have been observed in clinical studies with LY3002813.  Although there were no serious adverse 
events (SAEs) related to the development of ADAs in Study  AACC, the incidence of TEADAs 
in LY3002813 -exposed pati ents and subjects was >90%; in Study  AACD, the incidence of 
TEADAs to date (final protocol) in LY3002813 -exposed pati ents and subjects is approximately  
75%.  In AACD, o n 10mg/kg Q2WK dosing, one patient was observed wit h a highly elevated 
I5T-MC-AACG(d)Clinical Protocol Page 29
LY3002813ADA titer of 1:163840 on Day  144 postbaseline, wit h no clinical consequences.  Ant i-drug 
antibodies levels may affect PD levels of drug effect.  Infusio n reactions and ADAs are potenti al 
risks common to all large mo lecules.  See the IB for details regarding TEADAs .
As a high prevalence of ADAs was observed in Study  AACC, a ri sk management plan for 
immune safet y will be incorporated into the clinical trial including a protocol for manage ment of 
infusion reactions, and standardized data collection for infusio n reaction AEs.
Hypersensitivity (Immediate and Non -immediate, including infusion -related reactions) :  There 
is a risk of an infusio n-related reacti on with LY3002813 therapy .  In Study AACC, AEs of mild 
or moderate infusion react ions were reported in 6 of 37 patients with AD who received mult iple 
IV doses of LY3002813 and in 0 of the 6 healt hy volunteers. In AACD one patient receiving 10 
mg/kg IV every  2 weeks had a mild infusio n-related reacti on and 2 mild inject ion site react ions.  
To mitigate the risk of hypersensit ivity (immediate and non -immediate),  including infusio n-
related reacti ons, specific stud y exclusion criteria related to allergy are defined in the clinical 
protocol; guidance regarding use of premedicat ions and slowing or stopping the LY3002813 
infusion is provided in Sections 9.4.7.1.1 and 9.4.7.1.2, respectively; and a protocol for 
management of infusio nreactions is included in the trial Manual  of Operations.
Amyloid-Related Imaging Abnormalities :  Some ant i-amyloid therapies desi gned to rem ove 
amyloid have been associat ed with ARIA–edema/effusio ns and –hemorrhage/hemosiderin 
deposition (ARIA -E and ARIA -H; also known as vasogenic edema and cerebral 
microhemorrhage, respect ively)(Sperling et al . 2011).  These abnormalit ies are best detected on 
an MRI using fluid attenuation inversio n recovery  (FLAIR) sequences for ARIA -E and the T2* 
gradient-recalled echo for ARIA -H.
Potential symptoms of ARIA -E include headache, gait instabilit y, dizziness, tremor, worsening 
cognitive function, alteration of consciousness, seizures, unsteadiness, and vo miting (Ostrowitzki 
et al. 2012; Sperling et al. 2012). However, ARIA- E can also be unaccompanied by any 
symptoms.
Microhemorrhages and superficial siderosis (ARIA -H) are often associated with ARIA -E and 
both are thought to be possibly related to removal of vascular Aβ or amylo id trafficking at the 
blood–brain barrier (Ketter et al. 2017). Moreover, ARIA-H are believed to indicate a higher 
risk for macrohemorrhage as well as for the presence of significant cerebral amylo id angiopathy .  
While ARIA does occur during the natural course of AD, there appears to be an increased risk of 
microhemor rhage wit h anti-amyloid antibody treatment in preclinical models and ARIA -H and 
ARIA-E in humans (e.g., bapineuzumab, gantenerumab, aducanumab [Black et al. 2010]) as 
well.
In Study AACC, two cases of asymptomat ic ARIA-H, but no ARIA -E were detected by  MRI.  In 
the ongoing study AACD 42 subjects received up to 13 doses of LY3002813 (~32 subjects) or 
placebo (~10 subjects) as of 03 August 2017.  Of these, one mildly symptomat ic and four 
asymptomat ic cases o f ARIA-E, and 5 events of ARIA -H in 4 pati ents(including in 3 pati ents 
who also experienced ARIA -E) have been reported.  Two cases occurred in subjects dosed with 
10mg/kg Q2W K, 2 occurred in subjects who received a single dose of 20 mg/kg, and one in a 
I5T-MC-AACG(d)Clinical Protocol Page 30
LY3002813patient who received 10 mg/kg Q4W K.  There was no cle ar relationship to APOE4 carrier status , 
ADA, PK or PD in these cases.  All ARIA -E resolved wit hout clinical consequence after 
treatment discont inuation, except for one patient wit h asymptom atic ARIA-E that was ongoing 
on MRI as of 10 August 2017.
To mitigate the potenti al risk of ARIA -H and ARIA -E during treatm ent with LY3002813, a dose 
titration regimen will be emplo yed utilizing an init ial dose that has lower risk of ARIA -E prior to 
increasing to full study  dose.  In addit ion, a dose reduction algorithm will be em ployed for 
incident ARIA during the trial (see Sect ion 7.4.1).  No cases of ARIA will have 
dose-reintroduction if permanent dose discontinuation rules (described in Sect ion 8.1) are met.
To further aid in mit igation of potenti al risks of ARIA -H and ARIA -E during treatm entwith 
LY3002813, the current study  includes a screening MRI scan that will be used to exclude 
patients with preexisting ARIA -E, >4 microhemorrhages or more than one area of superficial 
siderosis.  In addi tion to scheduled MRIs, unscheduled MRIs may to be o btained at the discret ion 
of the invest igator upon suspicio n of ARIA.  It is recommended to repeat MRIs approximately 
every 4to 6 weeks until reso lution of ARIA-E or stabilizat ion of incident ARIA -H is 
documented.
Further gui dance for management of ARIA -Eand incident ARIA -H is provided in the 
Operations Manual  and the protocol  includes guidance on dose reducti on (Section 7.4.1), 
temporary treatmentdiscontinuation (Sect ion 8.1.1, permanent treatm ent discontinuation 
(Section 8.1), and continued safet y monitoring and treatment options (Section 9.4.7.4).
3.3.3.Benefit/Risk Assessment Summary
To mitigate the potential risks described in Sect ion 3.3.2, the current study will include standard 
safety assessments ;i.e., reported AEs, clinical laboratory  tests, immunogenicit y assessments, 
vital sign and body  weight m easurements, 12 -lead electrocardi ograms (ECGs), and physical 
examinations.
Additional safety assessments will include neuro logical examinat ions (as part of each physical 
examination), MRI examinat ions, and suicidalit y evaluations using the Co lumbia-Suicide 
Severity Rating Scale (C -SSRS).  The current study  will use an independent external Data 
Monitoring Committee (DMC) to monitor data on an ongoing basis to ensure the continuing 
safety of patients enrolled in this study .
The current study  includes placeb o as a comparator, and approximately one-halfof the patients 
will be rando mized to placebo.  In addit ion, all patients participat ing in the study will have a 
designated study  partner who will have regular contact with the patient, accompany the patient to 
study visits, and liaise wi th the study  staff between visits as needed (see Sect ion 6.1for 
additional information about the rol e of the study  partner).
In conclusio n, the available non -clinical and clinical data support the intravenous administration 
of LY3002813 t o the intended study  population according to the proposed clinical invest igation 
plan and also provi de a sufficient margin of safet y for the proposed design and doses.  There are 
I5T-MC-AACG(d)Clinical Protocol Page 31
LY3002813currently no disease -modifying treatments for AD.  The potential benefits of LY3002813 
showing disease -modifying properti es in AD are considered to outweigh the potential risks.
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of LY300281 3 are to be found in the IB.
I5T-MC-AACG(d)Clinical Protocol Page 32
LY30028134.Objectives and Endpoints
Table AACG. 4.1shows the object ives and endpoints of the study.
Table AACG. 4.1. Objectives and Endpoints
Primary Objective Primary Endpoint
To test the hypothesis that LY300281 3 
administered for up to 72weeks will decrease 
the cognitive and/or functional decline in 
patients with early symptomatic ADChange in cognition and function as measured by the 
change in integrated Alzheimer’s Disease Rating Scale 
(iADRS) score from baseline to 18 months
Secondary Objectives Secondary Endpoints
To assess the effect of LY300281 3 vs. placebo
on clinical progression in patients with early 
symptomatic ADChange from baseline to 18 months as measured by:
the change in Alzheimer’s Disease Assessment 
Scale-Cognitive subscale (ADAS -Cog13) score
the change in Clinical Dementia Rating Scale 
Sum of Boxes (CDR -SB) score
the change in Mini Mental State Examination 
(MMSE) score
the change in Alzheimer’s Disease Cooperative 
Study-instrumental Activities of Daily Living 
scale (ADCS -iADL) score 
To assess the effect of LY300281 3 vs. placebo 
on brain amyloid depositionChange in brain amyloid plaque deposition from 
baseline through 18 months as measured by florbetapir
F18PET scan
To assess the effect of LY300281 3 vs. placebo 
on brain tau depositionChange in brain tau deposition from baseline to 
18months as measured b y flortaucipir F18 PET scan
To assess the effect of LY3002813 vs. placebo 
on brain volume measuresChange in volumetric MRI measures from baseline to 
18 months.
I5T-MC-AACG(d)Clinical Protocol Page 33
LY3002813Safety Objective Safety Endpoints
To evaluate safet y and tolerability of 
LY300281 3Standard safety assessments:
ospontaneously reported adverse events 
(AEs)
oclinical laboratory tests
ovital sign and body weight 
measurements
o12-lead ECGs
ophysical and neurological 
examinations
MRI (ARIA and emergent radiological 
findings)
Columbia Suicide Severity Rating Scale
(C-SSRS)
Exploratory Objectives Exploratory Endpoints
To assess the effect of LY300281 3 vs. placebo 
on clinical progression in patients with early 
symptomatic ADthe change in dependence level derived from 
ADCS-ADL scale scores
To assess peripheral PK and presence of 
anti-LY3002813 antibodie s over 72weeksPlasma Pharmacokinetics of LY3002813
Anti-drug -antibodies (ADA) against LY3002813 
including treatment -emergent ADA and 
neutralizing antibodies.
I5T-MC-AACG(d)Clinical Protocol Page 34
LY30028135.Study Design
5.1.OverallDesign
StudyAACG is a m ulticenter, randomized, double- blind, placebo -controlled, Phase 2 study of 
LY300281 3 in subjects with early symptomat ic AD.  The 133-week study  includes a screening 
period of up to 9weeks, a treatment period of up to 72weekswith final evalua tions occurring
4 weekslater at Week 76, and a 48-week immunogenicit y and safet y follow-up period. Subjects 
who meet entry  criteria will be rando mized in a 1: 1ratio to one of the fo llowing treatm ents:
LY300281 3:  IV LY3002813 (700 mg Q4WK for the first 3 doses, then 1400 mg Q4WK)
for up to 72 weeks or
Placebo:  IV placebo Q4WKfor up to 72 weeks .
The primary  hypothesis being tested is that LY3002813 administere d for up to 72weeks will 
result in a significant sl owing in cognit ive/functional decline com pared with placebo as 
measured by the change from baseline to the end of the double blind treatment period (Week 76) 
on the integrated Alzheimer’s Disease Rating Scale (iADRS), in subjects with early symptomat ic 
AD (where early  symptom atic AD refers to the combinat ion of 2 stages:  prodromal AD 
[MCI-AD] and mild AD dement ia; Alaka et al. 2015).
Under previous versio ns of this protocol, LY3002813 was administered in co mbination with 
LY3202626, an inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 .  
However, as of this amendment ( d), the combinat ion therapy and the oral placebo have been 
discontinued fro m the study.
Abbreviat ions and definit ions are provided in Appendix 1 ; clinical laboratory  tests are described 
in Appendix 2 ; Study governance considera tions are described in detail in Appendix 3 ; and
Hepatic monitoring tests for treatm ent-emergent abnormalit y is provided in Appendix 4 .
I5T-MC-AACG(d)Clinical Protocol Page 35
LY3002813Figure AACG. 5. 1.Illustration of study design for Clinical Protocol I5T -MC-AACG.

I5T-MC-AACG(d)Clinical Protocol Page 36
LY30028135.1.1.Screening Period (Visit 1)
At or before Visit 1, the study  will be explained to the patient (and his or her legal representative, 
if applicable) and study  partner.  Informed consent must be obtained before any study  procedures 
are conducted.  The screening period spans the time between Visit 1 to Visit 2.  Study  
assessments are shown in the Schedule of Act ivities (Section 2).
A preliminary  screening informed consent may be obtained to conduct init ial screening to collect 
demographics data and administer the Mini-Mental State Examinat ion (MMSE) and CogState 
Brief Battery(CBB).  Pati ents who do not meet the MMSEscreening criteria are not to have any  
other screening procedures performed with the excepti on of the CBB.  The CBB should be 
administered to all pat ients at the screening visit, regardless of the MMSE score.  They may be 
rescreened for the MMSE8weeks or more after the first screen (see Sect ion6.4). Patients who 
screen failed on the CBB in the previous versio n of this protocol may be reconsented and 
immediately  rescreened using the MMSE (see Sectio n6.4).
Patients who m eet the MMSEscreening criteria may proceed to the remaining screening 
procedures once th ey have given signed/dated informed consent for the full study .
Once the MMSEcriteria are met, 63days are allo wed for com pletion of Visit1 screening 
assessments, procedures, and evaluat ion of results fro m laboratory  tests, ECGs, phy sical and 
neurological examination , flortaucipir F18 PET, MRI, and florbetapir F18 PET.  Even though 
florbetapir F18 PET imaging may  be the last screening procedure of the study , it is expected that 
the centrally read florbetapir F18 PET resul ts will be available within the timeframe of 63days.  
However, it will not be a protocol deviationshould the screening florbetapir F18 PET results not 
be available until after 63days.
Patients whose screening florbetapir F1 8 PET resul ts are not available until after 63days will 
remain eligible wit hin Visit 1 unt il these results become available.  Note:  If a patient’s screening 
florbetapir F18 PET resul ts confirming evidence of amylo id burden are received by the site after 
63days, laboratory  tests (blood hematol ogy, chemistry , and serum human chori onic 
gonadotropin [ HCG] for females of childbearing potential) are to be repeated for that patient.  
Results of the repeated labs are to be reviewed by  the invest igator or qualifi ed designee for 
assessment of the patient’s continued eligibilit y.  Repeat screening for MMSE, CBB, C-SSRS, 
ECG, flortaucipir F18 PET imaging, and MRI, and laboratory  testing for hepatitis B surface 
antigen(HBsAg)and hepatitis C virus (HCV)RNA polymeras e chain reaction (PCR), is not 
required.
Patients in active screening prior to implementation of amendment ( d) remain eligible wit hin 
Visit1 until all screening procedures are completed and results are available. This will not be a 
protocol deviation.Patients who complete Visit 1 beyond63 days are to repeat laboratory  tests 
(blood hematology, chemistry , and serum HCG for females of childbearing potential) prior to 
being rando mized. The results of these laboratory  testsare to be reviewed by the inve stigator or 
qualified designee for assessment of the patient’s continued eligibility.  Repeat screening for 
MMSE,CBB, C-SSRS,ECG,flortaucipir F18 PET imaging ,MRI,and laboratory testing for 
HBsAg and HCV RNA PCR is not required .
I5T-MC-AACG(d)Clinical Protocol Page 37
LY3002813Visit 1 is not consi dered complete until all screening procedures have been completed, results 
have been reviewed by the invest igator or qualified designee, and the investigator or qualified 
designee has confirmed that the patient is eligible to be rando mized. Only then can the patient 
proceed to Visit 2.
Current or planned use of conco mitant medications, the effects of vacat ions or absences on 
protocol compliance, and general compliance wit h the protocol will be discussed at Visit 1.  
Patients must meet eligibilit y criteria (Section 6.1and Section 6.2) to continue to Visit 2.  
Patients who do not meet all inclusio n criteria or who meet any  exclusion criteria may be 
discontinued fro m the study.
5.1.1.1. Screening Procedures
Screening entry  and administrative procedures, cognit ive assessments, safet y assessment s,and 
laboratory  assessments (see Schedule of Act ivities in Section 2) are to be done at Visit 1 before 
the screening flortaucipir F18 PET scan, MRI, and florbetapir F18 PET scan procedures.
5.1.1.1.1. Modified Hachinski Ischemi c Scale (MHIS)
The Modified Hachinski Ischemic Scale (MHIS) will be co mpleted at Visit 1 to exclude pat ients 
likely to have dement ia of vascular etio logy.  The MHIS (Hachinski et al. 1975) is an 8 -item 
scale that examines clinical features that may be consistent with vascular dement ia and is 
commonly used as a screening tool to exclude pat ients with mult i-infarct dement ia from entrance 
into clinical trials assessing neuropsy chopharm acologic therapy  in patients with AD.  The scal e 
is completed by the physician based on clinical information obtained from diagnost ic 
information and physical examinat ion.  The scale takes about 10 to 15 minutes to complete, 
depending on the availabilit y of the data needed .  Scores for the 8 items are added together for a 
total score.  Pati ents who score ≥4 are more likely to have a dement ia of vascular etio logy and 
are excluded fro m participating in the trial.
5.1.1.1.2. Mini-Mental State Examination (MMSE)
The MMSE will be administe red to pati ents at Vi sit 1 to determine if the pat ient meets entry  
criteria for cogni tive impairment . The MMSE is a brief instrument used to assess cognit ive 
function in patients (Fol stein et al . 1975).  The MMSE should be administered by  the same rater 
from visit to visit to reduce potenti al variabilit y.  The instrument is divided into 2 sections.  The 
first section measures ori entation, memory, and attent ion.  The m aximum score for the first 
section is 21.  The second sect ion tests the abilit y of the patient to name objects, follow verbal 
and written commands, write a sentence, and copy  figures.  The maximum score for the second 
section is 9.  The range for the total MMSE score is 0 to 30, with lower scores indica ting great 
level of impairment.
5.1.1.1.3. CogState Brief Battery
The CBB is a brief (15 -18 minute), com puter-based cognitive test battery  designed to m easure 
psychomotor funct ion, attention, working memory , and memory (Maruff et al. 2009, 2013; 
Fredrickson et al . 2010;Darby et al. 2012).  The CBB has been shown to be sensit ive to 
AD-related cognit ive decline in healt hy older adults and in adults wit h amnestic MCI (Darby et 
I5T-MC-AACG(d)Clinical Protocol Page 38
LY3002813al. 2002, 2012; Lim et al. 2013a, b) as well as to improvement in cognit ion arising fro m 
treatment with cognitive-enhancing drugs (Davi son et al. 2011; Jaeger et al. 2011; Nathan et al. 
2013).  The CBB will be administered at Visit 1 tobetterunderstand the utilit y of this test in 
assessment of cognit ive impairment, but patient eligibilit y will not depend on the CBB results to 
determine if the patient meets the cognit ive criteria for the study .The CBB will be administered 
to patients at Visit 1 after administrati on of the MMSE regardl ess of whether the pati ent meets 
MMSE entry  criteria.  Prior to performing the screening CBB, patients m ust perform  a practice 
CBB to familiarize themselves with the instrument.
5.1.1.1.4. Columbia Suicide Severity Rating Scale –Adult Version
The C-SSRS will be administered to patients at Visit 1 to assess psycho logical health.  The 
C-SSRS is a scale that captures the occurrence, severit y, and frequency of suicide -related 
thoughts and behaviors during the corresponding assessment period.  The C -SSRS, included here 
as a screening assessment, is described in detail in Section 9.4.6.1.  The C-SSRS “Baseline” 
version will be used at screening, and the findings will const itute the baseline assessment.  
Patients at imminent risk o f suicide (posit ive response to ques tion 4 or 5 on the C -SSRS) will be 
excluded fro m participating in the study .
The C-SSRS will be administered to the subject after the cognit ive assessments.  Responses from 
subject will be considered when administering the scale.  The Self-Harm Supplement form 
(SHSF) will be completed after each C -SSRS administration to enter the number of discrete 
events of suicidal behavior ident ified.  If, based on administration of the C -SSRS, it is 
determined that suicide -related behaviors have occurred, then the Lilly Self-Harm Follow-Up 
form will be used to collect addit ional information to allow for a more complete assessment of 
these behaviors.
5.1.1.1.5. Screening Positron Emission Tomography and Magnetic Resonance 
Imaging
All other screening criteria should be met in order f or the patient to proceed with flortaucipir F18 
PET scan, fo llowed by MRI, and a florbetapir F18 PET scan procedure.
5.1.1.1.5.1. Screening Flortaucipir F18 PET Scan
A screening flortaucipir F18 PET scan will be performed as part of the study  eligibility criteria 
(see Appendix 5 ).  The flortaucipir F18PET scan will be submitted to a centralized PET imaging 
vendor designated by  Lilly for assessment of patient’s el igibility.
A historical flortaucipir F18 PET scan may be submitted to be considered for eligibilit y if the 
PET scan was performed within 6months of Visit 1.  If a historical flortaucipir PET scan is 
deemed acceptable for m eeting entry criteria, then the MMSE, which is st ill to be administered at 
Visit 1, will serve as the baseline MMSE for statistical analyses, but will notbe used for meet ing 
entry criteria.
The flortaucipir F18PET screening criteria shouldbe met (scan results consistent with sponsor -
derived eligibilit y limits for flortaucipir F18 PET ) beforethe patient can undergo the MRI and 
florbetapir F18 PET scan.
I5T-MC-AACG(d)Clinical Protocol Page 39
LY3002813Specific instructions for the flortaucipir F18 PET scan itself will be provided in the PET Imaging 
Manual.
5.1.1.1.5.2. Screening MRI
A local screening MRI will be performed at Visit 1 as part of the study  eligibility criteria.  Wi th 
the exception of the evidence of amylo id pathology by florbetapir F18 PET scan , apatient should 
meet all other Visit 1 eligibilit y criteria before having an MRI.  T he MRI scans will be reviewed 
by the investigator or qualified designee for immediate patient management .  After the MRI scan 
is read locally, the scan is to be submitted to the centralized MRI vendor designated by Lilly for 
final determinat ion of MRI eligibili ty.  Results o f centrally read MRIs will  be used for data 
analysis and report -writing purposes and patient safet y and eligibilit y will be reported back to 
sites.
5.1.1.1.5.3. Screening Florbetapir F18 PET Scan
A screening florbetapir F18 PET scan will be performed as p art of the study  eligibility criteria 
(see Appendix 6 ).  With the except ion of theMRI,a patient shoul d meet all other Visi t 1 
eligibility criteria before having a screening florbetapir F18 PET scan .  The florbetapir F18PET 
scan will be submitted to a centralized PET imaging vendor designated by  Lilly for assessment 
of patient’s eligibilit y.
The florbetapir F18 PET screening criteria must be met (scan results consistent with 
sponsor-derived eligibilit y limits for amylo id plaque pathol ogy) in order for the patient to 
proceed to Visit 2 and be rando mized to treatment assignment.
Specific inst ructions for the florbetapir F18 PET scan itself will be provided in the PET Imaging
Manual.
5.1.2.Double-Blind Period (Visit 2 through Visit 21)
The treatment period is a double -blind treatment phase beginning at Visit 2.  At Visit 2, 
appointments should be mad e for all remaining visi ts and shoul d be scheduled as close as 
possible to the target date, relat ive to Visit 2.  Patients who meet entry criteria will be enro lled 
and randomized to receive up to 72weeks of treatment with LY300281 3 or placebo.
Every 4 weeks during this treatment period, all patients will be administered IV study  medication 
(placebo or LY3002813) onsite as an IV infusio n of approximately  140 mL over a minimum of 
30 minutes, and assessments will be made.
Final endpoint measuresandsafetyassessmentsfor the doubl e-blind period will be performed at 
Visit 21(Week 76) 4weeks following the patient’s last dose of study  medication.  See the 
Schedule of Act ivities (Section 2) for the timing of events and the measures to be assessed.  
Procedures for some visits may  take more than 1 day .
The study investigator and site clinical study team will not have access to any florbetapir F18 
and flortaucipir F18 follow-up PET scans, as the investigator and site clin ical study team must 
remain blinded to any potential changes in amyloid deposition.
I5T-MC-AACG(d)Clinical Protocol Page 40
LY30028135.1.3.Immunogenicity and Safety Follow -up Visits (Visit s801
through 804 )
Patients are to return to the site for an immunogenicit y and safety follow-up visits(Visit 801
through Visit 804 ) beginning at Week 88 (or 12 weeks after their last dose of LY3002813 )for 
collection of blood samples for anti-drug antibody (ADA; anti -LY3002813 antibody)and PK 
measurement ,assessment of adverse events , C-SSRS,concomitant medicat ions, and vital signs.
A patient will continue to return to the site for quarterly immunogenicit y and safety follow-up 
visits (V802 [Week 100], V803 [Week 112], and V804 [Week124])until the pat ient completes 
V804 or the site is notified that the patient meets criteria for discharge fro m immunogenicit y and 
safety follow-up, whichever occurs first (see Section 9.4.7.2for details).  S ee the Schedule o f 
Activities (Section 2) for the timing of events and the measures to be assessed.
5.2.Number of Participants
Approximately  266participants will be randomized .
5.3.End of Study Definition
End of the study  is the date of th e last visit or last scheduled procedure shown in the Schedule o f 
Activities(Section2) for the last patient.
5.4.Scientific Rationale for Study Desig n
Continuing Standard of Care .  Patients may take AD symptomat ic medications such as 
concomitant acetylcho linesterase inhibitors (AChEIs) and/or memantine and/or Axona if such 
medications are standard of care (SOC) in the patient’s country  and have been gi ven for at least 
4months and stable dosing has been maintained for at least 2 months before Visit 2.  During the 
double-blind treatment period (V2 toV21), changes in doses of available symptomat ic 
medications for MCI or AD will require reporting to the sponsor and these changes should occur 
only when necessary  for the adequate overall care of the patient.  The effect of LY3002813 
treatment plus SOC will be co mpared with placebo plus SOC.
Dosing.  As described more fully in Section 7.1, LY3002813 (700 mg or 1400 mg) will be 
administered every  4 weeks as an IV infusio n of approximately  140 mL over a minimum of 
30minutes.
Design.  Study AACG is a m ulticenter, randomized, double -blind, placebo -controlled study  of 
LY300281 3 in patients with early  symptomatic AD (where early  symptomatic AD refers to the 
combination of 2 stages:  prodromal AD [MCI -AD] and mild AD dement ia) (Alaka et al. 2015).  
The study  is intended to characterize the benefit s and risks of treatment with LY300281 3 versus 
placebo in pati ents early symptom atic AD.
Study AACG includes a placebo treatment arm and allows all pat ients to continue their AD 
standard of care concomitant medications .  Inclusion of a placebo treatment arm is acceptable in 
Study AACG because there are no available disease-modifying treatments for AD; this approach 
is in agreement with the use of placebo described in the Declaration of Helsinki (World Medical 
I5T-MC-AACG(d)Clinical Protocol Page 41
LY3002813Association 2013).  The use of a placebo comparator in Study  AACG is needed to determine 
efficacy and safety of LY3002813 t herapy.
The study  includes a screening visit, which can last up to 63 days, at which pat ients are required 
to have PET flortaucipir F18 PET and florbetapir F18 PET imaging results consistent with tau 
and amylo id pathology  in order to be rando mizedto the double -blind period.  The duration of the 
double-blind period of the study  is 76weeks and includes up to 72weeks of treatment ,with 
endpoint measures and safety assessments at the end of the double -blind treatment period (Week 
76), to assess the safet y, tolerability and efficacy of LY300281 3 versus placeb o.
In addition to AE reporting, safet y measures such as laboratory  assessmen ts, immunogenici ty 
testing, vital signs and weight monitoring, ECG monitoring, physical examinat ions, neurological 
examinations,MRI assessments, and assessments of suicidal ideat ion and behavior are included 
to facilitate a comprehensive safet y evaluation.  For patients enro lled under previous versio ns of 
this protocol , which included a combinat ion arm of LY3002813 ( N3pG) and LY3202626 (BACE 
inhibitor-IV), final dermatologicalexaminations by a dermatologist and finalcomprehensive 
ophthalmo logicalexaminations by an ophthalmo logist or optom etrist (where permitted by  law) 
will be performedat the next visit occurring after the pat ient stopped receiving LY3202626/oral 
placebo.
5.5.Justification for Dose
LY3002813 doses of 700 mg and 1400 mg administered intraven ously once every  4 weeks were 
selected based on current preclinical pharmaco logy and toxicology data and clinical PK, PD ,and 
safety data.  Prior and ongoing exposures include 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 
10mg/kg, 20 mg/kg, and 40 mg/kg in sing le and/or mult i-dose dosing schedules.  Data from 
Study AACC and AACD suggested that PK of LY3002813 is linear when the dose is not less 
than 10 mg/kg.  Mean half -life was about 9 -11 days when dose is ≥10 mg/kg, so minimal 
accumulat ion in plasma PK was pre dicted for 700 mg and 1400 mg Q4 week IV dosing.  High 
levels of florbetapir F18 PET si gnal reductions were seen wit h a single dose of 20 mg/kg, and 
were comparable to florbetapir F18 PET reductions seen wi th a 10 mg/kg Q2 week dosing 
schedule at 3 months ( see Section 3.2and the IB for details).  Based on this as well as decreased 
patient burden wit h an every 4 week dosing schedule co mpared with an every 2 week dosing 
schedule and comparable safet y (see Section 3.3), 1400 mg Q4 week dosing was selected as the 
highest dose regimen for robust amylo id plaque lo wering.  As noted in Section 3.3.2, the lowest 
rate of ARIA -E has been observed with 10 mg/kg mo nthly dosing.  For thi s reason, a ti tration 
schedule (700 mg Q4 week for the first 3 doses, then 1400 mg Q4 week) is proposed to reduce 
ARIA incidence while enabling pat ients to achieve high PD effects.  In addit ion, dose re duction 
rules have been established for incident ARIA -E (see Section 7.4.1).
I5T-MC-AACG(d)Clinical Protocol Page 42
LY30028136.Study Population
Prospective approval o f protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exempt ions, are not permitted.
6.1.Inclusion Criteria
Patients are eligible for enrollment in the study  only if they meet all of the following criteria:
Type of Patient and Disease Characteristics
[1]Gradual and progressive change in memory  function reported by  patients or 
informants for ≥ 6 months .
[50][Note:  Criterion # 50has been replaced by  criterion #59.]
[59]An MMSE score of 20 to 28 (inclusive) at Visit 1 or an acceptable historical 
flortaucipir PET scan within 6 months prior to Visit 1that meets the central  read 
criteria.
[51]Meet flortaucipir F18 scan (central  read) criteria.
[52]Meet florbetapir F18 scan (central read) criteria .
Patient/Subject Characteristics
[2]Men or women, 60 to 85 y ears of age , inclusive, at the time of informed consent .
[3]Contraception
a.  Male subjects
i. Male subjects, regardless of thei r fertility status, wi th non-pregnant female 
partners of childbearing potential must agree to either rem ain abstinent (if 
this is their preferred and usual lifest yle) or use condo ms as well as one 
additional highly effective (l ess than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted 
contraceptives, or intrauterine devices) or effect ive method of contraception 
(such as diaphragms wit h spermicide or cervical sponges) for 90 days after 
study drug dosing.
ii. Men and their partners may choose to use a double –barrier method of 
contraception.  Barrier protection methods without concomitant use of a spermicide 
are not an effect ive or acceptable method of contraception.  Thus, each barrier 
method must include use o f a spermicide.  It should be noted, however, that the use 
of male and female condo ms as a double barrier metho d is not considered 
acceptable due to the high failure rate when these barrier methods are combined.
iii. Male subjects with pregnant partners should use condoms during intercourse for 
the duration of the study  and until the end of est imated relevant poten tial exposure 
in women of childbearing potential, predicted to be 90 days fo llowing last dose of 
study drug.
I5T-MC-AACG(d)Clinical Protocol Page 43
LY3002813iv. Male subjects should refrain fro m sperm donation for the duration of the study  
and until 90 days fo llowing last dose of study  drug.
v. Male subjects who are in exclusively same sex relat ionships (as their preferred 
and usual lifest yle) are not required to use contraception.
b. Women
i. Women of childbearing potential (WOCBP) must be using or willing to use two
forms of effective contraception (e.g., combined oral contraceptive, in trauterine 
device, spermicide), for the duration o f their participation in the trial and for an 
additional 3 months after thei r participation endsor
ii. Women not of childbearing potential are defined as those who are:
a) Infertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal ligation),
b) Post-menopausal –defined as either
i) A woman 55 or older not on hormone therapy , who has had at l east 
6 months of spontaneous amenorrhea; or
ii) A woman at least 55 years of age with a diagnosis of menopause 
prior to starting hormone replacement therapy .
iii. All femalepatients of child-bearing potenti almust test negative for pregnancy  at 
Visit 1 based on serum  pregnancy  test.
[4]Have a study partner who will provide written informed consent to participate, is 
in frequent  contact with the patient (defined as at least 10 hours per week), and 
will accompany the pat ient to study visits or be available by  telephone at 
designated times.  
A second study  partner m ay serve as backup.  The study  partner(s) i s/are requi red 
to accompany the pati ent for signing consent.  One study  partner is requested to be 
present on all days the C -SSRS/Self-Harm Supplement Form is administered and 
must be present on all da ys thecognitive and functio nal scales are administered
(i.e., Visits 1, 2, 5, 8, 11, 15, 18, and 21/early discont inuation [ED]).  If a patient 
has a second study  partner, i t is preferred that one study  partner be primarily  
responsible for the CDR and ADCS-ADL assessments.  If a study  partner(s) i s not 
able to accompany  the patient inpersonfor visits other than those listed above , 
they must be available by  telephone for the following assessments:
AEs and conco mitant medications
relevant porti ons of the C-SSRS/Self -Harm Supplement Form s
If a study  partner m ust withdraw from  study participation, a replacement maybe allowed 
at the investigator’s discret ion.  The replacement will need to sign a separate informed 
consent on the first visit that he/she acc ompanies the pat ient to participate.
I5T-MC-AACG(d)Clinical Protocol Page 44
LY3002813Study partners m ust be able to communicate with site personnel and be willing to comply 
with protocol requirements, and in the investigator’s opinio n must have adequate literacy 
to complete the protocol -specified quest ionnaires.
[5]Have adequate prem orbid literacy, vision, and hearing for neuropsychological 
testing in the opinio n of the invest igator.
[6]Have given wri tten inform ed consent approved by Lilly and the ethical review 
board (ERB) governing the site .
[7]Are reliable and willing to make themselves available for the duration of the study  
and are willing to follow study  procedures .
6.2.Exclusion Criteria
Patients will be excluded from  study enrollment if they meet any o f the following criteria:
Medical Conditions
[8]Have a Modified Hachinski Ischemia Scale (MHIS; Hachinski et al. 1975) score of 
≥4.
[9]Lack, in the invest igator’s opinio n, of adequate premorbid literacy, adequate 
vision, or adequate hearing to complete the required psy chometric tests.
[10]Significant neurological disease affect ing the central nervous system (CNS), other 
than AD, that may affect cognit ion or abilit y to complete the study , including but 
not limited to, other dement ias, serious infect ion of the brain, Parkinson’s disease, 
multiple concussions, or epilepsy or recurrent seizures (except febrile childhood 
seizures).
[11]Current serious or unstable illnesses including cardio vascular, hepat ic, renal, 
gastroenterologic, respiratory , endocrino logic, neurologic (other than AD), 
psychiatric, i mmunologic, or hematologic disease and other condit ions that, in the 
investigator’s opinion, could interfere wit h the analyses in this study; or has a life 
expectancy  of <24 months.
[12]History of cancer wi thin the last 5 years, with the except ion of non-metastatic 
basal and/or squamous cell carcino ma of the skin, in situ cervical cancer, non-
progressive prostate cancer, or other cancers wit h low risk of recurrence or spread.
[13]Patients with any current primary  psychiatri c diagnosis other than AD if , in the 
judgment of the investigator, the psy chiatric disorder or symptom is likely  to 
confound interpretation of drug effect, affect cognitive assessment, or affect the 
patient’s abilit y to complete the study .[Patients with history of schizophrenia or 
other chronic psychosis are excluded.]
[14]Have a history of long QT syndrom e.
[15]Are clinically judged by the invest igator to be at serious risk for suicide as 
assessed by  medical history, examinat ion, or the C -SSRS.
[16][Note:  Criterion #16 has been replaced by criterion #57.]
I5T-MC-AACG(d)Clinical Protocol Page 45
LY3002813[57][Note:  Cri terion #57 has been deleted.]
[17]History of alcohol or drug use di sorder (except tob acco use disorder) within 2 years before 
the screening visit.
[18][Note:  Cri terion #18 has been deleted.]
[19]Have a history of clinically significant mult iple or severe drug allergies ,or severe post -
treatment hypersensitivity reactions (including but not limited to ery thema multiforme 
major, linear immunoglobulin A dermatosis, toxic epidermal necrolysis, and/or exfo liative 
dermatitis).
[20]Known positive serologic findings for human immunodeficiency virus (HIV) antibodies.  
Local laws and regul ations may apply to whether testing is required.
Magnetic Resonance Imaging, Vital Signs, Electrocardiograms, Laboratory Tests, and 
Physical Examination
[21]Have any clinically  important abnorm ality at screening, as determined by invest igator, in 
physical or neurological examinat ion, vital signs, ECG, or clinical laboratory  test resul ts 
that could be detrimental to the patient, could compromise the study , or show evi dence of 
other etio logies for dementia.
[22]Screening MRI which shows evidence of significant abnormalit y that woul d suggest 
another potential et iology for progressive dement ia or a clinically significant finding that 
may impact the patient’s abilit y to safely participate in the study .
[23]Have any contraindications for MRI, including claustrophobia or the presence of 
contraindicated metal (ferromagnet ic) implants/cardiac pacemaker .
[24][Note:  Criterion #24 has been repl aced by criterion #58.]
[58]Have a centrally  read MRI dem onstrating presence of ARIA -E, >4 cerebral  
microhemorrhages, more than 1 area of superficial siderosis, any  macrohemorrhage or 
severe white matter disease.
[25]An average (ECG in triplicate) correc ted QT (QTcF) interval measurement >450 msec 
(men) or >470 m sec (women) at screening (as determined at the invest igational site).  The 
site may request a central  read prior to making determinat ion of this criterion.
[26][Note: Criterion #26 has been replaced by criterion #53.]
[53]Patients with a past history of Hepatitis B should have HBsAg testing at screening and are 
excluded if HBsAg is positive.
[27][Note: Criterion #27 has been replaced by criterion #54.]
[54]Patients with past history  of Hepatitis C should have HCV RNAPCR testing at screening 
and are excluded if HCV RNA PCR is posit ive.
[28]Calculated creatinine clearance <30 mL/min (Cockcroft -Gault formula; Cockcroft 
and Gault 1976) at screening.
I5T-MC-AACG(d)Clinical Protocol Page 46
LY3002813[29]Alanine transaminase (ALT) ≥2X the upper limit of normal (ULN) of the performing 
laboratory , aspartate aminotransferase (AST) ≥2X ULN, total bilirubin level (TBL) ≥1.5X 
ULN, or alkaline phosphatase (ALP) ≥1.5X ULN at screening.
NOTE:  Patients with TBL ≥1.5X ULN are not excluded if they  meet all of the 
following criteria for Gilbert syndro me:
1.Bilirubin is predo minantly indirect (unconjugated) at screening (direct bilirubin 
within norm al limits).
2.Absence of liver disease .
3.ALT, AST, and ALP ≤1X ULN at screening .
4.Hemoglobin is not si gnificantlydecreased at screening.
Prior/Concomitant Therapy
[30]Have received treatm ent with a stable dose of an acetylcho linesterase inhibitor 
(AChEI) and/or memant ine for less than 2 m onths before randomizat ion.[If a 
patient has recent ly stopped an AChEI and/or memantine, he or she must have 
discontinued treatm ent at least 2 months before randomizat ion.]
[31]Changes in concomitant medications that could potentially  affect cogni tion and 
their dosing shoul d be stable for at l east 1 month before screening, and bet ween 
screening and randomization (does not apply to medicat ions discontinued due to 
exclusions or with limited duration of use, such as ant ibiotics).
[32][Note:  Cri terion #32 has been deleted.]
[33]Current use of drugs known to significant ly prolong theQT interval ( see the 
Manual o f Operations for a list of excluded drugs).
[34]Have had prior treatment with a passive anti -amyloid immunotherapy  <5 half-lives 
prior to randomizat ion.
[35]Have received act ive immunization against Aβ in any other study.
[36] Have known allergi es to LY3002813, related compounds, or any  components of 
the formulation; or history  of significant atopy .
[37][Note: Criterion #37 has been deleted.]
[38]Have allergies to either monoclonal ant ibodies, diphenhydramine, epinephrine, or 
methylpredniso lone.
Procedural
[39]Sensitivity to florbetapir F18or flortaucipir F18.
[40]Intend to use drugs known to significant ly prolong the QT interval wit hin 14 days 
or 5 half-lives, whichever is lo nger, of a scheduled screening/baseline flortaucipir 
F18PET scan, or have a medical history  of a risk factor of torsades de pointes.
[41]Poor venous access.
I5T-MC-AACG(d)Clinical Protocol Page 47
LY3002813[42]Contraindicat ion to MRI.
[43]Contraindicat ion to PET.
[44]Present or planned exposure to ionizing radiat ion that, in co mbination with the 
planned administrati on of study PET ligands, would result in a cumulat ive 
exposure that exceeds local reco mmended exposure limit s.
Prior/Concurrent Clinical Trial Experience
[45]Are currently enrolled in any other intervent ional clinical trial in volving an 
investigat ional product or any  other type of medical research judged not to be 
scientifically or medically co mpatible wit h this study .
[46]Have participated, within the last 30 days (4 months for studies conducted in 
Japan; 3 m onths for studi esconducted in the UK), in a clinical trial invo lving an 
investigat ional product.  If the previous investigational product is scient ifically or 
medically inco mpatible with this study  and has a long half -life, 3 months or 5 half -
lives (whichever is longer) s hould have passed prior to screening (Participat ion in 
observational studies may be permitted upon review of the observat ional study 
protocol and approval by the sponsor).
[47][Note: Criterion #47 has been replaced by criterion #55.]
[55]Have previously completed or withdrawn fro m this study  or received LY3002813 
in any prior investigational study.  (This exclusio n criterion does not apply to 
patients who are allowed to rescreen before randomizat ion in this study ).
[56][Note: Criterion #56 has been delet ed.]
Other Exclusions
[48]Are investigator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted.
[49]Are Lilly employees or are em ployees of third-party organizati ons (TPOs) 
involved in study  who requi re exclusio n of their emplo yees, or have study  partners 
who are Lilly emplo yees or are emplo yees of TPOs invo lved in a study  which 
require exclusio n of their em ployees.
6.2.1.Rationale for Exclusion of Certain Study Candidates
The use of LY3002813 in o lder patients is ant icipated;thus this study  will specifically  examine 
the efficacy  and safet y in an elderly populat ion.  Criterion [2] defines the populat ion age range 
for the purposes of this study .  Therefore, patients not meeting the age criterion are excluded.
6.3.Lifestyle Restrictions
1.Patients shoul d refrain from  donating blood or blood products from the time of their 
screening visit until 6 months fo llowing the last d ose of study  drug.
I5T-MC-AACG(d)Clinical Protocol Page 48
LY30028132.Patients shoul d avoid excessive use of alcoho l from the screening visit until the study 
ends.  Excessive alcoho l consumption is defined for men as consuming an average of 
more than 3 drinks per day, or more than 21 drinks per week.  For women, excessive use 
of alcohol is defined as consuming an average of more than 2 drinks per day , or more 
than 14 drinks per week.
6.4.Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay not be 
rescreened if the screen failure is due to non -eligible imaging results.  If the screen failure is due 
to not meeting cognit ive criteria on the MMSE, then one rescreen will be allowed after 8 weeks.  
Ifa patient failed the CBB screening in the previous versio n ofthis protocol, then the pati ent 
may be reconsented and immediately rescreened using the MMSE .Other reasons for screen fail 
will require sponsor approval for rescreen.
I5T-MC-AACG(d)Clinical Protocol Page 49
LY30028137.Treatments
7.1.Treatments Administered
This study  involves a comparison of LY3002813 administered as an IV infusion o f 
approximately  140 mL over a minimum of 30 minutes compared wit h placebo.  In the double -
blind period, the treatment groups will be given anIV infusio n of LY3002813 or placebofor up 
to 72weeks.
Patients whose amylo id plaque reducti on as measured by  florbetapir F18 PET scans at Visit 8 
(Week 24) and/or Visit 15 (Week 52) meet criteria will have a double -blinded dose reduction of 
LY3002813 to 700 mg or IV placebo, based on the specific level o f florbetapir F18 PET si gnal at 
that time, for the remaining duration o f the double-blind treatment period.  These dose reduction 
rules may be modified by  the sponsor based on ongoing collection of PD and safe ty data.  If 
ARIA-E occurs pri or to Visit 5 (Week 12 ), the LY3002813 dose will not be escalated.
Table AACG. 7.1shows the 2treatment regimens during t he double -blind period.
The study  also includes the use of the diagnostics flortaucipir F18 PET (for the determinat ion of 
paired helical  filament deposi ts of tau [tau PHF deposits]) and florbetapirF18PET(for the 
determinat ion of brain amylo id plaque deposi ts).  Inform ation regarding the use of these 
diagnostics in the study  is provided in Appendix 5 and Appendix 6 , respectively.
Table AACG. 7.1. Treatment Regimens, Double -Blind Period
RegimenDose
Visit 2 (Week 0) through Visit 21 (Week 76)
LY3002813 LY3002813 (700 mg intravenous infusion every 4 weeks x 3 doses, then 1400 mg 
intravenous infusion ev ery 4 weeks for up to 72 weeks)
Placebo Intravenously dosed placebo infusion ever y 4 weeks for up to72 weeks 
LY3002813 will be prepared by  anunblinded pharmacist or other qualified unblinded personnel.  
LY3002813 will be administered by  a blinded nurse or other qualified blinded personnel.  The 
investigator or his/her designee is responsible for the fo llowing:
explaining the correct use of the investigational agent(s) to the subject and/or 
legal representative
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing and co llection
at the end of the study  returning all unused medication to Lilly, or its designee, 
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law
7.1.1.Packaging and Labelling
Clinical study  materials will be l abeled according to the country ’s regulatory requirements.
I5T-MC-AACG(d)Clinical Protocol Page 50
LY30028137.1.1.1. LY3002813 Packaging and Labelling
The drug product LY3002813 is supplied  
.  The drug 
product should be stored according to instructions on the label. 
 
 
Placebo is 0.9% (normal)saline.
7.2.Method of Treatment Assignment
Patients who m eet all criteria for enrollment will be assigned a study  (patient) number at Visit 1 
and randomized to double -blind treatment at Visit 2.  Patients will be randomized to LY3002813 
or Placebo in a 1: 1ratio.  For between -group com parability for site factor, pati ent randomizat ion 
will be stratified by invest igative site.  Assignment to treatment groups will be determined by a 
computer-generated random sequence using an interactive web response system (IWRS).
The IWRS will be used to assign a dosing regimen to each patient.  Site personnel will confirm 
that they have located the correct packages by  entering a confirmat ion number found on the label 
into the IWRS.
7.2.1.Selection and Timing of Doses
Assessment of LY300281 3 safety and tolerability is a central  objective; therefore, monitoring 
100 patients on LY3002813 over 72weeks provides data to assess safet y for further clinical 
development.
The actual  time of LY3002813 dose administrati onon the day  of study visits will be recorded in 
the subject’s case report form (CRF).
Note that at visits at which cognit ive assessments are to be done, all cognit ive scales are to be 
administered before IV study  medication (LY3002813 or IV placebo) is administered.
7.2.1.1. LY3002813:  Selection and Timing of Doses
The actual  time of LY3002813 dose administrations on the day  of study visits will be recorded in 
the subject’s CRF.  Intravenous study  medication (i.e., IV placebo or LY3002813) is t o be 
administered once every  4 weeks.  Based on the permitted visit window ( see Section 2), IV study  
medication could theoreti cally be administered at a 2-week interval.  However, IV study 
medication must notbe given at a dosing interval of less than 21 days at any t ime during the 
study.  Intravenous study  medication given at a dosing interval o f less than 21 day s at any time 
during the study  will be considered a protocol deviation.  The dose of LY3002813 was chosen 
based on PK/PD and safet y from StudiesAACC and AACD ( see Section 5.5).
CCI
CCI
I5T-MC-AACG(d)Clinical Protocol Page 51
LY3002813Infusions should occur over the course of a minimum of 30 minutes.  I f a patient demonstrates an 
infusion reaction to LY3002813, rescue medicat ions may be administered at the discretion of the 
investigator (see Section 7.7). If indicated, the patient may be premedicated for subsequent 
infusions. See Section 9.4.7.1.1or contact sponsor for further guidance.  Patients should be 
observed for approximately  2hours following each infusio n of LY3002813 for the first 6
infusions.  After the first 6 doses, a minimal post -infusion observat ion time of 60 minutes will be 
required for all subsequent infusions.  However, patients who have had dosing restarted after 
ARIA-E are required to be m onitored for 2 hours following infusio n for a minimum o f 3 
subsequent infusio ns, and a minimum o f 60 minutes postinfusio n observat ion thereafter.
Sites must have resuscitat ion equipment available.
7.3.Blinding
This is a double -blind study , with design to m aintain blinding to treatment.  To preserve the 
blinding of the study , a minimal  number of Lilly  personnel will  see the randomizat ion table and 
treatment assignments before the study is co mplete.  The independent external DMC will 
potentially be unblinded for safet y evaluations and dose reduction decisio ns related to safet y.
Emergency  unblinding for AEs m ay be perform ed through the IWRS.  This opti on may be used 
ONLY if the subject’s well-being requires knowledge of the subject’s treatment assignment.  All 
unblinding events are recorded and reported by  the IWRS.
If an invest igator, site personnel performing assessments, or subject is unblinded, the subject 
must be discont inued from the study.  In cases where there are ethical reasons to have the subject 
remain in the study , the investigator must obtain specific approval fro m a Lilly clinical research 
physician (CRP) for the subject to continue in the study.
In case of an emergency , the invest igator has the sole responsibilit y for determining if unblinding 
of a patient’s treatm ent assignment is warranted for medical management of the event.  The 
patient’ssafety must always be the first consideration i n making such a determinat ion.  If a 
patient’s treatment assignment is unblinded, Lilly must be notified immediately.  If the 
investigator decides that unblinding is warranted, it is the responsibilit y of the investi gator to 
promptly docum ent the decisio n and rationale and notify Lilly as soon as possible.
7.4.Dosage Modification
7.4.1.LY3002813 Dosage Modification for ARIA -E
LY3002813 dosage modificat ions will be done for the occurrence of ARIA- E in the fo llowing 
instances shown in Table AACG.7 .2.
If a dosage reduction is required, then the LY3002813 dose will be reduced to the next lower 
dose (from 1400 mg to 700 mg or from 700 mg to placebo).
I5T-MC-AACG(d)Clinical Protocol Page 52
LY3002813Table AACG. 7.2. LY3002813 Dosage Modifications for First Occurrence of A RIA-E
ARIA-E 
SYMPTOMSARIA-E on MRI
Mild Moderate Severe
  No symptoms Continue on current dosing aLY3002813
Dose reduction a,bTemporary Discontinuation
of LY3002813
(refer to Section 8.1.1.1)b
  Mild LY3002813
Dose reduction a,bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)b
  Moderate Temporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)b
  Severe Temporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)bTemporary Discontinuation 
of LY3002813
(refer to Section 8.1.1.1)b
aInvestigat or may choose to temporarily discontinue LY3002813 after discussion with the sponsor.
bIf the patient has a second incidence of ARIA -E and has previously been dose reduced or temporarily 
discontinued from LY3002813, then LY3002813 will be permanently disc ontinued (see Section 8.1).
All Cases of ARIA -E will require unscheduled MRI scans every 4- 6 weeks until ARIA -E has 
resolved.  Further details are provided in the Operations Manual .
7.4.2.LY3002813 Dosage Modification forARIA-H
There will be no dose reductions for changes in ARIA -H.  Patients will be discontinued from 
dosing and IV administration if ARIA -H discont inuation rules are met (see Section 8.1).  Patients 
will not be re -challenged wit h LY3002813 after dose discontinuation for ARIA -H.
All new cases of ARIA- H will requi re unscheduled MRI scans every  4-6 weeks unt il ARIA-H 
has stabilized without new findings.
7.5.Preparation/Handling/Storage/Accountability
Theinvestigator or his/her designee is responsible for the fo llowing:
confirming appropriate temperature condit ions have been maintained during 
transit for all study  treatment received and any discrepancies are reported and 
resolved before use of the study  treatment.
ensuring that only participants enro lled in the study may receive study treatment 
and only authorized site staff may  supply or administer study  treatment.  All study 
treatments must be stored in a se cure, environmentally  controlled, and m onitored 
(manual or autom ated) area i n accordance with the labeled storage condit ions 
with access limited to the invest igator and authorized site staff.
I5T-MC-AACG(d)Clinical Protocol Page 53
LY3002813the investigator, inst itution, or the head of the medical inst itution (where 
applicable) is responsible for study  treatment accountabilit y, reconciliat ion, and 
record maintenance (such as receipt, reconciliat ion and final disposit ion records).
7.6.Treatment Compliance
The administration of all study  medication should be recorded in the appropriate sections of the 
electronic case report form (eCRF).
7.6.1.LY3002813 Treatment Compliance
Because dosing occurs at study  visits, patients who attend all visits and successfully  receive 
LY3002813 infusio ns are autom atically compliant withthis treatm ent.  Any infusio n at which 
75% (approximately  105mL) or more of the infusion solut ion is given will be considered a 
complete infusi on.
If a patient attends a visit but does not receive a complete infusion ( e.g., due to technical 
complications), every effort should be made to complete the infusio n within 24 hours if possible.  
If less than 75% of the infusio n solution is given, this must be recorded as an inco mplete infusio n 
on the CRF.
Missed infusio ns should be recorded on the CR F.
7.7.Concomitant Therapy
All concomitant medication taken during the study must be recorded on the Concomitant 
Medication CRF.  Patients and their study  partners will be instructed to consult the invest igator 
or other appropriate study  personnel at the site before init iation of any new medicat ions or 
supplements and before changing dose of any current concomitant medications or supplements.
To ensure standard of care for AD, use of approved treatments for AD is permitted in this study , 
and no medications are explicitly excluded from  use.  The sect ion below provides addit ional 
guidance on managing concomitant medicat ion use.
Allowed Medications.   Use of approved or standard of care treatments for AD is permitted during 
the study, provided that such m edications dose has been unchanged for 2 months before Visit 2.  
Doses of these medicat ions should remain constant throughout the double -blind period (Visit 2 
toVisit 21).
If a patient has recent ly stopped AChEIs and/or memant ine, he or she must have discont inued 
treatment at least 2 months before Visit 2.
Other vitamins, medical food, or nutraceuticals given for their possible effects on AD may be 
continued on stable doses beginning 2 months before Visit 2.
Prior to V 21, before a patient starts, stops, or changes do ses of AChEIs and/or memantine or 
other treatments for their AD, the Sponsor or designee must be contacted to determine 
whether or not the patient should continue in the study and whether or not clinical outcome 
measures should be performed.  Failure to no tify Lilly or its designee regarding starting, 
I5T-MC-AACG(d)Clinical Protocol Page 54
LY3002813stopping or changing doses of AChEIs and/or memantine or other treatments for their AD
prior to V 21will be considered a protocol deviation .
Nonmedication treatments for AD such as behavioral management are pe rmitted but are subject 
to the same restrict ions as medicat ion treatment taken for AD.
Other concomitant medicat ions that affect CNS funct ion may be given if the dose remains 
unchanged throughout the study .  Doses of these compounds should remain constant from 1 
month before screening (Visit 1).
If unforeseen starting, stopping, or changing of stable doses of drugs affect ing CNS function 
occurs pri or to V21of the study , Lilly or its designee m ust be contacted to determine whether or 
not the patient should continue in the study  and whether or not outcome measures should be 
performed.  Failureto notify Lilly or its designee regarding starting, stopping or changing 
doses of CNS medications prior to V 21of the study will be considered a protocol deviation .
Use of benzodiazepines for treatment on an as -needed basis for inso mnia or daily dosing as
anxiolytics is permitted.  Use of sedat ives or hypnotics should be avoided for 8 hours before 
administration of the cognit ive and funct ional tests unless they are given chronically.
If an infusio n reaction occurs, rescue medicat ions such as, but not limit ed to, diphenhydramine, 
epinephrine, and/or methylpredniso lone may be administered at the discret ion of the investigator.  
Administrati on of medications before an infusio n to prevent a reaction does not cause a 
discontinuat ion of the patient from the study .  If the need for concomitant medicat ion arises, 
inclusion or continuat ion of the patient may  be at the discret ion of the investigator after 
consultation wit h a Lilly CRP.  Concomitant therapy  administered to treat an infusion react ion or 
as premedicationfor infusions should be docum ented.
Excluded Medications.
IgG therapy  (also known as gamma glo bulin or intravenous immunoglobulin [IVIG]) is not 
allowed during the study .
7.8.Treatment after the End of the Study
7.8.1.Treatment after Study Completion
There is no planned open l abel extension at this time, or plan to otherwi se make LY3002813 
available to patients after conclusio n of the study .
I5T-MC-AACG(d)Clinical Protocol Page 55
LY30028138.Discontinuation Criteria
8.1.Discontinuation from Study Treatment
Possible reasons leading to permanent discontinuatio n of study  treatment:
Subject Decisio n
othe subject or the subject’s designee ;for example, legal guardian requests to 
discontinue investigat ional product.
Discontinuati on due to a hepati c event or liver test abnormalit y
Subjects who are discontinued from invest igational product due to a hepatic event or liver 
test abnorm ality should have addi tional hepatic safety data collected via CRF/electroni c 
data entry .
Discontinuati on of the invest igational product for abnormal liver tests should be 
considered by the investigator when a subject meets one of the fo llowing condi tions after 
consultation wit h the Lilly-designated m edical monitor:
oalanine aminotransferase (ALT) or aspartate amino transferase (AST) >8X 
upper limit of normal (ULN)
oALT or AST >5X ULN for more than 2 weeks
oALT or AST >3X ULN and total bilirubin level (TBL) >2X ULN or 
international normalized rati o (INR) >1.5
oALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, 
right upper -quadrant pain or tenderness, fever, rash, and/or eosinophilia 
(>5%)
oalkaline phosphatase (ALP) >3X ULN
oALP >2.5X ULN and TBL >2X ULN
oALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)
In addition, subjects will be discont inued from the investigational product in the fo llowing 
circumstances:
Treatment with LY3002813 will be permanent ly discontinued in patients with:
oa second incidence of ARIA -E after a previ ous dose reducti on or temporary 
discontinuat ion ofLY3002813
oany increase in ARIA -H accompanied by  clinically significant symptoms
o>4 new microhemorrhages, >1 new area of superficial siderosis or significant 
worsening of pre -existing superficial siderosis, or any macrohemorrhage 
regardless of symptom s
oan ARIA-E event reported as an SAE, regardless of severit y of symptoms or MRI 
findings
I5T-MC-AACG(d)Clinical Protocol Page 56
LY3002813Treatment with LY3002813 will also be permanently discont inued in pat ients with:
oProlonged acute infusio n reaction ( i.e., not responsive to medicat ion such 
as antihistamines, nonsteroidal ant i-inflammatory dr ugs, and/or narcotics 
and/or bri ef interruption of infusion).
oAdverse event or clinically significant laboratory  value, ECG resul t, physical 
examination finding, MRI finding (such as symptomat ic ischemic stroke), 
C-SSRS result, or vital sign measurement of such severit y that, in the opinio n of 
the investigator or Lilly -designated m edical monitor, continued treatment is not in 
the best interest of the patient.
oSevere non -compliance to the study  protocol that results in a safet y concern, in 
the judgment of th e investigator.
oThe patient, for any  reason, requi res a treatm ent with an excluded therapeutic 
agent and temporary  discontinuation criteria cannot be m et (see Secti on8.1.1.2).
Patients may permanently discont inue studytreatment and remain in the trial.  If LY3002813 
infusion is permanent ly discont inued but the patient remains in the study, one PK sample should 
be collected at the soonest scheduled visit regardless if serum LY3002813 is on the Schedule o f 
Activities at that visit . Dosing dates and times should be collected.  Subsequent PK sample 
collection should follow the protocol  Schedule o f Activities for serumLY3002813 co llection 
unless the sc heduled visit exceeds6 months since di scontinuat ion of infusio ns. No additional 
serum collection for LY3002813 is required oncethe patient exceeds6 months since 
discontinuat ion of LY3002813 infusions.
Subjects permanently discontinuing fro m the study prematurely for any reason shoul d complete 
AE and other fo llow-up procedures per Section 2(Schedule of Act ivities), Section 9.2(Adverse 
Events),and Section 9.4(Safety) of this protocol.
8.1.1.Temporary Discontinuation from Study Treatment
8.1.1.1. Temporary Discontinuation from LY3002813 Study Treatment Due to 
ARIA-E
Temporary discontinuation from LY3002813 treatment is allowed for ARIA- E if the ARIA -E 
meets the temporary  discontinuation criteria shown in Table AACG.7 .2.
In cases of ARIA -E where the protocol indicates continued dosing or a dose reduction rather 
than temporary discontinuation(see Table AACG. 7.2), the invest igator may choose to 
temporarily discont inue LY3002813 after discussion with the sponsor. This will require 
choosing not to dispense LY3002813 through IWRS at relevant visits.
Study drug (LY3002813) may  be restarted following a first incidence of ARIA -E at the 
discretion of the invest igatorif dosing is temporarily discont inued due to ARIA -E and there is 
complete resol ution of symptom s and radi ologic findings wit hin 16 weeks after the temporary  
drug discontinuati on.
If ARIA-E symptom s and radi ologic findings have not completely  resolved wi thin 16 weeks, 
then the patient will be permanently discontinued from LY3002813 tre atment.
I5T-MC-AACG(d)Clinical Protocol Page 57
LY3002813Study drug may be restarted at either 700 mg or placebo, double blinded, depending on the 
original study arm to which the pati ent is rando mized.
An unscheduled safet y MRI scan will be required 4 -6 weeks after dose restarts.
8.1.1.2. Temporary Discontinuation from LY3002813 Study Treatment for 
Reasons Other than ARIA -E
Temporary discontinuation from LY3002813 treatment is allowed if a short- term treatment of an 
excluded medicat ion is necessary, secondary  to hospitalization, personal  circumstance s or to 
evaluate the study  drug impact on an uncertain AE.  Study  drug may be restarted at the 
investigator’s discret ion.  If temporary  discontinuati on is due to an AE, it should be reported to 
the Lilly CRP.  Tem porary treatment discontinuation and re -starting should be documented.  
Restarting treatm ent after a di scontinuat ion period that is greater than 12 weeks should be 
discussed between the invest igator and Lilly CRP.
8.1.2.Discontinuation of Inadvertently Enrolled Subjects
If the sponsor or invest igator ide ntify a subject who did not meet enrollment criteria and was 
inadvertent ly enrolled, then the subject should be discontinued fro m study treatment unless there 
are extenuat ing circumstances that make it medically necessary for the subject to continue on 
study treatment.  If the invest igator and the sponsor CRP/CRS agree it is medically appropriate 
to continue, the investigator must obtain documented approval from the sponsor CRP/CRS to 
allow the inadvertent ly enrolled subject to continue in the study  with orwithout treatment with 
investigat ional product.
Safety follow-up is as outlined in Sect ion 2(Schedule of Act ivities), Section 9.2(Adverse 
Events) and Section 9.4(Safety) of this protocol.
8.2.Discontinuation from the Study
Patients who do not meet entry  criteria or who are excluded by  exclusion criteria from Visit 1 
tests and procedures should be discont inued from the study before randomizati on as an entry  
failure.
Patients who exhibit an y of the following condi tions during the study  that may possibly be 
related to study  drug will  be discontinued from the study, but will be encouraged to undergo final 
assessment visits and procedures as outlined in the Schedule of Activit ies (Section 2):
Patients who requi re a ferromagnetic implant or insertion of a cardiac pacemaker 
that is not MRI-compatible will be discont inued from study  drug and from the 
study;and, with the except ion of an MRI, should have end -of-therapy and/or end-
of-study procedures performed as shown in the Schedule of Act ivities (Section 2).
Subjects will also be discont inued from the study in the foll owing circumstances:
enrollment in any other clinical study invo lving an invest igational product or enrollment 
in any other type of medical research judged by sponsor n ot to be scient ifically or 
medically co mpatible with this study
I5T-MC-AACG(d)Clinical Protocol Page 58
LY3002813participation in the study needs to be stopped for medical, safet y, regulatory, or other 
reasons consistent with applicable laws, regulations, and good clinical pract ice (GCP)
investigator dec ision
othe investigator decides that the subject should be discontinued from the study
oif the subject, for any reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indication, 
discontinuat ion from the study occurs pri or to introducti on of the new agent
subject decisio n
othe subjector thesubject’s legal representative requests to be withdrawn fro m the 
study
Subjects discontinuing fro m the study prematurely for any  reason must co mplete AE and other 
safety follow-up per Secti on 2(Schedule of Activit ies), Section 9.2(Adverse Events) ,and 
Section 9.4(Safety) of this protocol .In addition, subjects discontinuing fro m the study 
prematurely should be encouraged to return to the site beginning 12 weeks after their ED visit for 
immunogenicit y and safety assessments (Visits 801through 804, as descri bed in Sect ion 5.1.3).
8.3.Lost to Follow -Up
A subjectwill be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by the study  site.  Site personnel are expected to make 
diligent attempts to contact subjects who fail to return for a schedule d visit or who were 
otherwise unable to be fo llowed up by the site.
Site personnel, or an independent third party , will attempt to collect the vital status of the subject 
within legal and ethical  boundaries for all subjects randomized, including those who did not get 
investigat ional product.  Public sources may  be searched for vi tal status inform ation.  If vital 
status is determined, this will be documented and the subject will not be considered lost to 
follow-up.
Lilly personnel will not be invo lved in anyattempts to coll ect vital status inform ation.
I5T-MC-AACG(d)Clinical Protocol Page 59
LY30028139.Study Assessments and Procedures
Section 2lists the Schedule of Act ivities, with the study  procedur es and their timing (including 
tolerance limit s for timing).
Appendix 2 lists the clinical laboratory  tests that will be performed for this study .
Unless otherwise stated in the subsect ions below, all samples collected for specified laboratory 
tests will be destroy ed within 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit happlicable laws, regulat ions, or 
laboratory  certificati on standards.
9.1.Efficacy Assessments
Screening measures used for diagnosis and establishment of study  eligibility are described 
elsewhere (Section 5.1.1.1).
Cognitive and funct ional testing will be administered using an eCOA tablet.  The audio vo ice 
recordings of the rater’s questions and the patient’s and study  partner’s responses will also be
collected via the eCOA tablet during administration of the cognit ive and funct ional testing for 
central monitoring of rater scale administration( Appendix 3 , 3.2.1).  Cognitive and funct ional 
testing for each pat ient should be perform ed at approximately  the same t ime on each day that 
testing occurs to reduce potential variabilit y.  Note that the ADAS -Cog and MMSE mustbe 
administered by  a different rater than the ADCS -ADL and CDR .  These 2 r aters should cont inue 
doing the same scale with the same pat ient throughout the study .  If possible, each assessment 
should be perform ed on a given pat ient by the same rater at each visit.  The p rincipalinvestigator 
(PI) has the responsibilit y of selecting the raterswho will administer the instruments at the site, 
as long as all  training requi rements have been met by  those raters ( Appendix 3 , 3.1.5).
When administered, cognit ive and funct ional testing should be performed first, before medical 
procedures that could be stressful for the patient ( e.g., blood draws).  Note that some procedures 
(MRI, flortaucipir F18 PET tau imaging, florbetapir F18 PET amylo id imaging) can be 
conducted on other day s within the visit window.
9.1.1.Primary Efficacy Assessments
Integrated Alzheimer’s Disease Rating Scale (iADRS; Wessels et al. 2015).   The iADRS 
represents a com posite that was developed using both a theory -driven approach (incorporating 
measures of both cognit ion and funct ion) and a data -mining approach (ident ifying the most 
sensitive combination o f scales through analysis o f data from the Alzheimer’s Disease 
Neuroimaging Init iative and the LY2062430 EXPEDITION ,EXPEDITION2 , and 
EXPEDITION3 studies).  The iADRS is a simple linear combinat ion of scores fro m 2 well-
established, therapeutically sensit ive, widely accepted m easures in AD, the ADAS -Cog13 and the 
ADCS-iADL, measuring the core domains of AD .  All items of these 2 scal es are included 
without additional weight ing of items, yielding face validit y and ease of interpretation of the 
composite relative to its components.
I5T-MC-AACG(d)Clinical Protocol Page 60
LY3002813The iADRS score will be derived from  the ADAS -Cog13and the ADCS -iADL and will be the 
primary efficacy measure.  The ADAS-Cog13and the ADCS -ADL will be the actual scales 
administered to patients.
9.1.2.Secondary Efficacy Assessments
Additional clinical outcome measures should be admin istered in the same order at every  visit, 
immediately  following assessment of the ADAS -Cog13.  To minimize missing data, the rater 
should include each measure orally wit h the patient or study  partner (as desi gnated in 
instructions), recordi ng responses appropri ately.  The same study  partner shoul d be used as the 
informant at all visits.
9.1.2.1. Alzheimer’s Disease Assessment Scale —Cognitive subscale 
(ADAS-Cog13)
The ADAS -Cog13is a rater-administered instrument that was designed to assess the severit y of 
the dysfunction in the cognit ive and noncognit ive behaviors characterist ic of persons with AD 
(Rosen et al. 1984).  The ADAS -Cog13should be administered by the same rater from visit to 
visit to reduce potential variabilit y.  The cogni tive subscale o f the ADAS, the ADAS-Cog13, 
consists of 13 items assessing areas of cognit ive function most typically impai red in AD:  
orientation, verbal memory , language, praxis, delayed free recall, digit cancellation, and maze -
completion measures (Mohs et al. 1997).  The ADAS -Cog13allows better discriminat ion of 
differences amo ng mild patients than the ADAS -Cog11, which will be included as a secondary  
outcome.  The ADAS -Cog13scale ranges fro m 0 to 85, with higher scores indicating greater 
disease severi ty.
9.1.2.2. Alzheimer’s Disease Cooper ative Study —Activities of Daily Living 
Inventory (ADCS -ADL)
The ADCS -ADL is a 23- item inventory  developed as a rater -administered quest ionnaire that is to 
be answered by the patient’s study  partner (Galasko et al. 1997, 2004).  The ADCS- ADL should 
be administered by  the same rater from  visit to visit to reduce potential variabilit y.  The ADCS -
ADL subset of items (items 7 to 23) for instrumental act ivities of daily living (ADCS -iADL) will 
be used as a secondary  efficacy measure.  The focus in the early sympt omatic AD popul ation is 
on the instrumental act ivities of daily living (iADLs) rather than the basic activities of daily 
living(bADLs), which are thought to be affected in more severe stages of the disease.  The range 
for the iADL score is 0 to 56, with l ower scores indi cating greater disease severit y.  For each of 
the specific items, the study  partner is first asked if the patient attempted the ADL during the past 
4weeks.  If the patient did attempt the ADL, the study  partner is asked to rate the patient ’s 
performance level based on a set of performance descript ions.  Scores for each item and the 
overall score for the tool are calculated.  The range for the total ADCS -ADL score is 0 to 78, 
with higher scores indicat ing greater level o f impairment.  Separa te scores for the bADLs (0 to 
22) will also be computed.
I5T-MC-AACG(d)Clinical Protocol Page 61
LY30028139.1.2.3. Clinical Dementia Rating Scale (CDR -SB)
The CDR is a semi -structured interview performed with the patient and study  partner (informant) 
that provides an index of global funct ioning (Berg e al. 1992).   The CDR should be administered 
by the same rater fro m visit to visit to reduce potential variabilit y.  The informant is queried 
about the patient’s memory , orientation, judgment and problem so lving, communit y affairs, 
home and hobbies, and personal care.   The patient’s memory, orientation, judgment, and 
problem-solving abilit y are assessed.  Hi gher scores indicate greater disease severit y.  By 
assigning a severit y score for each of the 6 domains, a total score known as sum of boxes is 
obtained—hence the a bbreviation, CDR-SB.
9.1.2.4. Mini-Mental State Examination (MMSE)
The MMSE is a brief instrument used to assess cognit ive function in patients (Folstein et al. 
1975).  The MMSE should be administered by the same rater from visit to visit to reduce 
potential variability.  The instrument i s divided into 2 sections.  The first section measures 
orientation, memory, and attenti on.  The maximum score for the first section is 21.  The second 
section tests the abilit y of the patient to nam e objects, follow verbal and writt en commands, write 
a sentence, and copy  figures.  The maximum score for the second sect ion is 9.  The range for the 
total MMSE score i s 0 to 30, wi th lower scores indicat ing great level of impairment.
9.1.3.Biomarker Efficacy Measures (Double -Blind Period)
Florbetapir F18 PET scan.  Change in amylo id burden (as assessed by  florbetapir F18 PET 
signal) will be com pared in LY3002813- and placebo -treated patients for those patients who 
undergo florbetapir F18 PET scans at baseline, Week 52 [ Visit 15], and Week 76 [Visit 21]or 
ED)as described in the Schedule of Act ivities (Section 2).
Flortaucipir F18 PET scan.  Change in tau burden (as assessed by flortaucipir F18 PET signal) 
will be co mpared in LY3002813- and placebo -treated pati ents for those patients who undergo 
both baseline and endpoint (Visit 21 [Week 76] or ED) flortaucipir F18 scans as described in the 
Schedule of Act ivities (Section 2).
Volumetric MRI .  Magneticresonance imaging of the brain will be performed according to the 
Schedule of Act ivities (Section 2). LY3002813 -and placebo -treatment effects on volumetric 
MRI will be assessed and co mpared to evaluate the loss of brain vo lume that occurs in A D 
patients.
9.1.4.Appropriateness of Efficacy Assessments
The iADRS, the primary  efficacy measure, is a simple linear combinat ion of scores fro m 2 
well-established, therapeutically  sensitive, widely accepted m easures in AD, the ADAS -Cog13 
and the ADCS -iADL, measuring the core domains of AD .  It represents a composite that was 
developed using both a theory -driven approach (incorporating measures of both cognit ion and 
function) and a data -mining approach (identifying the most sensit ive combination of scales 
throughanalysis of data fro m the Alzheimer’s Disease Neuroimaging Init iative and the 
LY2062430 EXPEDITION, EXPEDITION2, and EXPEDITION3 studies).  Composite 
endpoints have been increasingly used as primary endpo ints in clinical trials ( Freemant le et al. 
I5T-MC-AACG(d)Clinical Protocol Page 62
LY30028132003).  Liu-Seifertet al. (2017) demonstrated that the treatment effect size of the iADRS 
composite is greater than the minimum treatment effect size of its components and that above 
certain thresho lds of correlat ions of components and ratios of component effect sizes, the 
composite may outperform its components.
The secondary  efficacy measures described in Sectio n 9.1.2are established measures of 
cognitive and funct ional outcomes, as well as behavioral symptoms associated with AD 
dementia, and considered appropriate assessments for the early symptomat ic AD population.
In addition, the primary target engagement outcome is the reduction of cerebral amylo id as 
measured by quantitative amylo id PET imaging (florbetapir F18 PET SUVr) assessed at 
baseline, 24 weeks, 52 weeks and at 76 weeks after starting treatment .  The postbaseline amylo id 
PET scans are aimed to assess the time course of amylo id reduction and sustainabilit y of amyloid 
reduction.  Reducti on of paired helical filaments of cortical tau will be quantitatively assessed by  
tau PET imaging at baseline an d 76 weeks.
9.2.Adverse Events
Investigators are responsible for monitoring the safety of patientswho have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of patientsduring the study.
Investigators must document their review of each laboratory  safety report.
The invest igator remains responsible for fo llowing, through an approp riate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product or the study , or that caused the patient to discontinue the invest igational product before 
completing the study.  The patientshould be followed until the event resolves, stabilizes with 
appropriate diagnostic evaluation, or is reasonably explained.  The frequency o f follow-up 
evaluations of the AE is left to the discret ion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the informed consent form (ICF) is signed, study  site personnel  will record vi a 
CRF/electronic data entry  the occurrence and nature of each pat ient’s preexisting condit ions, 
including clinically significant signs and symptoms of the disease under treatment in the study.  
In addition, site personnel will record any  change in the condi tion(s) and any new condit ions as 
AEs. Investigators should record their assessment of the potential relatedness of each AE to 
protocol procedure, invest igational product , including radiopharmaceut ical tracers, via 
CRF/electronic data entry .
The invest igator will interpret and document whether or not an AE has a reasonable poss ibility 
of being related to study  treatment, study  device, or a study  procedure, taki ng into account the 
disease, concomitant treatment or pathologies.
I5T-MC-AACG(d)Clinical Protocol Page 63
LY3002813A “reasonable possibilit y” means that there is a cause and effect relat ionship between the 
investigat ional product, study  device and/or study  procedure and the AE.
The invest igator answers yes/no when making this assessment.
Planned surgeries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened duri ng the course of the study .
If a patient ’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via CRF/electroni c data entry , clarifying if possible, the 
circumstances leading to any  dosage m odifications, or discontinuati ons of treatment.
9.2.1.Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life-threatening experience ( i.e., immediate risk of dying)
persistent or significant disabilit y/incapacity
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in 
death or hospitalizat ion but may jeopardize the patient or may  require intervent ion 
to prevent one of the other outcomes listed in the definit ion above.  Examples of 
such medical events include allergic bronchospasm requiring intensive treatment 
in an emergency room  or at hom e, blood dyscrasias or convulsions that do not 
result in inpatient hospitalization, or the development of drug dependency  or drug 
abuse.
All AEs occurring after signing the ICF are recorded in the CRF/electronic data entry  and 
assessed for serious criteria.  The SAE reporting to the sponsor begins after the patient has 
signed the ICF and has received invest igational product , including radiopharmaceut ical tracers.  
However, if an SAE occurs after signing the ICF, but prior to receiving invest igational product, 
the SAE should be reported to the sponsor as per SAE reporting requirements and timelines (see 
Section 9.2) if it is considered reasonably possibly related to study procedure.
Study site personnel must alert Lilly or i ts designee of any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed with official notification on study -specific SAE forms.  This 24-
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow-up SAE 
information.Patients with a serious hepat ic AE should have addit ional data collected using the 
CRF/electronic data entry .
Pregnancy (during materna l or paternal exposure to invest igational product) does not meet the 
definition of an AE.  However, to fulfill regulatory requirements any pregnancy should be 
reported fo llowing the SAE process to collect data on the outcome for both mother and fetus.
I5T-MC-AACG(d)Clinical Protocol Page 64
LY3002813Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study  (thepatientdisposition CRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time af ter a subject has 
been discharged from the study , and he/she considers the event reasonably  possibly related to the 
study treatment or study  participation, the invest igator must promptly notify Lilly .
9.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse react ions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as related to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory  requirements in parti cipating countries 
require the reporting of SUSARs.  Lilly has procedures that will be followed for the 
identification,recording and expedited reporting of SUS ARs that are consistent with global 
regulations and the associated detailed guidances.
9.2.1.2. Adverse Events of Special Interest
Specific safet y topics of interest for this study  include, but are not limited to, the fo llowing:
ARIA-E
ARIA-H
Hypersensitivity (immediate and non -immediate), including infusio n-related 
reactions
Peripheral nervous system , central nervous system  and muscle effects
The topics listed above, as well as other topics which may  be subsequent ly determined by the 
sponsor, will be subject t o enhanced surveillance activit ies.  Addit ionally, the topics above will 
be analyzed for presentation in the Clinical Study  Report in accordance with the Statist ical 
Analysis Plan.
9.2.2.Complaint Handling
Lilly collects product complaints on invest igational products and drug delivery  systems used in 
clinical studies in order to ensure the safet y of study participants, m onitor quality, and to 
facilitate process and product improvements.
Patientswill be instructed to contact the investigator as soon as possible i f he or she has a 
complaint or probl em with the invest igational product so that the situation can be assessed.
9.3.Treatment of Overdose
There is no known ant idote to LY3002813.  In case of overdose, use appropriate monitoring and 
supportive therapy .
I5T-MC-AACG(d)Clinical Protocol Page 65
LY30028139.4.Safety
9.4.1.Physical and Neurological Examinations
Complete physical  examinat ions will be performed at screening, baseline, and Weeks 12, 24, 52, 
76, and ED as indicated in the Schedule of Act ivities (Section 2).  Brief physical examinat ions 
will be performed at Weeks 36 and 64.  The complete phy sical examinat ion will include 
assessment of the fo llowing:  general appearance; skin, head and neck; lym ph nodes; thy roid; 
abdomen (bowel sounds, liver and spleen palpat ion); back (costovertebral angle tenderness); and 
musculoskeletal, cardiovascular, and respiratory  systems.  The brief physical examinat ion will 
include assessments of the skin, lungs, cardi ovascular system, and abdo men (bowel sounds, liver 
and spleen palpat ion).
Complete neurol ogical examinat ions will be performed as indicated in the Schedule of Activit ies 
(Section 2).  The examinat ions will include a thorough assessment of gait, balance, coordinat ion, 
cranial nerves, sensory  and motor system s, and reflexes.  If necessary given the training of the 
principal investigator, a neurologist w ill be consult ed in the event of significant new findings.
If a clinically meaningful change in an MRI is noted during the study, an addit ional full 
neurological exam will be performed as soon as possible, along with any  other medical follow-
up deemed necessary by the invest igator.
9.4.2.Electrocardiograms
For each patient, 12 -lead digital ECGs will be co llected as triplicates during the double -blind 
period according to the Schedule of Act ivities (Section 2).  Patients must be supine for 
approximately  5 to 10 minutes before ECG collect ion and remain supine but awake during ECG 
collection.
Consecutive replicate ECGs will be obtained at approximately 1 -minuteintervals.  
Electrocardiograms may be obtained at addit ional times, when deemed clinically necessary .  
Collection of more ECGs (more replicates) than expected at a particular time point is allowed 
when needed to ensure high -quality records.
Electrocardiog ramswillinitiallybe interpreted by  a qualified physician (the investigator or 
qualified designee) at the site as soon after the time of ECG collection as possible, and ideally  
while the patient is st ill present, to determine whether the subjectmeets entry  criteriaatthe 
relevant visit(s) and for immediate patientmanagement, should any clinically relevant findings 
be identified.
After enro llment, if a clinically significant increase in the QT/corrected QT (QTc) interval fro m 
baseline or other clinically significant quant itative or qualitat ive change fro m baseline is 
identified, the patientwill be assessed by  the investi gator for symptoms ( e.g., palpitations, near 
syncope, syncope) and to determine whether the patientcan continue in the study .  The 
investigator or qualified designee is responsible for determining if any change in patient 
management is needed.  T he investigator or qualified designee must document his/her review of 
I5T-MC-AACG(d)Clinical Protocol Page 66
LY3002813the ECG printed at the time of evaluat ion from at least 1 of the replicate ECGs from each time 
point.
All digital ECGs will be electronically  transmittedto adesignated centralECG laboratory.  A
cardiologist at the central ECG laboratory  will then conduct a full overread on 1 of the replicates 
(including all intervals ).  A report based on data from this overread will be issued to the 
investigat ive site.  For each set of replicates, the cardiologist will determine the RR and QT 
intervals, and heart rate on the ECGs that were not fullyoverread.  These data are not routi nely 
reported back to the invest igative site.  All data from the overreads will be placed in the Lilly 
database for analy tical and study  report purposes.
When there are differences in ECG interpretationbetween the invest igator (or qualified 
designee) and the cardiologist at thecentral ECG laboratory , the investigator’s (or qualified 
designee’s) interpretation will be used for study  entry and immediate patient management.  
Interpretations from the cardio logist at the central  ECG laboratory  will be used for data analysis 
and report writ ing purposes.
The investigator (or qualified designee )must document his/her review of 1 of the replicate ECGs 
printed at the time of co llection, the final overread ECG report issued by the central ECG 
laboratory ,and any alert reports.
9.4.3.Vital Signs
Vital signs, including temperature, will be measured at all visits.
9.4.3.1. Blood Pressure
Sitting blood pressure and pul se will be measured after 5 minutes in the sitting posit ion at all
visits.  In addit ion, orthostatic blood pressure and pulse will be measured supine and standing at 
designated visits, as detailed in the Schedule of Activit ies (Section 2).
Orthostatic Blood Pressure Monitoring:  For orthostatic blood pressure monitoring, subjects 
should be supine for at l east 5 minutes and stand for at least 3 minutes prior to taking the 
respective measurements.  If the subject feels unable to stand, only supine vital signs will be 
recorded.
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or 
posture-induced symptoms.
Any clinically  significant fi ndings fro m vital signs measurement that result in a diagnosis and 
that occur after the patient receives the first dose of study treatment should be reported to Lilly or 
its designee as an AE via CRF/electronic data entry .
9.4.3.2. Height, Weight, and Body Temperat ure
Height and body  weight will be m easured.  Measurements should be taken without shoes and, 
when possible, the same scale should be used for all measurements.  Body mass index (BMI) 
will be calculated from the height and body  weight.  Tem perature will be recorded using an oral 
or tympanic (or other acceptable route) thermometer.
I5T-MC-AACG(d)Clinical Protocol Page 67
LY3002813Body weight will be collected on the laboratory  requisition forcreatinine clearance calculat ions.  
Any body  weight data entered into the eCRF will be used for the overall data an alysis.
9.4.4.Laboratory Tests
For each patient, laboratory  tests detailed in ( Appendix 2 ) should be conducted according to the 
Schedule of Act ivities (Section 2).
With the exception o f laboratory test resul ts that may  unblind the study , Lilly or i ts designee will 
provide the invest igator with the results of laboratory  tests analyzed by  a central vendor, if a 
central vendor is used for the clinical trial.
Any clinically  significant findings from laboratory tests that result in a diagnosis and that occur 
after the pati ent receives the first dose of i nvestigational product should be reported to Lilly or its 
designee as an AE via CRF/electronic data entry .
9.4.5.Immunogenicity Assessments
Where local regulat ions and ERBs allow, at the visits and times specified in the Schedule o f 
Activities (Section 2), venous blood sam ples of approximately  10 mL each will be collected to 
determine antibody  production against LY3002813.  To interpret the results of immun ogenicity, 
a venous blood sample will be collected, if warranted, at the same time po intsto determine the 
serum concentrati ons of LY3002813.  All samples for immunogenicit y should be taken predose 
when applicable and possible.
Immunogenicity will be assessed by  a validated assay  designed to detect ADAs in the presence 
of LY3002813 at a l aboratory  approved by  the sponsor.  Antibodies may  be further characteri zed 
and/or evaluated for their abilit y to neutralize the activit y of LY3002813.   The testing paradig m 
is outlined in Section10.3.4.6.
Samples will be retained for a m aximum of 15 years after the last patient visit, or for a shorter 
period if loca l regulations and ERBs allow, at a facilit y selected by  the sponsor.  The durati on 
allows the sponsor to respond to future regulatory  requests rel ated to LY3002813 .  Any samples 
remaining after 15 y ears will be destroy ed.
9.4.6.Other Tests
9.4.6.1. Columbia Suicide Sever ity Rating Scale –Adult Version
Consistent with Food and Drug Administration (FDA) regulatory  guidance (FDA 2012), any  
occurrence of suicide -related thoughts and behavio rs will be assessed as indicated in the 
Schedule of Act ivities (Section 2).  The C-SSRS is a scale that captures the occurrence, severit y, 
and frequency  of suicide-related thoughts and behaviors during the corresponding assessment 
period.  The scal e includes sugges ted questi ons to elicit the ty pe of informat ion needed to 
determine if a suicide -related thought or behavior occurred.
The first time the scale is administered in this study , the C-SSRS “Baseline” versio n will be 
used, and the findings will const itute the baseline assessment.  The C -SSRS “Since Last Visit” 
scale will be used for all subsequent assessments.
I5T-MC-AACG(d)Clinical Protocol Page 68
LY3002813The C-SSRS will be administered to the patient with the study  partner/study  informant present or 
available by  telephone, after the cognit ive and function al assessments.  Responses from both the 
study partner/study  informant and patient will be considered when administering the scale.  If a 
suicide-related though t or behavior is ident ified at any time during the study , a thorough 
evaluation will be performe d by a study  physician, and appropriate medical care will be 
provided.
The Lilly Self -Harm Supplement shoul d be completed every  time the C -SSRS is administered.  
If, based on administration of the C -SSRS, it is determined that suicide -related behaviors hav e 
occurred, then the Lilly Self -Harm Follow-Upform will be used to collect additional information 
to allow for a more complete assessment of these behaviors.
9.4.6.2. Magnetic Resonance Imaging
Magnetic resonance imaging o f the brain will be performed according to the Schedule o f 
Activities (Section 2) and as clinically  indicated.  This technology  will be used to check for 
evidence of ARIA-H or ARIA -E, and other clinically relevant inclusio n/exclusion and safet y 
findings(The MRI data will also be used to calculate brain vo lumes, as noted in Section 9.1.3).
The MRI scans will be reviewed by  the invest igator or qualified designee for immediate patient 
management.  Any clinically significant findings noted at baseline that result in a diagnosis 
should be recorded as a preexist ing condit ion or AE.  After the MRI scan is read locally, t he MRI 
scans will be sent for analysis to a centralized MRI vendor designated by  Lilly.  Final MRI 
eligibility at screening will be determined by the centralized MRI vendor designated by  Lilly and 
the MRI results will be reported to the site as “does” or “does not” meet MRI eligibilit y criteria.  
Specific analyses of the scans including assessments of ARIA -H and ARIA -E and calculat ions of 
brain volumes will be interpreted by  the centralized MRI vendor for data analysis and report -
writing purposes.  Results of centrally  read MRIs regarding patient care/safety  will be reported 
back to si tes.
9.4.6.3. Ophthalmological E xamination
While the BACE inhibitor LY3202626 is no longer being administered in this study (see 
Section5.1),ophthalmological examinations in patients who previously received LY32026 26 or 
oral placebowill be perform edat the next scheduled examinat ion time po int aftertheir final dose 
of oral study medication(see the Schedule of Activit ies [Section 2]).  Patients who received 
LY3202626/oral placebo after their Visit 9 ophthalmo logicalexamination are to have an 
unscheduled ophthalmo logical examinat ion at the next available opportunit y.  Patients screened 
or randomized under the current amendment are not required to undergo any  ophthalm ological
examinations at baseline or any  other study  visits.
Patientswho previously received LY3202626 or oral placebo will undergo comprehensive 
ophthalmo logical examinations performed by an ophthalmo logist or optom etrist (where 
permitted by  law) to assess visual function and mo rphology.  Schedul ed examinat ions will 
include the fo llowing:  visual acuit y, intraocular pressure, dilated funduscopic exam (dilat ion 
only performed in patients without contraindicat ion to mydriat ics), slit lamp exam , color 
photography  of the retina, and optical coherence tomography  (OCT) or equivalent; examinat ions 
I5T-MC-AACG(d)Clinical Protocol Page 69
LY3002813willalso include col or vision assessment.  Assessments will preferablybe perform ed by the same 
ophthalmo logist or optom etrist for each pat ient’s visit.  Patients who complain of visio n 
disturbance, such as change in field of visio n, color, acuity or anything potenti ally localizable to 
the retina, during the clinical trial should be referred to the ophthalmo logist or optom etrist 
(where permitted by  law)for unscheduled evaluat ion.
Data from the ophthalmo logicalexamination visits will be provided fro m the local 
ophthalmo logist or optom etrist to the invest igator.
The local ophthalm ologistor optometrist will review the color photography  and OCT to ai d in 
immediate patient management.  Addit ionally, the color photography  of retina and OCT will be 
analyzed by a central reader.
Unblinded results of the eye safet y data will be r eviewed by  theDMC.
Any clinically  significant findings that result in a diagnosis should be reported to Lilly  or its 
designee as a pre -existing condit ion or AE vi a eCRF per Section 9.2.  The PI will make all final 
determinat ions of AEs in consultat ion with performing eye examiner, if applicable.
9.4.6.4. Dermatological Examination
While the BACE inhibitor LY3202626 is no longer being administered in this stu dy, complete 
dermatological examinations in patients who previously received LY3202626 or oral placebo 
will be performed at the next scheduled examinat ion time po int aftertheir final dose of oral  study 
medication(see the Schedule o f Activities [Section 2]). Patients who received LY3202626/oral 
placebo after thei r Visit 8 dermatological examinatio n are to have an unscheduled dermatological 
examinationat the next available opportunit y.  Patients screened or randomized under the current 
amendment are not required to undergo any  skin exams at baseline or any  other study  visits.
Thisexamination will preferably be perform ed by the same dermatol ogist for each patient’s visit.  
All dermatologicalexaminations must be performed by a dermatologist who will inspect the 
patient’s uncl othed full body using an ul traviolet (UV) light.  The init ial examinat ion will 
include Fitzpatrick skin -type classifica tion scale.
At each examinat ion, abnormal hypopigmentation will be assessed by location, percentage of 
body surface area involvement, degree (partial/decreased pigmentation to complete 
depigmentation), and other findings in or around the hypopigmented area (such as redness or 
induration).  A static physician’s global assessment (sPGA) will be used to determine the 
patient’s overall hypopigmentation severit y at a given time po int using a visual analog scale 
(VAS) ranging from 0 to 100.  In addit ion, patientsnoted to have evidence of hypopigmentation 
will be asked to record how bothersome they  find the hypopi gmentation on a VAS ranging fro m 
0 to 100.  Skin photographs may be taken as appropriate for generating supporting 
documentation, but not for the purpose of primary clinical dermatologic evaluat ion or for data 
generation or analysis.  A punch biopsy  may be obtained at the di scretion of the dermatologist.
Unblinded results of the dermatological safet y data will be reviewed by the DMC.
I5T-MC-AACG(d)Clinical Protocol Page 70
LY3002813Any clinically  significant findings that result in a diagnosis should be reported to Lilly  or its 
designee as a pre -existing condit ion or AE vi a eCRF per Section 9.2.  The PI will make all final 
determinat ions of AEs in consultat ion with the dermatol ogist.
9.4.7.Safety Monitoring
Lilly will periodically  review evolving aggregate safet y data within the study  by appropriate 
methods.
In the event that safet y monitoring uncovers an issue that needs to be addressed by unblinding at 
the group level, only members of the data monitoring board (an advisory  group for thi s study 
formed to protect the integrity  of data; refer to Interim Analyses section [Section 10.3.6]) can 
conduct addit ional analyses of the safet y data.
Lilly will review SAEs wit hin time frames mandated by co mpany procedures.  The Lilly clinical 
research physician or scientist will, as appropriate, consult with the functionally independent 
Global Patient Safet y therapeutic area physician or clinical scient ist, and periodically review:
trends in safety  data
laboratory  analytes including bl ood hematology, chemistry , andurinalysis
AEs including mo nitoring of hypersensit ivity and infusio n reactions, AEs 
associated with anti-LY3002813 ant ibodies (immunogenicit y), ARIA -H, 
ARIA-E, ECG findings, neurological findings, hemorrhagic stroke, 
microhemorrhage ( cerebral microhem orrhage, cerebellar microhemorrhage, brain 
stem microhem orrhage) as i dentified by  investigator, and suicide -related thoughts 
and behaviors.
9.4.7.1. LY3002813 Hypersensitivity (Immediate and Non -immediate), Including 
Infusion-Related Reactions
9.4.7.1.1. Premedication for Infusio ns
Premedication for dosing is not planned.  However, if an infusio n reaction occurs, appropriate 
medication may be used as determined by the study  investigators (see Section 7.7).  The patient 
may be premedicated for subsequent infusio ns.  If infusio n reactions are observed, but review of 
the data suggests that dosing may  continue, administration of medicines such as acetaminophen 
(500 to 1000 mg) an d/or an ant ihistamine, and/or methylpredniso lone (or other corticosteroid) 
may be administered before starting subsequent infusionsat the discret ion of the invest igator.  
Any premedicat ion given will be documented as a concomitant therapy (see Sect ion 7.7).
9.4.7.1.2. Management of Infusion Reactions
There is a risk of an infusio n reaction wit h any biological agent; therefore, all pat ients should be 
monitored closely.  Symptom s and signs that may  occur as part of an infusio n reaction include, 
but are not limited to, fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, 
throat irritation, rash, pruritus, myalgia, and dizziness.  In the event th at an infusio n reaction 
occurs, the fo llowing guidance should be fo llowed:
I5T-MC-AACG(d)Clinical Protocol Page 71
LY3002813the investigational product infusion should be slowed or stopped, depending on the 
symptoms/signs present
if slowed, the infusio n should be completed at the sl ower rate, as tol erated and 
documented in the CRF
if stopped, no further attempts to administer the investigational product will be made, and 
this will be docum ented in the CRF
supportive care should be emplo yed in accordance with the symptoms/signs.
Management of the infusio nreaction should proceed according to the severit y of the reacti on as 
per the flowchart in the Manual o f Operations.  This may include, but is not limited to, rescue 
medications such as diphenhydramine, epinephrine, and/or methylpredniso lone.
Additional data should also be collected via the CRF/electronic data entry . Please see the 
Operations Manual  for more detail.
Additional, unscheduled stored serum samples for possible immune safet y laboratory  testing 
(including but not limited to β try ptase, total  immunoglobulin E, and immune complex testing) 
should also be collected as close to the onset of the event as possible, but within 120 minutes ,
and 4-6 weeks after moderate or severe infusio n reactions.
9.4.7.2. LY3002813 Immunogenicity
Patients are to return to the si te for immunogenicit y and safety follow-up visits(Visit 801
through Visit 804) beginning at Week 88 (or 12 weeks after their last dose of LY3002813 ) for 
collection of blood samples for anti-drug antibody (ADA; anti-LY3002813 ant ibody) and PK
measurement , assessment of adverse events , C-SSRS,concomitant medicat ions, and vital signs. 
The results of ADA testing remain blinded.
In order to preserve the blind, patients will need to complete Visits 801 through804 until all 
patients in the trial have reached Visit 21and datalock for the treatment period has been 
achieved. After datalock, the central laboratory  will notify the sites and sponsor (or desi gnee) as 
to whether a patient requires addit ional clinic visi ts beyond Visit 801, or meets criteria for 
discharge from  immunogenicit y follow-up.A patient will stop immunogenicit y follow-up visits 
when he or she either completes 3 addit ional quarterly visit s (e.g., Week 100, Week 112, and 
Week 124) or completes a visit at which his or her ADA returns to baseline (2 -fold titer from 
baseline), whichever occurs first.  Each subsequent visit after V801 will be scheduled only for 
those patients who meet the criteria for continued testing.  Once the patient meets the criteria for 
discharge from  follow-up, eithera telephone contact or clinic visit should be conducted to 
complete the pati ent’s part icipation in the study.  See the Schedule of Activit ies (Section 2) for 
the timing of events and the measures to be assessed.
Treatment -emergent ADAs are defined in Sect ion 10.3.4.6.  A PK sample may be collected at 
the follow-up immunogenicit y assessment(s) if warranted and agreed upon between both the 
investigator and sponsor.
In the event of drug hypersensit ivity reactions (immediate or non -immediate), addit ional samples 
will be co llected as close to the onset of the event as possible, but within 120 minutes, at the 
I5T-MC-AACG(d)Clinical Protocol Page 72
LY3002813resolution of the event, and 4-6 weeks following the event.  Instructions for the collection and 
handling of blood samples will be provi ded by the sponsor.  The actual date and time (24 -hour 
clock time) of each sampling will be recorded. In the event of a finding of hypersensit ivity, the 
investigator is to complete the CRF regarding the presence or absence of symptom s related to the 
hypersensit ivity.
9.4.7.3. Hepatic Safety Monitoring
If a study  patient experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X 
ULN, liver testing ( Appendix 4 ) should be repeated wi thin 3 to 5 days including ALT, AST, 
ALP, TBL, direct bilirubin, gamma -glutamyl transferase, and creat ine kinase to confirm the 
abnormality and to determine if it is increasing or decreasing.  If the abnormalit y persists or 
worsens, clinical and laboratory  monitoring shoul d be initiated by the invest igator and in 
consultation wit h the study  medical mo nitor.  Monitoring of ALT, AST, TBL, and ALP should 
continue until levels normalize or return to approximate baseline levels.
Hepatic Safety Data Collection
Additional safety data should be co llected via the CRF/electronic data entry if 1 or more of the 
following condit ions occur:
elevation of serum  ALT to ≥5X ULN on 2 or more consecutive blood tests
elevated serum  TBL to ≥ 2X ULN (except for cases of known Gilbert’s 
syndrome)
elevation of serum  ALP to ≥2X ULN on 2 or more consecutive blood tests
patient discont inued from treatment due to a hepatic event or abnormalit y of 
liver tests
hepatic event considered to be a SAE
9.4.7.4. Amyloid -Related Imaging Abnormalities (ARIA- E and ARIA -H)
To ensure patient safet y and to com ply with regulatory  guidance, the investigator is to consult 
with the Lilly-designated Medi cal Monitor regarding collect ion of specific reco mmended clinical 
information and follow-up MRIs.  In the event of a finding of ARIA -E on MRI, the investigator 
is to complete the CRF regarding the presence or absence of symptoms related to the ARIA -E.  
While most cases of ARIA -E are asymptomat ic, when sy mptoms do occur, they  are reported to 
be most commonly headache, worsening of cognit ive function, alteration of consciousness, 
seizures, unsteadiness, and vo miting.  Even when symptomat ic ARIA-E is present, in most cases, 
treatment is not required bey ond adose reduction (see Section 7.4.1) or temporary  (see 
Section8.1.1.1)or permanent (see Secti on 8.1) discontinuat ion of the LY3002813 treatment until 
the imaging abnormalit ies have reso lved.  If a patient simultaneously develops more than one of 
the symptom s suggestive of ARIA -E, then an unscheduled MRI should be performed.  A single 
symptom suggestive of ARIA -E of sufficient severit y may also warrant an MRI.
I5T-MC-AACG(d)Clinical Protocol Page 73
LY3002813If the above -mentioned sympt oms are reported, and ARIA -E is suspected, then the abnormalit y 
is best detected by  fluid attenuation inversio n recovery (FLAIR) sequences on MRI and ARIA -H 
is best detected with the T2* gradient -recalled echo on MRI.
An unscheduled MRI with these imaging sequences should be obtained upon suspicion o f ARIA.  
If ARIA is present, it is reco mmended to repeat MRIs with these sequences every 4 to 6 weeks 
until resolution of ARIA -E or stabilizat ion of ARIA -H is docum ented.  For asymptomat ic or 
mild symptoms, the patient can be observed; for moderate symptoms associated with ARIA -E, 
the use of oral or IV steroids can be considered.  In the case of severe symptoms associated with 
ARIA-E, it is recommended to hospitalize the patient for close observat ion and consider the use 
of IV steroi ds such as high -dose dexamethasone or a similar agent.
The unscheduled MRI should be performed in the same manner as the current ly scheduled MRIs 
in the protocol ,which includes sending the images for central review.
9.4.8.Appropriateness of Safety Assessments
The clinical safet y measurements (AE reporting, physical examinat ions, neurological 
examinations, vital signs, ECGs, and clinical safety  laboratory  tests [incl uding immunogenicit y]; 
Section9.2and Section 9.4) are well-established methods in drug development research and ar e 
standard procedures for clinical trials.
Performance of MRIs is indicated based on the potent ial for the occurrence of ARIA during 
treatment with LY3002813.  Therefore, Study AACG will include serial MRIs beginning at 
baseline and fo llowing dosing accord ing to the Schedule of Act ivities for assessment of ARIA.
LY3002813 is an ant ibody therapy.  As noted previously, a high prevalence of LY3002813 
ADAs was observed in Study  AACC and AACD; therefore, immunogenicit y analyses are 
indicated.  Blood samples for the assessment of immunogenicit y will be taken at regular intervals 
throughout the dosing and fo llow-up periods.
Performance of ophthalmo logical and dermatological examinat ions isindicated in subjects who 
were previously  treated wi th LY3202626, based on t he potential for the occurrence of adverse 
retinal effects and hypopigmentation, respect ively, during treatment with LY3202626.   While 
LY3202626 is no longer being administered in this study ,dermatological and ophthalmological 
examinations in subjects who previously received this therapy or oral placebowill be performed 
at the next scheduled examinat ion time po intaftertheir final dose of oral  study medication, in 
accordance with the Schedule o f Activities (Section2).  Patients who received LY3202626/oral 
placebo after thei r Visit 8 or 9 derm atological or ophthalm ological examination are to have an 
unscheduled examination at the next available oppo rtunity.  Patients screened or randomized 
under the current amendment are not required to undergo any  dermatologicalor 
ophthalmo logicalexaminations at baseline or any  other study  visits.
9.5.Pharmacokinetics
At the visits and times specified in the Schedule of Activities(Section 2),venous blood samples 
of approximately  4 mL each will be collected to determine the serum concentrations of 
I5T-MC-AACG(d)Clinical Protocol Page 74
LY3002813LY300281 3.  Instructions for the collect ion and handling of blood samples will be provided by 
the sponsor .  The actual date and time (24 -hour clock time) of each sampling will be recorded.
Drug concentration informat ion that may unblind the study  will not be reported to invest igative 
sites or blinded personnel unt il the study has been unblinded.
A maximum of 3 blood samples per patient may be drawn at addit ional time points during the 
study, if warranted and agreed upon between both the invest igator and sponsor.  Instructions for 
the collection and handling of blood samples will be provi ded by the sponsor.
If LY3002813 infusio n is permanent ly discont inued but the patient remains in the study, one PK 
sample should be co llected at the soonest scheduled visit regardless if serum LY3002813 is on 
the Schedule of Act ivities at that visit . Dosing dates and t imes should be collected.  Subsequent 
PK sample co llection should fo llow the protocol  Schedule o f Activities for serum LY3002813 
collection unless the scheduled visit exceeds6 months since discontinuati on of infusions. No 
additional serum collection for LY3002813 is required oncethe patient exceeds6 months since 
discontinuat ion of LY3002813 infusions.
Bioanalyticalsamplescollected tomeasureLY3002813 or LY3202626 concentrations will be 
retained for a maximum of1yearfollowinglastsubject visit for the study.During this time, 
samplesremaining after the bioanalyses m aybeusedforexploratory analyses such as 
metabolism, protein binding, or bioanalytical method development/validat ion work.
9.6.Pharmacodynamics
9.6.1.Clearance of Amyloid De posits
Florbetapir F18 PET provi des quant itative assessment of amylo id plaque deposi tion in the brain 
and can serve as a PD bio marker of clearance of amylo id deposits.
Clearance of amylo id deposits (as assessed by  florbetapir F18PET signal) will be com pared in 
LY3002813 -and placebo -treated pati ents for those pati ents who undergo baseline, Visit 8 (Week 
24), Visit 15 (Week 52) and endpoint Visit 21(Week 76) or ED florbetapir F18PET scans as 
described in the Schedule of Act ivities (Section 2).
9.6.2.Accumulation of Tau Deposits
Flortaucipir F18 PET provi des quant itative assessment of tau PHF in the brain and can serve as a 
PD biomarker of accumulat ion of tau deposits as AD progresses.
Extent of accumulation o f tau PHF deposits (as assessed by flortaucipir F18PET signal) will be 
compared in LY3002813- and placebo -treated patients for those patients who undergo baseline 
and endpo int Visit 21 (Week 76) or ED) flortaucipir F18PET scans as described in the Schedule 
of Activities (Section 2).
I5T-MC-AACG(d)Clinical Protocol Page 75
LY30028139.7.Pharmacogenomics [OR] Genetics
9.7.1.Apolipoprotein E Genotyping
Apolipoprotein E (APOE) genotyping is a mandatory  part of this study , unless country -specific 
laws and regulations prohibit this t ype of testing.  Blood sampling for APOE genotyping will be 
performed as shown in the Schedule of Act ivities(Section 2).  Neither patients nor investigators 
will receive the genoty pe results unless there is a country -specific law or regulat ion that requires 
notification o f the results.  Failure to collect samples for APOE will not be considered a protocol 
deviation if country -specific regulat ions prohibit the testing of genet ic material or transportation 
of such material outside of the country .
9.7.2.Whole Blood Samples for Pharmacogenetic Research
A whole bloodsample will be collected for pharmacogenet ic analysis as specified in the 
Schedule of Act ivities (Section 2) where local regulations allow.
Sampleswill notbe used to conduct unspecified disease or populat ion genetic research either 
now or in the future.  Samples will be used to investigate variable response to LY3002813 and to 
investigate genet ic variants though t to play a role in AD.  Assessment o f variable response may 
include evaluat ion of AEs or differences in efficacy.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by the invest igator site personnel.
Samples will be retained at a facilit y selected by  Lilly or its designee for a m aximum of 15years 
after the last patient visit for the study , or for a shorter period if local regulations and/or 
ERBs/invest igational review boards (IRBs) impose shorter time limits.  This retention period 
enables use of new techno logies, response to regulatory  questions, and invest igation of variable 
response that may not be observed unt il later in the development of LY3002813 and LY3202626 
or after LY3002813 and LY3202626 beco me commercia lly available.
Molecular techno logies are expected to improve during the 15 -year storage period and therefore 
cannot be specifically  named.  However, exist ing approaches include who le genome or exome 
sequencing, genome wide association studies, and candida te gene studi es.  Regardl ess of 
technology utilized,genotyping data generated will be used only for the specific research scope 
described in this sect ion.
9.8.Biomarkers
Biomarker research is performed to address questions of relevance to drug disposition, target 
engagement, PD, mechanism of act ion, variabilit y of patient response (including safety ), and 
clinical outcome.  Sample co llection is incorporated into clinical studies to enable examinat ion of 
these questions through measurement of bio molecules including deoxy ribonucleic acid (DNA), 
ribonucleic acid (RNA), proteins, lipids, and other cellular elements.
Serum, plasma, and who le blood RNA samples for bio marker research will be collected at the 
timesspecified in the Schedule of Act ivities (Section 2)where local regulat ions allow.
I5T-MC-AACG(d)Clinical Protocol Page 76
LY3002813Samples will be used for research on the drug target, disease process, variable response to 
LY3002813 and/or LY3202626, pathways associated with AD, mechanism o f action of 
LY3002813 and LY3202626, and/or research method or in validat ing diagnost ic tools or assay(s) 
related to AD.
All samples will be coded with the patient number.  These samples and any data generated can 
be linked back to the patient only by  the invest igator site personnel.
Samples will be retained at a facilit y selected by  Lilly or its designee for a m aximum 15 years 
after the last patient visit for the study , or for a shorter period if local regulations a nd ERBs 
impose shorter time limits.  This retention period enables use of new technologies, response to 
regulatory questions, and invest igation of variable response that may not be observed unt il later 
in the development of LY3002813 and LY3202626 or after LY3002813 and LY3202626 beco me 
commercially  available.
9.9.Medical Resource Utilization and Health Economics
Dependence, or the level o f assistance required by  a patient, has been suggested as a construct 
for assessing the effect of AD treatment.  The process of increasing dependence on others is 
intended as a com plementary  measure to exist ing clinical measures in order to help explain the 
impact of AD on economic issues such as the risk of inst itutionalization and caregiver burden 
(McLaughlin et al. 2010; Spa ckman et al . 2013).  Recent ly, the Alzheimer’s Disease Cooperative 
Study Activities of Daily Living Inventory  (ADCS-ADL)scores were used to map individuals 
into one of six dependence levels (0 to 5):  Level 0 –No iADL/bADL impairment; Level 1 –
Some supervision needed on i solated iADLs; Level 2 –Supervisio n on multiple iADLs or l oss of 
at least 1 househo ld activity; Level 3 –Supervisio n on all types of iADLs or homebound; Level 
4 –Supervisio n on some bADLs; and Level 5 –Impaired transfer or com plete incontinence 
(Kahle-Wrobleski et al. 2015). An approach to transforming continuous funct ional scale scores 
into discrete l evels of dependence was examined previously in a lo ngitudinal observat ional 
study, with preliminary  results suggesting acceptable vali dity and progressi on in dependence 
level over time (Kahle -Wrobleski et al. 2017). At baseline, 49.6% of those with mild AD 
dementia were dependence level 2 and 42.7% were at levels 3 or 4. At 18 months, the 
proportion of patients at level 2 declined to 3 1.2% while that at levels 3 and 4 rose to 
58.8%.Analyses will be conducted to examine changes in dependence levels across the trial 
population as well as potential differences on dependence level by treatment group assignment.
I5T-MC-AACG(d)Clinical Protocol Page 77
LY300281310.Statistical Considerations
10.1.Sample Size Determination
Approximately  250subjects will be enro lled and rando mized in a 1:1 ratio to the 2treatment 
arms (placeboandLY3002813).  It is expected that approximately 200subjects will co mplete 
the double-blind treatment period of the study  (approximately  100 per treatm ent arm). This 
sample size will provide approximately  84% power to dem onstrate that theactive treatment arm 
has a ≥ 0.6 posterior probabilit y of slowing do wn iADRS progression over placebo by at least 
3points.  The assumpt ion for power calculat ion is that mean progression levels in theplacebo 
and LY3002813 arms are approximately  12 and 6 points (50% sl owing) over 18 m onths, 
respectively , with common standard deviation of 17.  If theactive treatment arm isplacebo-like 
with no efficacy , the probabili ty of passing the efficacy  criterion specified above (i.e., false 
positive) is approximately 6%.  The simulat ion for the power calculat ion and sample size 
determination was carried out in FACTS Version 6.0.
10.2.Populations for Analyses
For purposes of analysis, in general the fo llowing popul ations are defined unless otherwise 
specified:
For efficacy  analysis, the Full Analysis Set will group patients according to ran domized 
treatment assignment(LY3002813 or placebo) , even if the patient does not take the assigned 
treatment, does not receive the correct treatment, or otherwise does not follow the protocol.  
When change fro m baseline is assessed, patients will be inclu ded in the analysis only  if both a 
baseline and at least 1 valid post- baseline measure are available.
For safety analysis, all patients who received at least 1 dose of rando mized study treatment 
(LY300281 3 or placebo) will be included in the safet y analysis set.  In safet y data presentati ons, 
erroneously treated patients (e.g., those rando mized to “Treatment A” but actually given 
“Treatment B”) will be accounted for in their actual treatment groups.
There were approximately 4 8patients randomized before the removal o f LY3202626 treatment 
in protocol amendment (d)(about 16 each in the LY3002813 and LY3202626 combinat ion 
therapy arm, LY3002813 m onotherapy arm, and placebo arm ).Patients alreadyrandomized to 
the former LY3002813 monothe rapy arm and placebo arm will be pooled with pat ients 
randomized after protocol amendment (d) to form the Full Analysis Set and safet y analysis set 
specified above . Data from patient srandomized to the LY3002813 and LY3202626 
combinationtherapy arm will be summarized sep arately and will not be included in treatment 
comparisonson efficacy  and safet y endpoints.The total number of patients to be randomized in 
the study is approximately  266. 
I5T-MC-AACG(d)Clinical Protocol Page 78
LY300281310.3.Statistical Analyses
10.3.1.General Statistical Considerations
Unless otherwise noted, all p airwise tests of treatment effects will be conducted at a 2 -sided 
alpha level of0.05; 2-sided CIs will  be displayed wi th a 95% confidence level. All tests of 
interactions between treatment and other factors will be conducted at an alpha level o f 0.05.  
Bretz’ graphical approach may  be utilized to provide strong control of the study wise Type I 
error rate for the primary  and key secondary  hypotheses at al pha level of 0.05 (Bretz et al. 2009; 
Bretz et al. 2011).  Details on the graphical approach and testin g strategy  will be specified in the 
statistical analysis plan (SAP).
All efficacy analyses will fo llow the intent -to-treat (ITT) principle unless otherwise specified. 
An ITT analysis is an analysis of data by  the groups to which subjectsare assigned by r andom 
allocation, even if the subjectdoes not take the assigned treatment, does not receive the correct 
treatment, or otherwi se does not fo llow the protocol .
When change fro m baseline is assessed, subjects will be included in the analysis only if both a 
baseline and a postbaseline measure are available.  Unless otherwise defined, a baseline measure 
is the last nonmissing observation collected prior to the first administration of study  medications.  
Endpoint i s the last nonmissing postbaseline measurement.
For MMRM models, observat ions collected at nonscheduled visits will not be included in the 
analyses.
A database lock is expected to occur after all randomized subjects have had chance to complete 
double-blind period of the study . Efficacy and safety  analyses will be conducted based on data 
collected during double -blind period. Data collected during immunogenicit y and safety follow-
up period will be summarized and analyzed separately.
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol.  Any other change to the data analysis 
methods described in the protocol and the justificatio n for making the change will be described 
in the SAP and clinical study  report.  Addi tional exploratory analyses of the data will be 
conducted as deemed appropriate.
Details of the statistical methods are specified in the SAP for Study  AACG.
10.3.1.1. Handling of Missing Items for Scales
If any of the individual items for ADAS-CogorADCS-ADL are mis sing or unknown, every  
effort will be made to ob tain the score for the missing item or items.
For ADAS -Cog13, if 4 or fewer of a total of 13 items are missing, the total score (maximum =85)
will be imputed as fo llows:  The total fro m remaining items will b e multiplied by a factor that 
includes the maximum score for the missing items.  For example, if the first item, “Word -Recall
Task,” which ranges from a score of 0 through 10 (maximum = 10), is missing, and the second 
item “Commands,” which ranges from a s core of 0 to 5 (m aximum = 5),is missing, then the 
I5T-MC-AACG(d)Clinical Protocol Page 79
LY3002813multiplication factor = 85/(85 - [10 + 5])= 85/70 = 1.21.  Thus, the total score for this example 
will be the sum o f the remaining 12 i tems multiplied by 1.21.  The imputed number will be 
rounded up to th e nearest integer.  If more than 4 items are missing, the total score for 
ADAS-Cog13at that visit will be considered missing.
For the ADCS -iADL, if <30% of the items are missing, the total score will be imputed.  The sum 
of the nonmissing items will be pr orated to the sum o f total items.  The imputed number will be 
rounded up to the nearest integer.  If the nearest integer is greater than the maximum possible 
score, the imputed score will be equal to the maximum score.  If >30% of the items are missing, 
the total score for ADCS -iADL at that visit will be considered missing.  The same imputation 
technique will be applied to the ADCS -ADL total  score.  Note that, depending on the specific 
item responses that are missing ,it is possible to have an imputed total score for both the ADCS -
iADL and the ADCS -ADL, an imputed total score for one but not the other, or both total scores 
missing.
The same imputation technique will be applied to the CDR -SB.  If only 1 box (of 6) of the CDR 
is missing, the sum of the boxes w ill be imputed by prorating the sum fro m the other 5 boxes.  If 
the score from more than 1 box is not available, the CDR- SB at that visit will be considered 
missing.
iADRS score is calculated as –ADAS-Cog13score + 85 + ADCS -iADL score.  If either 
ADAS-Cog13or ADCS-iADL is missing, iADRS score will be considered missing.
For all other scales, if any item is missing, any  total or sum involving that item will be 
considered missing.
10.3.2.Treatment Group Comparability
10.3.2.1. Subject Disposition
All patients who discontinue from the study will be identified, and the extent of their 
participation in the study will be reported.  If known, a reason for their discont inuation will be 
given.
The reasons for discont inuation will be collected when the patient’s part icipation in the study 
ends and will be summarized by  treatment group for all rando mized subjects.  The percentage of 
subjects discont inuing from each treatment group will be co mpared between groups using 
Fisher’s exact test.  The comparisons will be done for th e overall percentage of patients who 
discontinue and for select specific reasons for discontinuat ion.
10.3.2.2. Subject Characteristics
The patient’s age, gender, race, height, body  weight, BMI (weight (kg) / [height (m)] 2), tobacco 
use, alcohol use, caffeine use, y ears of education, work status, time since onset of first AD 
symptoms, time since diagnosis, baseline MMSE, CBB score at Visit 1, apolipoprotein E 
(APOE) genoty pe (E4 carrier vs. non -carrier), having 1 or m ore first degree relat ives with AD, 
and AChEI and/ or memantine use at baseline will be recorded.
I5T-MC-AACG(d)Clinical Protocol Page 80
LY3002813Baseline characterist ics will be summarized by  treatment group and overall.  Summaries will 
include descript ive statist ics for continuous and categorical measures.  Fisher’s exact test or 
Pearson’s chi -square test will be used for treatment -group comparisons o f categorical data.  F or 
continuous data, analysis of variance (ANOVA), with independent factors for treatment and 
investigator, will be used.
10.3.2.3. Prior and Concomitant Therapy
Prior medicat ions are defined as those that stop before randomizat ion (Visit 2).  Concomitant 
medications are defined as those being taken on or after randomizat ion (Visit 2).  A summary  of 
concomitant medicat ions will be presented as frequencies and percentages for each treatment 
group.  Fisher’s exact test will be used to test for treatment differences between groups.
If the start or stop dates of therapies are missing or partial to the degree that determination cannot 
be made of whether the therapy  is prior or concomi tant, the therapy  will be deemed concomitant.
Prior and concomitant m edications will be listed.
Summary  tables will  also be provided for concomitant anticholinergics that affect cognit ive 
function and AChEI/memant ine medications.
Medications will be coded using the World He alth Organizat ion (WHO) drug dict ionary.
10.3.2.4. Treatment Compliance
Summary  statistics for LY3002813 treatment compliance will be provided for the total number 
of complete infusi ons received, durati on of complete infusion, and volume of com plete infusio n 
by treatment group.
Frequencies and percentages of reasons why infusion was stopped will also be presented.
Summary  statistics for LY3202626 treatment compliance will be provided for the proportion of 
patients who are compliant and nonco mpliant as noted i n Section 7.6of this protocol  by 
treatment group.
10.3.3.Efficacy Analyses
10.3.3.1. Primary Analyses
The primary  objective of this study  is to test the hypothesis that IV infusion of LY3002813 will 
slow the cogni tive and/or funct ional decline of AD as measured by  the composite measure 
iADRS co mpared with placebo in patients with early symptomatic AD.  This will be assessed 
using an MMRM analysis.
The change from baseline s core on the iADRS at each scheduled postbaseline visit (according to 
the Schedule of Act ivities) during the treatment period will be the dependent variable.  The 
model for the fixed effects will include the following terms:  baseline score, pooled invest igator, 
treatment, visit, treatment-by-visit interaction, baseline -by-visit interact ion, concomitant AChEI 
and/or memant ine use at baseline (yes/no), and age at baseline.  Visit will be considered a 
categorical variable.  The null hypothesis is that the contrast between the LY3002813 group 
versus placebo at the last visit equals zero.  An unstructured covariance matrix will be used to 
I5T-MC-AACG(d)Clinical Protocol Page 81
LY3002813model the within-subject variance -covariance errors.  If the unstructured covariance structure 
matrix results in a lack of con vergence, the fo llowing tests will be used in sequence:  
heterogeneous Toeplitz covariance structure, heterogeneous autoregressive covariance structure, 
heterogeneous compound symmetry  covariance structure, and compound symmetry  covariance 
structure.  The Kenward-Roger approximat ion will be used to estimate the denominator degrees 
of freedom.
The primary  time point for treatment comparison will be at Week 76.  The treatment group 
contrast in least -squares mean progression and its associated p -value and 95% CI will be 
calculated for the treatment comparisonof LY3002813 vs. pl acebo using the MMRM m odel 
specified above.  In addit ion, Bayesian posteri or probabilit y of the active treatment arm being 
superior to placebo by at least a margin of interest (25% slowi ng of placebo progression) will 
also be calculated assuming a non- informative prior.
10.3.3.2. Secondary Efficacy Analyses
Similar to the primary analysis, each of the secondary  efficacy outcom es will be assessed using 
an MMRM analysis.  These secondary efficacy out comes include ADAS -Cog13,ADCS-iADL,
CDR-SB, and MMSE.  For each secondary  efficacy measure, the change from baseline score at 
each scheduled postbaseline visit (according to the Schedule of Activit ies) during the treatment 
period will be analyzed using th e same MMRM model  described for the primary  analysis.
Longitudinal changes from baseline in amylo id plaque (as measured by florbetapir F18 PET 
scan) and vMRI parameters will be analyzed using MMRM including the fo llowing terms in the 
model:  baseline bio marker value, treatment, visit, treatment-by- visit interaction, and baseline -
by-visit interaction .  The change from baseline to endpo int in tau SUVr (as measured by 
flortaucipir PET scan) will be analyzed using an analysis of covariance (ANCOVA) model with 
terms of baseline value and treatment.
Any addit ional analyses of secondary  efficacy outcom es and biomarkers will be specified in the 
SAP.
10.3.4.Safety Analyses
All subjects who receive at least 1 dose of LY3002813 will be evaluated for safet y and 
tolerability.  Safety parameters (AEs, laboratory  analytes, vital signs, ECGs, and MRIs) will be 
summarized using descript ive statist ics for continuous vari ables and frequencies alo ng with 
percentages for categori cal variables during the treatment period.
10.3.4.1. Adverse Events
Treatment -emergent adverse events will be defined as events that first occurred or worsened on 
or after randomizat ion (Visit 2).  Should there be insufficient data for AE start date and stop date 
the AE will be considered treatment emergent.
Treatment -emergent adverse events will be calculated based on adverse event ident ifier (AEID) 
and coded according to established Medical Dictionary for Regulatory Act ivities (MedDRA) 
terms and summarized by MedDR A System Organ Cl ass (SOC) and Preferred Term.
I5T-MC-AACG(d)Clinical Protocol Page 82
LY3002813An overview of AEs, including the number and percentage of subjects who died, had SAEs, 
discontinued due to AEs, and who had treatment -emergent AEs (TEAEs), will be summarized by 
treatment group.
10.3.4.2. Vital Signs a nd Weight
Vital sign measurements and weight will be analyzed using continuous data (change fro m 
baseline) and categorical data (proportion of treatment -emergent abnorm alities).
Summary  statistics will be presented for observed values at baseline and for c hange fro m 
baseline results at each scheduled postbaseline visit and at endpoint(s).  Sy stolic and di astolic 
blood pressure and pulse (collected in sitting posit ion), temperature, and weight will be 
summarized.
The incidence of treatment -emergent abnorm al high or low vital signs and weight will be 
summarized by  treatment groups.  Treatm ent-emergent vital sign evaluat ions are defined for 
evaluations collected after the init iation of study  medication.  Abnormal criteria for vital signs 
and weight are presente d in Table AACG. 10.1.  Any vital sign or wei ght outside the criterion 
values will be considered abnormal.
Table AACG. 10.1. Criteria for A bnormal Vital Signs
Vital Sign Parameter (Unit) Postbaseline Low Criteria Postbaseline High Criteria
Sitting Sy stolic Blood Pressure 
(mmHg)Absolute value 90 and 20 decrease 
from baselineAbsolute value 160 and 20 increase 
from baseline
Sitting Diastolic Blood Pressure 
(mmHg)Absolute value 50 and 10 decrease 
from baselineAbsolute value 100 and 10 increase 
from baseline
Sitting Pulse (bpm) Absolute value <50 and 15 decrease 
from baselineAbsolute value >100 and 15 increase 
from baseline
Weight 4% decrease 4% increase
Vital Sign Parameter (Unit) Postbaseline Criteria for Abnormality
Orthostatic Systolic Blood 
Pressure (mmHg)20 mmHg decrease in systolic blood pressure (supine to standing) 
(i.e., supine minus standing 20)
Orthostatic Diastolic Blood 
Pressure (mmHg)≥10 mmHg decrease in diastolic blood pressure (supine to standing)
(i.e., supine minus standing ≥10 mm Hg)
Orthostatic Pulse (bpm) 30 increase in bpm (standing to supine) (i .e., standing minus supine 30)
Temperature Absolute value 38.3C and 1.1C increase from baseline
(Absolute value 101F and 2F increase from baseline)
Abbreviation:  bpm = beats per minute.
10.3.4.3. Laboratory Analyses
Laboratory  measurements will be analyzed as continuous data (change from baseline) measured 
as International System Units (SI) or as categorical data (proportion of treatment -emergent 
abnormalities).
I5T-MC-AACG(d)Clinical Protocol Page 83
LY3002813If there are mult iple records of laboratory  measurements at baseline or postbaseline vis its, the 
last record will be used.
Change from baseline to postbaseline visit s at which laboratory  measurements are taken will be 
summarized using descript ive statist ics.
For all laboratory  analytes, frequencies of subjects with notable changes ( i.e., increases or 
decreases o f a prespecified amount unique to each analyte) fro m baseline to each postbaseline 
visit will also be summarized for all subjects and stratified by low, normal, or high at baseline.
10.3.4.4. Electrocardiograms
The ECG m easurements will be analyz ed using cont inuous data (change from baseline) and 
categorical data (proportion of treatment -emergent abnormalit ies).
Since ECG is measured in triplicates during the double -blind period, the average of triplicates 
will be used at baseline and each double -blind period visit.  If there are mult iple records after 
averaging ECG triplicates within a visit, the last record of averages will be used.
The analysis will be done for the fo llowing ECG measurements:  heart rate, PR, QT, QTc, and 
RR intervals and QRS du ration.  All analyses of QTc will be carried out using the Fridericia 
correction (QTcF) method.  These summaries will include data fro m each visit ECG measures 
are perform ed.
Change from baseline to each postbaseline visit at which ECG measurements are tak en will be 
assessed using an MMRM model.  The model for the fixed effects will include terms for the 
following independent effects:  baseline ECG score, pooled invest igator, treatment, visit, 
treatment-by-visit interaction, baseline -by-visit interaction an d age at baseline.  This analysis 
will be done separately for each ECG parameter.
Incidence of treatment -emergent abnormal ECGs will be assessed by comparisons at (1) anyt ime 
and (2) each postbaseline visit between treatment groups with Fisher’s exact test .  For analyses 
of treatment-emergent abnorm al ECGs, baseline will be considered as all visits before the 
initiation of drug dose.
Abnormal ECG criteria are presented in Table AACG.10 .2and criteria for abnormal QTcF 
prolongation are presented in Table AACG.10 .3.
I5T-MC-AACG(d)Clinical Protocol Page 84
LY3002813Table AACG. 10.2. Criteria for A bnormal ECG Parameters
ECG Parameter Low Criteria High Criteria
Heart Rate <50 bpm >100 bpm
PR Interval <120 msec 220 msec
QRS Duration <60 msec 120 msec
QTc Interval
            males
            females
       males and females<330 msec
<340 msec450 msec
470 msec
> 500 msec
Abbreviations:  bpm = beats per minute; ECG = electrocardiogram; QTc = corrected QT.
Table AACG. 10.3. Criteria for Prolonged ECG QTcF Interval
QTc Delta Changes (msec)
>30
>60
>75
Abbreviations:  QTc = corrected QT; QTcF = Fridericia -corrected QT.
Treatment -emergent high ECG parameters (heart rate, PR interval, QRS duration, and QT and 
QTcF intervals) are the values that are low or normal at all baseline visits and fall into the high 
abnormal categories in Table AACG.10 .2and Table AACG. 10.3postbaseline.  Similarly, 
treatment-emergent low ECG parameters (heart rate, PR interval, and QRS duration) are the 
values thatare high or normal at all baseline visit s and fall into the low abnormal categories 
above.
For each treatment -emergent high ECG parameter in Table AACG.10 .2, only subjects who were 
low or norm al at baseline and hav e at least 1 postbaseline value will be included in the 
denominator when co mputing the proportion of subjects with treatment -emergent high values.  
Similarly, only subjects who were high or normal at baseline and have at least 1 postbaseline 
value will be included in the deno minator when comput ing the proportion of subjects with 
treatment-emergent low values.
For prolonged QTcF interval assessments, when comput ing the proportion of subjects with 
treatment-emergent high abnormalit ies, only subjects who were normal at baseline and had a 
nonmissing result at that postbaseline visit will be included in the deno minator.  A 
treatment-emergent high value is defined as a change fro m normal value at all  baseline 
assessments to a value greater than 450 msec for males and 470 msec for females at postbaseline.
In addition, treatment differences in the proportion of subjects who have normal baselines with a 
change to abnormal high or abnormal low values at any postbaseline visits will be summarized.   
Treatment -emergent qualitative ECG findings will also be summarized.
I5T-MC-AACG(d)Clinical Protocol Page 85
LY300281310.3.4.5. ARIA-E and ARIA -H
The incidence of ARIA -E will be summarized.  Change in ARIA -E status from  baseline, to each 
subsequent MRI (in the event of unscheduled MRIs), and to double -blind period endpoint 
(Visit 21) will be co mpared between treatment groups using Fisher’s exact test.
The incidence of changes in ARIA -H will be summarized.  Change in ARIA -H status from  
baseline to endpoint will be compared between treatment groups using Fisher’s exact test.  The 
number and percentage of subjects with increases in size of preexist ing ARIA-H, number of 
subjects wi th increases in number of ARIA -H, and number of subjects with increases in size of 
preexisting and/or number of ARIA -H from baseline to endpoint will be summarize d for both 
treatment groups and com pared using Fisher’s exact test.
Subjects with ARIA-E and subjects with ARIA -H that increased in size and/or number 
postbaseline, and subjects with any other MRI findings will be listed.
10.3.4.6. Evaluation of Immunogenicity
Subject samples will be analyzed using a 4 -tiered approach.  All samples will be assessed in Tier 
1 (screening) for the possible presence o f ADA.  Sam ples found to produce a signal above or 
equal to the screening cut point will be assessed in Tier 2 to confirm specificity to LY3002813 
(confirmat ion).  Any samples confirmed as specific for anti -LY3002813 ant ibodies will be 
reported as “detected.”  All samples below the screening cut point (Tier 1) or not confirmed (Tier 
2) will be reported as “not detected.”  Any “detected” sample in Tier 2 will be assessed in Tier 3 
(titer assessment) and Tier 4 (neutralizing ant ibodies).  Ant i-drug antibodies titer values will be 
reported from Tier 3 titer assessment.  Any samples above the Tier 4 assay cut point will be 
reported as “detected for neutralizing antibodies”; samples below the assay cut point in Tier 4 
will be reported as “not detected for neutralizing ant ibodies.”
The frequency and percentage of subjects with preexist ing (baseline) ADA, ADA at any t ime 
after baseline, and TE ADA to LY3002813 will be tabulated.  If no ADAs are detected at 
baseline, TE ADA are defined as those with a titer 2 fo ld (1 dilut ion) greater than the MRD of 
the assay.  For samples wit h ADA detected at baseline TE ADA are defined as those with a 4-
fold (2 dilut ions) increase in t iter compared to baseline.  For the TE ADA subjects, the 
distribution of maximum t iters will be described.  The frequency of neutralizing ant ibodies may 
also be tabulated.  The relationship between the presence of ant ibodies to LY3002813 and PK, 
PD, safety and/or efficacy  assessment m ay be assessed.
10.3.4.7. Suicidal Ideation and Behavior
Suicide-related thoughts and behaviors, based on the C -SSRS, will be listed by subject and visit.  
Only subjects that show suicidal ideation/behavior will be displayed ( i.e., if a subject’s answers 
are all “no” for the C -SSRS, then that subject will not be displayed).  However, if a subject 
reported any  ideation or behavior at any  time point, then all their ideat ion and behavior will b e 
displayed, even if not posit ive.
I5T-MC-AACG(d)Clinical Protocol Page 86
LY300281310.3.5.Pharmacokinetic/Pharmacodynamic Analyses
Compartmental modeling of LY3002813 P K data using nonlinear mixed effects modeling or 
other appropriate software may be explored, and populat ion estimates for clearance and central
volume of distribut ion may be reported.  Depending on the model selected, other PK parameters 
may also be reported.  Exploratory  graphical  analyses of the effect of dose level or demographic 
factors on PK parameters may be conducted.  If appropriate, data from other studies of 
LY3002813 may beused in this analysis.
Concentrations of LY3202626 were collected underthe original versi on of this protocol , as well 
as amendments (a-c). These data will be summarized in the final study  reportand may be 
analyzed graphically . If appropriate, exploratory analyses may  be conducted to evaluate 
potential relationships between LY3202626 concentrations and LY3002813 concentration .
The PK/PD relat ionships between plasma LY3002813 concentration and SUVr, cognit ive 
endpoints, ARIA incidence rate or other markers of PD act ivity may be explored graphically.  
The relationship between the presence of ant ibodies to LY3002813 and PK, PD, safet y and/or 
efficacy may be assessed graphically.
Additional modeling may  be perform ed based on the results of the graphical analyses.
10.3.6.Interim Analyses
A limited number of pre -identified individuals may gain access to the limited unblinded data, as 
specified in the unblinding plan, prior to the interim or final database lock, in order to initiate the 
final populat ion PK/PD model development processes for interim or final analyses.  Informat ion 
that may unblind the study  during the analyses will not be reported to study  sites or blinded study  
team until the study  has been unblinded.  It is intended that access prior to the final database lock 
will be granted after the last patient completes Visit 18 (after 64 weeks of treatment).
An independent external Data Monitoring Commit tee (DMC) is to monitor data on an ongoing 
basis to ensure the con tinuing safet y of patients enrolled in this study . There will be periodic
safety data reviews during the study  and the external DMC is authorized to evaluate results from 
unblinded safet y data reviews.The timing and operational details o f the DMC safet y data 
reviews are defined in DMC charter.
At least one interim analysis may  be conducted for StudyAACG;for example, when all 
randomized subjects have had a chance to complete 52 weeks of treatment (Visit 15) and data 
will be used to evaluate whether to st op the study  for futility.  Additional assessment of efficacy
may also be evaluated at the interim analyses to inform future development of the compound s
and platform. For such fut ility and efficacy  analyses, a n internal assessment committee (IAC), 
but external to the study  team, is authorized to evaluate resul ts from the unblinded interim 
analyses. Operational details and a quant itative framework to provide informat ion for these 
decisionswill be docum ented in the statistical analysis plan (SAP).Study sites will receive 
information about interim results ONLY if they need to know for the safet y of their patients.
Unblinding details are specified in the unblinding plan sect ion of the SAP or a separate 
unblinding plan document.
I5T-MC-AACG(d)Clinical Protocol Page 87
LY300281311.References
Alaka K, Campbell G, Fleisher A, Hake A, Irizarry  M, Miller B, Pon tecorvo M, Siemers E, Sims 
J, Yaari R. The nosology  of Alzheimer’s di sease and applicat ion of concepts to amylo id-
targeting treatments: an internal summary  of Lilly thinking. Whi te Paper. 2015.
Alzheimer’s A ssociation 2017a. Available at: http://alz.org/aaic/_downloads/draft -nia-aa-7-18-
17.pdf. Accessed August 24, 2017.
Alzheimer’s Associat ion 2017b. Available at: http://alz.org/aaic/nia -aa.asp. Accessed August 24, 
2017.
Berg L, Miller JP, Baty  J, Rubin EH, M orris JC, Figiel G. Mild senile dementia of the 
Alzheimer’s ty pe. 4. Eval uation of intervention. Ann Neurol . 1992;31(3):242 -249.
Black RS, Sperling RA, Safirstein B, Motter RN, Pallay  A, Nichols A, Grundm an M. A single 
ascending dose study  of bapineuzumab in patients with Alzheimer di sease. Alzheimer Dis 
Assoc Disord . 2010;24(2):198 -203.
Braak H, Braak E. Evolut ion of the neuropathology o f Alzheimer's disease. Acta Neurol Scand
Suppl. 1996;165:3-12.
Bretz F, Maurer W, Brannath W, Posch M. A graphical approa ch to sequentially reject ive 
multiple test procedures. Stat Med. 2009;28:586-604.
Bretz F, Posch M, Glimm E, Klinglmueller F, Maurer W, Rohmeyer K. Graphical approaches for 
multiple comparison procedures using weighted Bonferroni, Simes, or parametric test s. Biom 
J. 2011;53(6):894 -913.
Cockcroft DW, Gault MH. Prediction of creat inine clearance fro m serum creatinine. Nephron. 
1976;16(1):31 -41.
Darby, D, Maruff, P, Collie, A, McStephen, M. Mild cognit ive impairment can be detected by  
multiple assessments in a single day . Neurology. 2002;59(7):1042–1046.
Darby DG, Pietrzak RH, Fredri ckson J, Woodward M, Moore L, Fredrickson A, Sach J, Maruff 
P. Intraindividual cognit ive decline using a brief computerized cognit ive screening test. 
Alzheimer’s Dement. 2012;8:95 -104.
Davison, SL, Bell, RJ, Gavrilescu, M, Searle, K, Maruff, P, Gogos, A, Rossell SL, Adams J, 
Egan GF, Davis, SR. Testosterone improves verbal learning and memory  in postmenopausal 
women: results from a pilot study. Maturitas . 2011;70(3):307 -311.
DeMattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, 
McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML. A plaque -specific ant ibody clears 
existing β-amyloid plaques in Alzheimer's disease mice. Neuron. 2012;76(5):908 -920.
DoodyRS, Thom as RG, Farl ow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, 
Aisen P, for the Alzheimer's Disease Cooperative Study  Steering Committee ; Siemers E, Liu-
Seifert, Mohs R, for the Solanezumab Study  Group. Phase 3 trials o f solanezumab for mild -to-
moderate Alzheimer's disease. N Engl J Med . 2014;370:311 -321.
Doraiswamy PM, Sperling RA, Coleman RE, Johnson KA, Reiman EM, Davis MD, Grundman 
M, Sabbagh MN, Sadowsky  CH, Fleisher AS, Carpenter A, Clark CM, Joshi AD, Mintun MA, 
I5T-MC-AACG(d)Clinical Protocol Page 88
LY3002813Skovronsky  DM, Pontecorvo MJ, AV45- A11 Study Group. Amylo id-β assessed by florbetapir 
F 18 PET and 18 -month cognitive decline: a mult icenter study . Neurology . 2012;79(6):1636-
1644.
[FDA] United States Food and Drug Administration. Guidance f or Industry . Suicide ideat ion and 
behavior: prospective assessment of occurrence in clinical trials [draft guidance]. Available at: 
http://www.fda.gov/downloads/Drugs/Guidances/UCM225130.pdf. Accessed August 06, 
2017.
Fleisher AS, Chen K, Quiroz YT, Jakimo vich LJ, Guti errez Gom ez M, Lango is CM, Langbaum 
JBS Roontiva A, Thiyyagura P, Lee W, Ay utyanont N, Lopez L, Moreno S, Muñoz C, Tirado 
V, Acosta -Baena N, Fagan AM, Giraldo M, Garcia G, Huentelman MJ, Tariot PN, Lopera F, 
MD, Reiman EM. Associations betweenbiomarkers and age in the presenilin 1 E280A 
autosomal dominant Alzheimer disease kindred: a cross -sectional study . JAMA Neurol . 
2015;72:31 6-24.
Fleisher AS, Lowe SL, Liu P, Shcherbinin S, Li L, Chua L, Nakano M, Hawdon A, Willis BA, 
Schwarz AJ, DeMattos RB, Mintun MA, Irizarry MC. Significant and sustained florbetapir 
F18 uptake reduction in pat ients with symptom atic Alzheimer’s disease wit h LY3002813, a 
β-amyloid plaque-specific ant ibody. Presented at the Alzheimer’s Association Internat ional 
Conference 2018, July 22, 2018, Chicago, IL .
Fredrickson J, Maruff P, Woodward M, Moore L, Fredrickson A, Sach J, Darby  D. Evaluat ion of 
the usability of a brief co mputerized cognit ive screening test in o lder people for 
epidemiological studi es. Neuroepidemiol . 2010;34:65 -75.
Freemant le N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in rando mized 
trials. Greater precisio n but with greater uncertainty? JAMA. 2003;289(19):2554 -2559.
18F florbetapir Injection (AmyvidTM) Package Insert. Indianapolis, IN: E li Lilly and Company; 
2013.
Folstein MF, Fo lstein SE, McHugh PR. “Mini -Mental State”. A practical method for grading the 
cognitive state of patients for the clinician. JPsychiatr Res . 1975;12(13):189- 198.
Galasko D, Bennett D , Sano M,Ernesto C, Thomas R, Grundman M, Ferris S .An inventory  to 
assess act ivities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s 
Disease Cooperative Study . Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S33-S39.
Galasko D, Kershaw PR, Schneider L, Zhu Y, Tariot PN. Galantamine maintains abilit y to 
perform activities of daily living in pat ients with Alzheimer’s disease. J Am Geriat Soc . 
2004;52(7):1070 -1076.
Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, 
Symon L. Cerebral blood flow in dement ia. Arch Neurol . 1975;32(9):632 -637.
Jaeger, J, Hårdemark, H- G, Zettergren, A, Sjögren, N, Hannesdottir, K. Does repeated daily 
testing improve measurement sensit ivity to the cognit ive effects of donepezil in mild -to-
moderate Alzh eimer’s Disease? Alzheimers Dement . 2011:7(4):e59. (Paper presented at the 
Alzheimer’s Associat ion International Conference, Paris, France).
Jonsson T1, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, 
Gudbjartsson D, Maloney J, Hoy te K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, 
I5T-MC-AACG(d)Clinical Protocol Page 89
LY3002813Huttenlocher J, Bj ornsdottir G, Andreassen OA, Jönsson EG, Palotie A, Behrens TW, 
Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ, Stefansson K. A mutation in APP 
protects against Alzheimer's disease and age -related cogni tive decline. Nature. 
2012;488(7409):96 -99.
Kahle-Wrobleski K, Andrews JS, Belger M, Gauthier S, Stern Y, Ren tz DM and Gal asko D. 
Clinical and econo mic characterist ics of milestones along the continuum o f Alzheimer’s 
disease: transforming funct ional scores into levels of dependence. J Prevention of Alzheimer’s 
Dis. 2015;2(2):115-120.
Kahle-Wrobleski K, Andrews JS , Belger M, Ye W, Gauthier S, Rentz DM and Galasko D. 
Dependence levels as interim clinical milestones along the continuum o f Alzheimer’s disease: 
18-month results from the GERAS Observat ional Study. J Prev Alzheimers Dis. 2017;4(2):72-
80.
Ketter N, Brashe ar HR, Bogert J, Di J, Miaux Y, Gass A, Purcell DD, Barkho f F, Arrighi HM. 
Central review of amylo id-related imaging abnormalit ies in two phase III clinical trials of 
bapineuzumab in mild -to-moderate Alzheimer’s Disease pat ients. J Alzheimers Dis. 
2017;57(2):557-573.
Lichtenstein L, Ron Y, Kivit y S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, 
Confino-Cohen R, Weiss B. Infliximab -related infusi on reactions: systematic review. J Chron 
Colitis.2015;9(9):806 -815.
Lim YY, Ellis KA, Ames D, Darby  D, Harrington K, Martins RN, Masters CL, Rowe C, Savage 
G, Szoeke C, Villemagne VL, Maruff P; and the AIBL Research Group. Aβ amylo id, 
cognition, and APOE genoty pe in healt hy older adults. Alzheimers Dement. 2013a;9:538 -545.
Lim YY, Ellis KA, Harrington K, Pie trzak RH, Gale J, Ames D, Bush AI, Darby  D, Martins RN, 
Masters CL, Rowe CC, Savage G, Szoeke C, Villemagne VL, Maruff P, for the AIBL 
Research Group. Cognitive decline in adults with amnestic mild cognit ive impairment and 
high Aβ amylo id: prodrom al Alzheimer’s disease? J Alzheimers Dis. 2013b;33(4):1167 -1176.
Liu-Seifert H, Anderson S, Case M, Sparks J, Holdridge KC, Wessels AM, Hendrix S, Aisen P, 
Siemers E. Stati stical properties of continuous composite scales and implicat ions for drug 
development. J Biopharm Stats . 2017, DOI: 10.1080/10543406.2017.1315819
Maruff P, Thomas E, Cysique L, Brew B, Collie A, Sny der P, Pietrzak RH. Validit y of the 
CogState brief battery : relationship to standardized tests and sensit ivity to cognit ive 
impairment in mild traumat ic brain injury , schizophrenia, and AIDS dement ia complex. Arch 
Clin Neuropsychol. 2009;24(2), 165–178.
Maruff P, Lim YY, Darby  D, Ellis KA, Pietrzak RH, Sny der PJ, Bush AI, Szoeke C, Schembri 
A, Ames D, Masters CL, and for the AIBL Research Group. Clinica l utility of the cogstate 
brief battery in identifying cognit ive impairment in mild cognit ive impairment and 
Alzheimer’s disease. BMC Pharmacol Toxicol. 2103;1(1):30. doi : 10.1186/2050 -7283-1-30.
May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, 
Mergott DJ, Watson BM, Stout SL, Timm DE, Smit h Labell E, Gonzales CR, Nakano M, Jhee 
SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, 
Citron M, Audi a JE. Robust central reduction of amylo id-beta in humans with an orally 
available, non -peptidic beta-secretase inhibitor. J Neurosci . 2011; 31(46): 16507 -16516.
I5T-MC-AACG(d)Clinical Protocol Page 90
LY3002813McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan 
JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Ste rn Y. Dependence as a unifying 
construct in defining Alzheimer’s disease severit y. Alzheimers Dement. 2010;6(6):482 -493.
Mohs RC, Knopmann D, Petersen RC, Ferris SH, Ernesto C , Grundman M , Sano M, 
Bieliauskas L, Geldmacher D , Clark C, Thal LJ. Development of cognitive instruments for use 
in clinical trials of ant idementia drugs: addit ions to the Alzheimer’s Disease Assessment Scale 
that broaden its scope. The Alzheimer’s Disease Cooperative Study . Alzheimer Dis Assoc 
Disord. 1997;11(Suppl  2):S13-S21.
Nathan, PJ, Boardl ey, R, Scott, N, Berges, A, Maruff, P, Sivananthan, T, Upton N, Lowy  MT, 
Nestor PJ, Lai, R. The safet y, tolerabilit y, pharmacokinet ics and cognit ive effects of 
GSK239512, a selective histamine H3 receptor antagonist in patients with mild to mod erate 
Alzheimer’s disease: a preliminary invest igation. Current Alzheimer Res . 2013;10:240-251.
Ostrowitzki S, Deptul a D, Thurfjell L, Barkho f F, Bohrm ann B, Brooks DJ, Klunk WE, Ashford 
E, Yoo K, Xu Z -X, Loetscher H, Santarelli L. Mechanism o f amyloid removal in pat ients with 
Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198 -207.
Qian J, Hyman BT, Betensky  RA. Neurofibrillary tangle stage and the rate of progression of 
Alzheimer symptoms: modeling using an autopsy  cohort and applicat ion to clinical trial 
design. JAMA Neurol . 2017;74:540-548.
Rosen WG, Mohs RC, Davis KL. A new r ating scale for Alzheimer’s disease. Am J Psychiatry . 
1984;141(11):1356 -1364.
Selkoe DJ. The ori gins of Alzheimer disease: a is for amylo id. JAMA. 2000;283:1615-1617.
Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu- Seifert H, Dowsett SA, 
Pontecorvo MJ, Dean RA, DeMattos R. Phase 3 solanezumab trials: Secondary outcomes in 
mild Alzheimer's disease pat ients. Alzheimers Dement . 2016;12:110-120.
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validit y of dependence 
as a health outcome measure in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 
2013;28(3):245 -252.
Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, 
Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, 
Feldman HH, Schindler RJ. Amylo id-related imaging abnormalit ies in amylo id-modifying 
therapeutic trials: recommendat ions from the Alzheimer's Associat ion Research Roundtable 
Workgroup. Alzheimers Dement . 2011;7(4):367 -385.
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, 
Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, 
Brashear HR, Kinney  GG, Black R, Grundman M. Amylo id-related imaging abnormalit ies in 
patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. 
LancetNeurol. 2012;11(3):241 -249.
Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, Sundell K, Stern Y, 
Rentz DM, Dubois B, Jones RW, Cummings J, A isen PS. A Combined Measure of Cognit ion 
and Function for Clinical Trials: The Integrated Alzheimer’s Disease Rat ing Scale (iADRS). J 
Prev Alzheimers Dis . 2015;2(4):227 -241.
I5T-MC-AACG(d)Clinical Protocol Page 91
LY3002813World Medical Associ ation. Declarat ion of Helsinki –ethical principles for medica l research 
involving human subjects. Available at: https://www.wma.net/policies -post/wma-declaration -
of-helsinki-ethical-principles -for-medical-research-involving -human-subjects/. Accessed 
August 27, 2017.
I5T-MC-AACG(d)Clinical Protocol Page 92
LY300281312.Appendices
I5T-MC-AACG(d)Clinical Protocol Page 93
LY3002813Appendix 1. Abbreviations and Definitions
Term Definition
Aβ amyloid β
AD Alzheimer’s disease
ADA anti-drug antibodies
ADAS-COG13 Alzheimer’s Disease Assessment Scale –Cognitive subscale 13
ADCS-ADL Alzheimer’s Disease Cooperative Study —Activities of Daily Living Inventory
ADCS-bADL Alzheimer’s Disease Cooperative Study —basic activities of daily living
ADCS-iADL Alzheimer’s Disease Cooperative Study —instrumental activities of daily living
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporall y associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
ALT alanine aminotransferase
APOE Apolipoprotein subtype E
ARIA-E amyloid-related imaging abnormalities –edema/effusion s (also known as vasogenic 
edema)
ARIA-H amyloid-related imaging abnormalities –hemorrhage/hemosiderin deposition (also 
known as cerebral microhemorrhage)
AST aspartate aminotransferase
BACE β-site amyloid precursor protein cleaving enzyme
blinding/masking A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patients are not.
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the subjects are 
aware of the treatment received.
BMI body mass index
I5T-MC-AACG(d)Clinical Protocol Page 94
LY3002813bpm beats per min ute
CBB CogState Brief Battery
CDR-SB Clinical Dementia Rating Scale –Sum of Boxes 
CIOMS Council for International Organizations of Medical Sciences
Companion diagnostic An in vitro diagnostic device (assay or test) that provides information that is essential 
for the safe and effective use of a corresponding therapeutic product
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all study -related, good clinical practice (GCP), and applicable regulatory 
requirements.
CRF case report form
CRP clinical research physician:  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.
C-SSRS Columbia Suicide Severity Rating Scale
CTCAE Common Terminology Criteria for Adverse Events
CYP3A cytochrome P450 3A
DMC data monitoring committee
ECG electrocardiogram
eCOA Electronic Clinical Outcome Assessment
ED early discontinuation
ELISA enzyme-linked immunosorbent assay
End of Study End of the study is the date of the last visit or last scheduled procedure shown in 
theSchedule of Activities (Section2) for the last patient.
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the study are 
those who have been assigned to a treatment.
enter Patients entered into a study are those who sign the informed consent form directly or 
through their legally acceptab le representatives.
FAS full analysis set
FDA Food and Drug Administration
GCP good clinical practice
I5T-MC-AACG(d)Clinical Protocol Page 95
LY3002813HBsAg hepatitisB surface antigen
HCG human chorionic gonadotropin
HCV hepatitisC virus
IAC internal assessment committee
iADRS integrated Alzheimer’s Disease Rating Scale (iADRS)
IB Investigator’s Brochure
ICF informed consent form
ICH International Council for Harmonisation
Informed consent A process by which a patient voluntarily confirms his or her willingness to participate 
in a particular study, after having been informed of all aspects of the study that are 
relevant to the patient’s decision to participate.  Informed consent is documented by 
means of a written, signed and dated informed consent form.
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.
investigational 
productA pharmaceutical form of an active ingredient or placebo being tested or use d as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intention to treat:  The principle that asserts that the effect of a treatment policy can be 
best assessed by evaluating on the basis of the intention to treat a patient ( i.e., the 
planned treatme nt regimen) rather than the actual treatment given.  It has the 
consequence that patients allocated to a treatment group should be followed up, 
assessed, and analyzed as members of that group irrespective of their compliance to the 
planned course of treatm ent.
IVRS/IWRS interactive voice -response sy stem/interactive web -response system
MedDRA Medical Dictionary for Regulatory Activities  
MHIS Modified Hachinski Ischemic Scale
MMRM mixed-model repeated -measures
MMSE Mini-Mental State Examination
MOA mechanism of action
MRI magnetic resonance imaging
NIA-AA National Institute on Aging (NIA) and the Alzheimer’s Association (AA)
No number
I5T-MC-AACG(d)Clinical Protocol Page 96
LY3002813PCR polymerasechain reaction
PET positron emission tomography
PHF paired helical filament deposits
PK/PD pharmacokinetics/pharmacodynamics
PPS per-protocol set:  The set of data generated by the subset of patients who sufficiently 
complied with the protocol to ensure that these data would be likely to exhibit the 
effects of treatment, according to the underl ying scientific model.
PRO/ePRO patient-reported outcomes/electronic patient -reported outcomes
Q2WK once every 2 weeks
Q4WK once every 4 weeks
QD once a day
QW once a week
QT QT interval on the ECG
QTc corrected QT interval
QTcF Fridericia’s corrected QT interval
RBC red blood cell
SAE serious adverse event
SAP statistical analysis plan
screen The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. 
SHSF Self-Harm Supplement form
SPF skin protection factor
SUSARs suspected unexpected serious adverse reactions
TE treatment-emergent
TEADA treatment -emergent anti -drug antibod y
TEAE treatment-emergent adverse event:  An untoward medical occurrence that emerges 
during a defined treatment period, having been absent pretreatment, or worsens relative 
to the pretreatment state, and does not necessarily have to have a causal relationship 
with this treatment.
V visit
I5T-MC-AACG(d)Clinical Protocol Page 97
LY3002813WBC white blood cell
Wk week
WOCBP women of child -bearing potential
I5T-MC-AACG(d)Clinical Protocol Page 98
LY3002813Appendix 2. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology a,b Clinical Chemistry a,b,c
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocyte count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase (ALP)
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocytes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets Calcium
Glucose, nonfasting 
Urinalysis a,b Albumin
Specific gravity Cholesterol
pH Creatine kinase (CK)
Protein Other Tests
Glucose Human chorionic gonadotropin (HCG)(females) d,e,f
Ketones APOE genotyping a,c,g
Blood High sensitivity C -reactive protein c
Urine leukocyte esterase Calculated creatinine clearance (Cockcroft and Gault 
1976)
HBsAg h
HCV RNA PCR i
Immune Safety Labs j
Β tryptase
Total Immunoglobulin E
Immune complex testing
Abbreviations:  RBC = red blood cells; WBC = white blood cells.
aAssayed by Lilly -designated (central) laboratory.
bResults will be confirmed by the Lilly -designated (central) laboratory at the time of initial testing.
cSamples collected for specified laboratory tests will be destroyed within 60 days of receipt of confirmed test 
results.  Certain samples may be retained for a longer period, if necessary, to comply with applicable laws, 
regulations, or laboratory certification standards.
dFemales of childbearing potential are to have a central lab serum pregnancy test (HCG) at V1.  The serum 
pregnancy test will need to be repeated if the screening period lasts more than 63days.
eFemales of childbearing potential are to have a local urine pregnancy test (HCG) on the day of flortaucipir F18 
PET imaging before the scan is done to confirm they are not pregnan t.
fFemales of childbearing potential are to have a local urine pregnancy test (HCG) on the day of florbetapir F18 
PET imaging before the scan is done to confirm they are not pregnant.
I5T-MC-AACG(d)Clinical Protocol Page 99
LY3002813gNeither patients nor investigators will receive the genotype results unless there is a country -specific law or 
regulation that requires notification of the results.  Failure to collect samples for APOE genotyping will not be 
considered a protocol deviation if country -specific regulations prohibit the testing of genetic material or 
transportation of such material outside of the country.
hlaboratory test to be performed only for patients with a past history of Hepatitis B
ilaboratory test to be performed on ly for patients with a past history of Hepatitis C
jlaboratory tests to be performed only for patients with moderate to severe infusion reaction (see Section 9.4.7.1.2
for timing of sample collection).
I5T-MC-AACG(d)Clinical Protocol Page 100
LY3002813Appendix 3. Study Governance Considerations
I5T-MC-AACG(d)Clinical Protocol Page 101
LY3002813Appendix 3.1 .Regulatory and Ethical Considerations, Including the 
Informed Consent Process
Appendix 3.1.1 .Informed Conse nt
The invest igator is responsible for:
ensuring that the subject/subject’s legal representative understands the nature of the 
study, the potenti al risks and benefi ts of participating in the study , and that thei r 
participation is voluntary.
ensuring that i nformed consent i s given by each subject or legal representative.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the 
performance of any protocol  procedures and prior to the administration of invest igational 
product.
answering any quest ions the subject/ subject’s legal representative may have throughout 
the study and sharing in a t imely manner any  new inform ation that may be relevant to 
the subjects/ subject’s legal representative’s willingness to continue his or her 
participation in the study.
ensuring that a copy  of the ICF is provi ded to the subject or the subject’s legal 
representative and is kept on file.
ensuring that the medical record includes a statement that written informed consent was 
obtained before the subject was enrolled in the study  and the date the written consent 
was obtained.  The authorized person obtaining the informed consent must also sign the 
ICF.
Study partners will also sign the informed consent.  If it is not known that the study  partner will  
change, the new study  partner woul d need to si gn the ICF when he/she takes over the care for the 
subject and study  participation.  The change in study  partner woul d also need to be documented 
on the eCRF.
As used in this protocol, the term “informed consent” in cludes all consent and assent given by 
subject or their legal representatives and by study  partners.
Appendix 3.1.2 .Recruitment
Lilly or its designee is responsible for the central recruit ment strategy for subjects.  Individual 
investigators may have addi tional local requirements or processes.
Appendix 3.1.3. Ethical Review
The invest igator or an appropriate local representative must give assurance that the ethical 
review board (ERB) was properly  constituted and convened as required by Internat ional Council 
for Harmonisation (ICH) guidelines and other applicable laws and regulations.
Documentation of ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study may begin at the investi gative site(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs 
must be compliant with the ICH guideline on Good Clinical Pract ice (GCP).
I5T-MC-AACG(d)Clinical Protocol Page 102
LY3002813The study  site’s ERB(s) shoul d be provided wi th the following:
the protocol and related amendments and addenda, current Invest igator 
Brochure (IB) and updates during the course of the study
informed consent form
other relevant docum ents (e.g., curricula vitae, advertisements)
Appendix 3.1.4. Regulatory Consideration s
This study  will be conducted in accordance wit h the protocol and with the:
consensus ethics principles derived fro m international ethics guidelines, including 
the Declaration of Helsinki and CouncilforInternational Organizati onsof
MedicalSciences (CIOMS) Internati onal Ethical Guidelines
applicable ICH GCP Guidelines
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third -party.
Appendix 3.1.5. Investigator Information
Physicians with expert ise in neurology, geriatrics, or psy chiatry who have clearly documented 
extensive experience in AD trials will part icipate as invest igators in this clinical study .  In 
addition, licensed clinicians who have clearly  documented extensive experience in AD trials may  
participateas investigators in this clinical study  upon approval by  the Sponsor.  Contact 
information for investigators, clinical laboratories, and other medical and/or technical 
department(s) and/or institutions invo lved in the clinical study  is maintained in the s tudy records.
Cognitive assessments must be administered by an individual trained in the use of these 
instruments.  Invest igators and site personnel who will perform ratings will be trained and 
approved by  Lilly or i ts designee prior to parti cipating in th e study.  In most cases, evaluat ion 
and notificat ion will occur at the invest igator meet ing.  Individuals who do not attend the rater 
evaluation and training portion of the investigator meet ing and who wish to perform the ratings 
in this study  must be eval uated and approved by  Lilly or its designee pri or to performing any 
ratings.  Note that the ADAS -Cog and MMSE mustbe administered by different rater than the 
ADCS-ADL and CDR.   These 2 raters should continue doing the same scale with the same 
patient throughout the study .  These 2 or 3 raters should continue doing the same scale with the 
same patient throughout the study .  If possible, the measurements should be performed on a 
given patient by the same rater at each visit.  The PI has the responsibilit y ofselecting who will 
administer the instruments at the site, as long as all training requirements have been met by  those 
raters.
I5T-MC-AACG(d)Clinical Protocol Page 103
LY3002813Appendix 3.1.6. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately  describes the pl anned design and conduct of the 
study.
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly repr esentative.
Appendix 3.1.7. Final Report Signature
The CSR coordinat ing investigator will sign the final CSR for this study, indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study.
The invest igator with the most qualified subjects will serve as the CSR coordinat ing investigator.  
If this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by Lilly to 
serve as the CSR coordinating invest igator.
The sponsor’s responsible medical o fficer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
Appendix 3.2. Data Quality Assuran ce
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provide instructi onal materi al to the study  sites, as appropriate
sponsor investigator study  site trainings to instruct the invest igators and study  
coordinators.  This training will give instruction on the protocol, the complet ion 
of the CRFs, and study  procedures.
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, telephone,and/or fax
review and evaluate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addition, Lilly or its representatives will periodically check a sample of the subject data 
recorded a gainst source documents at the study  site.  The study  may be audited by Lilly or i ts 
representatives, and/or regulatory  agencies at any  time.  Invest igators will be given notice before 
an audit occurs.
The invest igator will keep records of all original sou rce data.  This might include laboratory 
tests, medical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to original source 
documents.
I5T-MC-AACG(d)Clinical Protocol Page 104
LY3002813Appendix 3.2 .1.Data Capture System
An electronic data capture sy stem will be used in this study .  The site maintains a separate source 
for the data entered by  the site into the sponsor -provided electronic data capture system.
Electronic Clinical Outcome Assessment (e COA) measures ( e.g., a rating scale , including audio 
voice recordings of the rater’s questions and the patient’s and study partner’s responses ) are 
entered into an eCOA instrument (at the time that the informat ion is obtained).  The eCOA tablet 
has both ke yboard entry and audio vo ice recording capabilit ies.  In these instances where there is 
no prior written or electronic source data at the site, the eCOA instrument record will serve as the 
source.
If eCOA records are stored at a third party  site, investi gator sites will have continuous access to 
the source documents during the study  and will receive an archival copy  at the end of the study  
for retention.
Any data for which the eCOA instrument record will serve to collect source data will be 
identified and d ocumented by each site in that si te’s study  file.
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central vendor, such as audio voice recordings, laboratory test data,or ECG data, will be stored 
electronically in the central vendor’s database syst em.  With the except ion of the audio vo ice 
recordings, which are only used for central mo nitoring purposes, dat awill subsequent ly be 
transferred from the central vendor to the Lilly data warehouse.
Any data for wh ich paper documentation provided by the subject will serve as the source 
document will be i dentified and documented by  each site in that si te’s study  file.
Data from co mplaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management sy stem.
Appendix 3.3. Study and Site Closure
Appendix 3.3.1. Discontinuation of Study Sites
Study site participation may be discont inuedif Lilly or its designee, the investigator, or the ERB 
of the study  sitejudges it necessary for medical, safety, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Appendix 3.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regulatory, or other reasons consistent with applicable laws, regulat ions, and GCP.
Appendix 3.4. Publication Policy
The publicat ion policy for Study AACG is described in the Clinical Trial Agreement.
I5T-MC-AACG(d)Clinical Protocol Page 105
LY3002813Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selectedtests may be obtained in the event of a treatment -emergent hepatic abnormalit y and may 
be required in fo llow-up with patients in consultat ion with the Lilly, or its designee,clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocytes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti-nuclear antibody a
AST
GGT Alkaline Phosphatase Isoenzymes a
CPK
Anti-smooth muscle antibody (or anti -actin 
antibody) a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma-glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssayed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability.
I5T-MC-AACG(d)Clinical Protocol Page 106
LY3002813Appendix 5. Flortaucipir F18 Tau PET Imaging
A screening flortaucipir F18 PET scan will be performed as part of the study  eligibility criteria.  
An additional flortaucipir F18 PET scan will be performed at Visit 21 or at early  discontinuat ion 
(if ED occurs m ore than 36 weeks after randomization Visit 2).
“Specific instructions for the flortaucipir F18 PET scan itself will be provided in the PET 
ImagingManual.
Inclusion Criteria for Flortaucipir F18 PET Scans
With the exception o f theMRI and flo rbetapir F18 PET scan , a patient should meet all other 
Visit 1 eligibili ty criteria before having a flortaucipir F18 PET scan.
[1]For female patients of childbearing potential, a negative urine pregnancy (HCG) test must be 
observed on the day  of flortaucipir F18 imaging before beginning imaging procedures.
Exclusion Criteria for Flortaucipir F18 PET Scans
A patient will be excluded from participation in flo rtaucipir F18 imaging if he or she meets any  
of the criteria below:
[2]Has any condit ion that, in the investigator’s opinio n, could increase risk to the patient, limit 
the patient’sability to tolerate the experimental procedures, or interfere with analysis of the 
data.  (For example, patients with chronic back pain might not be able to lie st ill during the 
scanning procedures.)
[3]Has abnormal findings on physical examinat ion, laboratory  screening tests, or screening  
ECGs that suggest the patient might have a condit ion that could, in the opinio n of the 
investigator, affect his or her response to the radiopharmaceut ical and related testing 
procedures.
[4]Is deemedlikely to be unable to complete the imaging procedure for any  reason.
[5]Is receiving other radiat ion exposure that, when added to the flortaucipir F18PET scan, 
would exceed l ocal or national regulatory  limits for a patient.
Site investigators, patients, and study partners will not be informed of the results of PET scans 
obtained fo llowing rando mization, as they relate to the study.  A ny findings that may be of 
potential medical concern will  be provided for appropri ate follow-up.
I5T-MC-AACG(d)Clinical Protocol Page 107
LY3002813PET Scan -Specific Information
PET Scan Procedures
Specific imaging acquisit ion protocols designed to ensure consistency across sites will be 
provided in an PET ImagingManual.  The sca nning techno logists will be blinded to pati ents’ 
treatment assignments.
Scan Safety
The primary  risk related to flortaucipir F18PETisradiation exposure.  Details on the amount of 
exposure estimated to occur on each imaging occasion and cumulatively are shown in Table 
APP.5.1 and will be provided in the ICF.  In addit ion, the tau ligand flortaucipir F18 continues to 
be in clinical evaluat ion, and risks fro m the agent are not fully known.  Details on the clinical 
information to date regarding flortaucipir F18 exposure will be provided in the ICF.  More 
detailed informat ion about the known and expected benefit s and risks o f flortaucipir F18 may  be 
found in the Invest igator’s Brochure.
Patients must minimize mo vement during each PET procedure, which can last 10 to 30 minutes 
for each scan.  Most state -of-the-art imaging systems are designed to reduce head motion and 
patient discomfort.
Table APP.5.1. Effective Radiation Dose (mSv)
Effective 
Dose 
(mSv) per 
Scan*Number of 
Scans in 
First 
Year**Effective 
Dose (mSv) 
for Scans in 
First YearNumber 
of Scans 
in Second 
Year**Effective 
Dose (mSv) 
for Scans in 
Second YearEffective 
Dose (mSv) 
for   Years 1 
and 2
Flortaucipir F 18 
Scan (10 mCi iv)9.10 1 9.10 1 9.10 18.20
Florbetapir F 18 
Scan (10 mCi iv)7.43 2 14.86 2 14.86 29.72 
Totals 3 23.96 3 23.96 47.92
Abbreviations:  CT = computerized tomography; IV = intravenous infusion; PET = positron emission tomography.
*Dose shown includes radiation exposure from the radiotracer and also assumes a non-clinical CT scan is obtained 
(estimated at 0.4 mSv) as part of the PET scan attenuation correction process when the scan is done on a PET/CT 
scanner.  A clinical CT scan is not needed during the PET scan session and because it will add additional 
radiation exposure is not recommended.
** In the event that the patient is discontinued from the Study AACG, the subject will be asked to participate in a 
discontinuation visit.  A flortaucipir F18 scan will not be done at the ET visit if it has been ≤12weeks since the 
previous scan.
In the case of early discont inuation from Study AACG, the final flortaucipir F18 PET scan will 
be obtained at the time of the early discont inuation visit (ED) if at least 36weeks have passed 
since the m ost recent flortaucipir F18 PET scan.
I5T-MC-AACG(d)Clinical Protocol Page 108
LY3002813Visits that include imaging should be completed over adjacent day s.  Note that florbetapir F18 
PET amylo id imaging and flortaucipir F18 PET tau imaging can be performed 1 or 2 days after 
cognitive and funct ional testing and additional timing considerations apply:
flortaucipir F18 PET scans should be performed at least 16 hours apart from the 
florbetapir F18PET scans due to the half- life of fluorine 18.
With respect to other compound -relatedrisks, flortaucipirwas positive in the in vitro hERG
assay.  Alt hough the margin of safet y appears high, and in vivo cardiovascular assessments in 
dogs showed no evidence of QT prolongat ion, subjects with a history  of risk factors for torsades 
de pointes and patients taking drugs known to prolong the QT int erval will be excluded from this 
study.
If it becomes necessary for a patient to start taking a medicat ion known to prolong QT interval 
prior to performance of any postbaseline flortaucipir F18 scan, do not perform the scan.  The 
patient may, however rem ain in the study .  Nonperformance of postbaseline flortaucipir F18 PET 
scans in pat ients taking a medication known to prolo ng QT interval will not be considered a 
protocol deviation.
I5T-MC-AACG(d)Clinical Protocol Page 109
LY3002813Appendix 6. Florbetapir F18Amyloid PET Imaging
Screening florbetapir F18PET scans wil l be performed as part of the study eligibilit y criteria to 
determine patient eligibilit y for participation in Study AACG.  Addit ional florbetapir F18PET 
scans will be performed at Visit 8 (Week 24), Visit  15 (Week 52), and Visit 21 (Week 76) or at 
early discontinuation (if ED occurs more than 8weeks after the previous visit at which a 
florbetapir F18PET scan was done).  Specific instructions for the florbetapir F18PET scan itself 
will be provided in the PET ImagingManual.
Inclusion Criteria for Florbetapir F18 PET Scans
With the exception o f theMRI,a patient should meet all other Visit 1 eligibilit y criteria before 
having a florbetapir F18PET scan.
[1]For female patients of childbearing potential, a negative urine pregnancy 
(HCG) test must be observed on the day of florbetapir F18PET imaging 
before beginning imaging procedures.
Exclusion Criteria for Florbetapir F18 PET Scans
A patient will be excluded from participation in flo rbetapir F18 PET amylo id imaging if he or 
she meets any of the criteria below:
[2]Has any condit ion that, in the investigator’s opinio n, could increase risk to the 
patient, limit the patient’s abilit y to tolerate the experimental procedures, or 
interfere with analysis of the data .(For example, patients with chroni c back 
pain might not be able to lie st ill during the scanning procedures .)
[3]Has abnormal findings on physical examinat ion, laboratory  screening tests, or 
screening MRI or ECGs that suggest the patient might have a condit ion that 
could, in the opinio n of the investigator, affect his or her response to the 
radiopharmaceut ical and related testing procedures.
[4]Is deemed likely to be unable to complete the imaging procedure for any 
reason.
[5]Is receiving other radiat ion exposure that, when added to the florbetapir F18
PET scan, would exceed local or national regulatory limits for a patient.
Site investigators, patients, and study partners will not be informed of the results of PET scans 
obtained fo llowing rando mization, as they relate to the study .  Anyfindings that may be of 
potential medical concern will  be provided for appropri ate follow-up.
I5T-MC-AACG(d)Clinical Protocol Page 110
LY3002813PET Scan -Specific Information
PET Scan Procedures
Specific imaging acquisit ion protocols designed to ensure consistency across sites will be 
provided in aPET ImagingManual.  The scanning technol ogists will be blinded to pati ents’ 
treatment assignments.
PET Scan Safety
The primary  risk related to florbetapir F18PET is radiat ion exposure.  Details on the amount of 
exposure estimated to occur on each imaging occ asion and cumulatively  are presented in Table 
APP.5.1 above and will be provided in the ICF.  Details on the clinical informat ion to date 
regarding florbetapir F18exposure will be provided in the ICF.  More detailed informat ion about 
the known and expecte d benefits and risks of florbetapir F18may be found in the United States 
Package Insert for florbetapir F18Injection (Amyvid TM).
Patients must minimize mo vement during each PET procedure, which can last 10 to 30 minutes 
for each scan.  Most state -of-the-art imaging systems are designed to reduce head motion and 
patient discomfort.
In the case of early discont inuation from Study AACG, the final florbetapir F18 PET scan will 
be obtained at the time of the early discont inuation visit (ED) if at least 8 weekshave passed 
since the m ost recent florbetapir F18 PET scan.
Visits that include imaging should be completed over adjacent day s.  Note that florbetapir F18 
PET amylo id imaging and flortaucipir F18 PET tau imaging can be performed 1 or 2 days after 
cognitive and funct ional testing and additional timing considerat ions apply:
florbetapir F18 PET scans should be performed at least 16 hours apart from the
flortaucipir F18PET scan due to the half -life of fluorine 18.
I5T-MC-AACG(d)Clinical Protocol Page 111
LY3002813Appendix 7. Protocol A mendment [I5T -MC-AACG(c)] 
Summary  [Assessment of Safety , Tolerability ,and 
Efficacy  of LY3002813 in Early  Symptomatic A lzheimer’s 
Disease]
Overview
Protocol I5T-MC-AACG Assessment of Safet y, Tolerability,and Efficacy o f LY3002813 in 
Early Symptomat ic Alzheimer’s Disease has been a mended.  The new protocol is indicated by  
amendment ( d) and will be used to conduct the study in place of any preceding version o f the 
protocol.
The main changes to this protocol include removing LY3202626 as a combination therapy .
The overall changes and rationale for the changes made to this protocol are described in the 
following table.  Note that minor edits have been made throughout the protocol, which are not 
captured i n the amendment summary  table.
I5T-MC-AACG(d)Clinical Protocol Page 112
LY3002813Amendment Summary for Protocol I5T -MC-AACG A mendment ( d)
Section # and Name Description of Change Brief Rationale
Title page Removed mention of LY3202626 and combination 
therapy.  Added amendment (d) to the list of 
amendments. Changed date of current protocol.To reflect the content of the current amendment .
Section 1. Synopsis Changed study title and removed mention of 
LY3202626 and combination therapy from the 
study description and the study objectives.  
Changed numbers of patients to reflect the 
elimination of the LY3202626 treatment arm.
Deleted the row for “Evaluable” under 
“Approximate Number of Patients.”To reflect the elimination of the LY3202626 
treatment arm.
Deleted to prevent confusion. Details are provided 
in Section 10.
Section 2. Schedule of Activities Removed ophthalmological and dermatological 
exams from screening assessments and changed 
timing of these assessments during the treatment 
period to reflect the elimination of the LY3202626 
treatment arm.  Removed mention of LY3202626 
administration, compliance che cks, and plasma PK 
sampling.  Deleted the column for Visit 22, as this 
visit is no longer needed. To reflect the elimination of the LY3202626 
treatment arm.
Section 3. Introduction Removed mention of LY3202626 as part of the 
combination.  Removed backgro und specific to 
LY3202626 and its mechanism of action.To reflect the elimination of the LY3202626 
treatment arm.
Section 3.2.2. LYL3002813 Phase 1 Studies Updated information about ongoing Phase 1b 
single-and multiple -dose study I5T -MC-AACD 
(Study AACD) .To provide updated information about this ongoing 
study.
Section 4. Objectives and Endpoints Removed mention of LY3202626 and combination 
therapy from the study objectives.   Removed 
ophthalmological and dermatological examinations 
from safety endpoints.To reflect the elimination of the LY3202626 
treatment arm.
Section 5 . Study Design Removed mention of LY3202626 and combination 
therapy from the study design.  Added description 
of screening policy for patients in active screening To reflect the elimination of the LY3202626 
treatment arm.
I5T-MC-AACG(d)Clinical Protocol Page 113
LY3002813Section # and Name Description of Change Brief Rationale
prior to implementation of amendment (d).  
Changed duration of double -blind period to 76 
weeks, with up to 72 weeks of treatment. Modified 
study design illustration and visits throughout.
Changed number of study participants.  
Removed ophthalmological and dermatological 
evaluation from Screening.To delete examinations and visit no longer needed 
after elimination of the LY3202626 treatment arm.
Section 5.1 .Overall Design Changed “124 -week study” to “133 -week study.” Correction
Section 5.1.3 .Immunogenicity and Safety 
Follow-up Visits (Visit 801)Changed heading to “Immunogenicity and Safety 
Follow-up Visits (Visits 801 through 804)”Clarification (made consistent with text)
Section 6.1.Inclusion Criteria From Inclusion Criterion #4, deleted the bullet 
regarding study partners being available by 
telephone forCDR and ADCS -ADL.Correction; this scale is not administered over the 
phone.
Section 6.2 .Exclusion Criteria From Exclusion Criterion #11, deleted “retinal” 
from the list of exclusionary conditions.
Deleted Exclusion Criterion #18, #32, #37, #56, and 
#57.To remove criteria specific to LY3202626.
Section 6.3. Lifestyle Res trictions Restrictions # 2and #3 were removed. To remove restrictions specific to LY3202626 .
Section 7. Treatments Deleted mention of LY3202626 dosage, 
administration, and packaging. To reflect the elimination of the LY3202626 
treatment arm.
Section 8. Discontinuation Criteria Deleted ophthalmological and dermatological
examinations as a factor in permanent treatment 
discontinuation.  Rephrased discontinuation to 
remove mention of discontinuing one treatment but 
continuing the other.  Deleted criteria specific to 
discontinuing treatment with LY3202626.   Changed 
timing of follow -up after early  discontinuatio n visit.To reflect the elimination of the LY3202626 
treatment arm.
Section 9. Study Assessments and Procedures Deleted administration of LY3202626. Removed 
AESIs specific to LY3202626.  Deleted inf ormation To reflect the elimination of the LY3202626 
treatment arm.
I5T-MC-AACG(d)Clinical Protocol Page 114
LY3002813Section # and Name Description of Change Brief Rationale
about treatment of LY3202626 overdose.  Edited 
text about ophthalmological and dermatological 
examinations to clarify that these will be done only 
in patients who received LY3202626 or oral 
placebo and only at 1 visit (scheduled or 
unscheduled) after the final dose of 
LY3202626/oral placebo.  Deleted information 
about PK sampling for LY3202626.
Addedstatements about completing CRFs for 
hypersensitivity and ARIA-E.
In Section 9.1 (and Appendix 3.1.5), changed the 
statement that ADAS -Cog and MM SE “should” be 
administered by a different rate rthan ADCS -ADL 
and CDR to “must” be administered by a different 
rater.Clarification
Clarification
Section 10. Statistical Considerations Changed numbers of patients and power 
calculations to reflect the elimination of the 
LY3202626 treatment arm.  Deleted mentions of 
combination therapy.  Provided information about 
how data from patients previously randomized to 
LY3202626 treatment will be handled.To reflect the elimination of the LY3202626 
treatment arm.
I5T-MC-AACG(d)Clinical Protocol Page 115
LY3002813Revised Protocol Sections
Note: Deletions have been ident ified by strikethroughs .
Additions have been identified by  the use of underscore .
The numbering system used for inclusio n and exclusion criteria provides a unique number for 
each criterion and all ows for efficiency in data collection.
In case an amendment to the protocol adds a criterion, that criterion will receive the next 
available number, regardless of whet her it is an inclusio n or exclusion criterion.
Title Page
Protocol I5T -MC-AACG( dc) Assessment of Safety, Tolerability, and Efficacy of 
LY3002813 Alone and in Combination with LY3202626 in Early Symptomatic 
Alzheimer’s Disease
Confidential Information
Theinformation contained in this document is confidential and is intended 
for the use of clinical investigators.  It is the property of Eli Lilly and 
Com pany or its subsidiaries and should not be copied by or distributed to 
persons not involved in the clinic al investigation of LY3002813 and 
LY3002813/LY3202626 combination , unless such persons are bound by 
a confidentiality agreement with Eli Lilly and Company or its subsidiaries.
LY3002813
&
LY3202626
Multicenter, randomized, double -blind, placebo -controlled, Phase 2 study 
comparing up to 1400 mg of LY3002813 alone and in combination with 
12 mg of LY3202626 with placebo over 7680 weeks in approximately 
250300 patients with early symptomatic AD.
Section 1. Synopsis
Title of Study:
Protocol I5T-MC-AACG(c).  Ass essment of Safety , Tolerabili ty and Efficacy o f LY3002813 
Alone and in Co mbination with LY3202626 in Early Symptom atic Alzheimer’s Disease.
I5T-MC-AACG(d)Clinical Protocol Page 116
LY3002813Rationale:
This study  evaluates use of two anti -amyloid therapies with different m echanisms of act ion 
targeting the amyloid cascade.   LY3002813 is an ant ibody directed at the py roglutamate 
modification of the third amino aci d of amyloid beta (N3pG Aβ) epitope that is present only in 
brain amylo id plaques.  It is being studied for the treatment of Alzheimer’s disease (AD ).  The 
mechanism o f action of LY3002813 is considered to be the targeting and removal of exist ing 
amyloid plaque, which is a key  pathological hallmark of AD.  The clinical strategy  for 
LY3002813 targets the N3pG Aβ specific to amyloid plaque in the popula tion of early 
symptomatic AD patients with exist ing brain amyloid load, as measured using the amylo id 
plaque biomarker, florbetapi r F18 posi tron emissio n tomography (PET) imaging.  
ThisLY3202626 i s a synthetic small mo lecule, an inhibitor of β- site amyloidprecursor protein 
(APP)-cleaving enzyme [BACE]1, being assessed for the treatment of AD in an ongoing phase 2 
study.  The mechanism  of action of LY3202626 is considered to be the reduction of Aβ 
monomer production through BACE 1 inhibit ion.  Combinat ion therapyrationale is based on the 
amyloid hypothesis of AD, which states that the production and deposition o f Aβ is an early  and 
necessary  event in the pathogenesis of AD (Selkoe 2000).  Clinical support for this hypothesis 
comes from the demonstration that parenchymal Aβ levels are elevated before the appearance of 
symptoms of AD, and supported by  genetic variants of AD that overproduce brain Aβ and 
genetic variants that protect against Aβ production (Jonsson et al. 2012; Fleisher et al. 2015).  
Furthermore, early in the disease, the presence of brain amylo id appears to increase the risk of 
conversio n from mild cognit ive impairment (MCI) to AD dement ia (Doraiswamy et al. 2012).  
This suggests that enhanced clearance of Aβ will lead to slowing of AD progress ion.
This study , I5T-MC-AACG (AACG), is evaluat ing LY3002813 alone or in co mbination with 
LY3202626 compared wit h placebo.  There i s evidence suggest ing that different forms of 
amyloid (monomeric, oligomeric and insol uble plaques) may all contribute neurot oxicity 
independent ly (Selkoe 2008).  Animal models suggest that treatment with a combinat ion of a 
BACE inhibitor and an ant i-plaque ant ibody will reduce sol uble forms of amylo id and contribute 
to a greater reduction of deposited plaques compared with a pl aque-specific ant ibody alone 
(Jacobsen et al. 2014).  This may also provide synergist ic effects on plaque removal co mpared to 
either drug given independent ly with more rapid and quanti tatively greater amylo id removal 
(DeMattos 2016).  Increased and more ra pid removal of amylo id plaque plus rem oval of soluble 
forms of amylo id by parallel administrati on of both LY3002813 and LY3202626 over time is 
therefore hy pothesized to have the potential for greater clinical efficacy  than either drug given 
alone, with broader target engagement.  Combinat ion of therapeut ics has been standard of care in 
most disease clinical pract ices, such as oncology, cardio logy, and endocrino logy.  Of late, there 
has been much discussio n of the need for combinatio n therapies in AD, as an ultimate path 
toward finding beneficial treatments for patients (Hendrix 2016).
Study I5T-MC-AACG (AACG) is a Phase 2, double -blind, placebo -controlled, study  to evaluate 
the safety and efficacy of N3pG antibody  (LY3002813) alone or in combinat ion with BACE 
inhibitor (LY3202626) in patients with early symptomat ic AD (prodromal AD and mild 
dementia due to AD).  Study  AACG will assess whether removal of exist ing amylo id plaque 
I5T-MC-AACG(d)Clinical Protocol Page 117
LY3002813alone or in combinat ion with lowering of A production via BACE inhibit ioncan slowthe 
progression of disease as assessed by clinical measures and bio markers of disease patho logy and 
neurodegenerat ion over up to 7276weeks of treatment.
Multiple biomarkers of disease progress will also be evaluated.  The bio marker florbetapir F18 is 
a PET ligand that binds to fibrillar amylo id plaque.  This bio marker can provide a qualitat ive and 
quantitative measurement of brain plaque load in patients with prodromal AD ormild AD 
dementia.  The absence of significant florbetapir F18 signal on a visual read indicates that those 
patients clinically  manifesting cognit ive impairment have sparse to no amylo id plaques.  As 
such, implementation o f florbetapir F18 will  provide a screening tool for entry  into the clinical 
trialtrialsand provi de a confirmat ion of amyloid pathology.  Florbetapir F18 PET al so provides 
quantitative assessment of fibrillar amylo id plaque in the brain and can assess amylo id plaque 
reductions from the brain by LY3002813 and in combinat ion with BACE inhibit ion with 
LY3202626 .
Objective( s)/Endpoints:
Primary Objective Primary Endpoint
To test the hypothesis that LY3002813 alone 
and/or in combination with LY3202626
administered for up to 7276weeks will decrease 
the cognitive and/or functional decline in 
patients with early symptomatic ADChange in cognition and function as measured by the 
change in integrated Alzheimer’s Disease Rating Scale 
(iADRS) score from baseline to 18 months
Secondary Objectives Secondary Endpoints
To assess the effect of LY3002813 alone and in 
combination with L Y3202626 vs. placeboson 
clinical progression in patients with early 
symptomatic ADChange in cognition from baseline to 18 months as 
measured by:
the change in Alzheimer’s Disease Assessment 
Scale—Cognitive subscale (ADAS -Cog13) 
score
the change in Clinical Dementia Rating Scale 
Sum of Boxes (CDR -SB) score
the change in Mini -Mental State Examination 
(MMSE) score
the change in Alzheimer’s Disease Cooperative 
Study-instrumental Activities of Daily Living 
scale (ADCS -iADL) score 
To assess the effect o f LY3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain amyloid depositionChange in brain amyloid plaque deposition from 
baseline through 18 months as measured by florbetapir
F18 PET scan  
To assess the effect of LY3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain tau depositionChange in brain tau deposition from baseline to 18 
months as measured by flortaucipir F18 PET scan  
To assess the effect of LY3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain volume measuresChange in volumetric MRI measures from baseline to 
18 months.
I5T-MC-AACG(d)Clinical Protocol Page 118
LY3002813To assess the effect of combination therapy with 
LY3002813 and LY3202626 vs LY3002813 
alone on clinical progression in patients with 
early symptomatic ADChange from baseline to 18 months in iADRS score, 
ADAS-Cog13score, CDR-SB score, MMSE score, 
ADCS-iADL score
Safety Objective Safety Endpoints
To evaluate safety and tolerability of 
LY3002813 alone and in combination with 
LY3202626Standard safety assessments:
ospontaneously reported adverse events 
(AEs)
oclinical laboratory tests
ovital sign and body weight 
measurements
o12-lead ECGs
ophysical and neurological 
examinations
MRI (amyloid-related imaging abnormalities 
[ARIAs]and emergent radiological findings)
Skin examination
Eye examination
Columbia Suicide Severity Rating Scale
(C-SSRS)
Summary of Study Design:
Study AACG is a m ulticenter, randomized, double- blind, placebo -controlled, Phase 2 study of 
LY3002813 alone andin combinat ion with LY3202626 in subjects with early symptomatic AD.  
The 133124-week study  includes a screening period of up to 9 weeks, a treatment period of up to
7276weeks with final evaluat ions occurring 4 weeks later at Week 76, and ,a 484-week 
posttreatment fo llow-up, and a 44 -week immunogenicit y and safet y follow-up period.
Treatment Arms and Duration:
Patients will receive the following treatments for up to 7276weeks:
LY3002813 monotherapy  (LY3002813 -M):  intravenous LY3002813 (700 mg Q4WK 
for the first 3 doses, then 1400 mg Q4WK) for up to 72 weeks,in combination with daily 
oral placebo,
LY3002813 in co mbination wit h LY3202626 ( LY3002813 -C):  intravenous LY3002813 
(700 mg Q4WK for the first 3 doses, the n 1400 m g Q4WK) in combinat ion with daily 
oral LY3202626 (12 mg), or
Placebo:  intravenous placebo Q4WK for up to 72 weeksin combination with daily oral  
placebo.
Abbreviat ions:  C = combinat ion therapy; M = monotherapy
I5T-MC-AACG(d)Clinical Protocol Page 119
LY3002813Approximate Number of Patients:
Screened – 1497
Randomized – 266375
Evaluable –300 (approximately 100 per treatment group)
Statistical Analysis:
Efficacy:
The primary  objective of this study  is to test the hypothesis that intravenous infusion o f 
LY3002813 alone or in combinat ion with LY32026 26will slow the cognit ive and/or funct ional 
decline of AD as measured by the co mposite measure iADRS compared wit h placebo in patients 
with early symptom atic AD.  The change fro m baseline score on the iADRS at each scheduled 
postbaseline visit during the tr eatment period will be analyzed using an MMRM model, which 
includes the fo llowing terms:  baseline score, pooled invest igator, treatment, visit, treatment -by-
visit interaction, baseline -by-visit interaction, concomitant AChEI and/or memantine use at 
baseline (yes/no), and age at baseline.  The primary  time point for treatment comparison will  be 
at the end of the double blind treatment period (Week 76).  The treatment group contrast in least -
squares mean progression and its associated p -value and 95% CI will be calculated for the
treatment comparisonof LY3002813-C vs. placebo and LY3002813 -M vs. placebo.  In addition, 
Bayesian posterior probabilit y of theactive treatment arm being superior to placebo by at least a 
margin of interest (25% slowing of placebo progressio n) will also be calculated.
Pharmacokinetics/Pharmacodynamics :
Compartmental modeling of LY3002813 and LY3202626 PK data using nonlinear mixed effects 
modeling or other appropriate software may  be explored, and populat ion estimates for clearance 
and central  volume of distribution may  be reported.  Depending on the model selected, other PK 
parameters may also be reported.  Exploratory  graphical analyses of the effect of dose level or 
demographic factors on PK parameters may  be conducted.  If approp riate, data from other 
studies of LY3002813 or LY3202626 may beused in this analysis.
Pharmacokinet ic/pharmacodynamic ( PK/PD) rel ationships between plasma LY3002813 
concentration and SUVr, cognit ive endpoints, ARIA incidence rate or other markers o f PD 
activity may be explored graphically .  The relati onship between the presence of ant ibodies to 
LY3002813 and PK, PD, safet y and/or efficacy  may be assessed graphically .  The effect of 
LY3202626 exposure on SUVr, cognit ive endpo ints, or other markers of PD act ivity may also be 
explored graphically.  Graphical and/or descript ive analyses may be explored to evaluate 
potential interactions between LY3002813 and LY3202626 for PK.   If warranted, addit ional 
analysis may  be explored to eval uate potenti al interactions for ADA, PD and other endpoints 
(PET scan, ARIA- E, etc.).  Additional modeling may  be performed based on the results of the 
graphical analyses.
Section 2. Schedule of Activities
I5T-MC-AACG(d)Clinical Protocol Page 120
LY3002813Schedule of Activities Protocol -I5T-MC-AACG Visit 1 (Screening Period)
Period:
Procedure
Visit No.: V1
End of Week Relative to Study Medication StartaWk -9 through Wk -1
Tolerance Interval for Visit (days)a,b63
PRELIMINARY SCREENING
Entry Diagnostics 
  MMSEc,d,suX
SCREENING
  Ophthalmological examinationfX
  Dermatological examinationgX
Safety Assessments
   Vital signsfhX
   Height and WweightgiX
   ECG in triplicatehjX
   C-SSRS/SHSF/SHFUi,jk,lX
Laboratory Specimens
  Human chorionic gonadotropin (HCG) (if applicable)k,l,m,n,oXb
  HBsAgnpX
  HCV RNA PCRoqX
Screening PET Scans and MRI
   Flortaucipir F18 PET Sscanl,pn,rX
   MRIqsX
   Florbetapir F18 PET scanb,m,ro,tX
I5T-MC-AACG(d)Clinical Protocol Page 121
LY3002813Abbreviations:  HBsAg = hepatitis B surface antigen; HCV = hepatitis C virus; MRI = Mmagnetic Rresonance 
Iimaging; PCR = polymerase chain reaction; SHFU = Self -Harm Follow -Up.
aThe interval between V1 and V2 may be up to 63 days to allow for completion of V1 screening procedures, 
assessments, and evaluation of results from laboratory tests and ECGs.  V1 is no t considered complete until all 
screening procedures have been completed and results reviewed by the investigator to determine patient 
eligibility.  V1 may be conducted over more than 1 day.  Subjects in screening at the time screening was paused 
are allowed to continue screening beyond the 63 days to allow for completion of V1 screening procedures; this 
will not be a protocol deviation.  Additio nal details are provided in Section 5.1.1.  Subjects who had completed 
screening but were not yet randomized at t he time randomization was paused are allowed to be randomized 
beyond 63 days; this will not be a protocol deviation.  Additional details are provided in Section 5.1.1.
bA florbetapir F18 PET scan is the final screening criterion for establishing patient e ligibility, although theMRI, 
ophthalmological and dermatological exams may be performed after the florbetapir F18 PET scan.  Patients 
whose screening florbetapir F18 PET scan results are not available within the 63 day screening window will 
remain eligibl e within V1 until these results become available if all other eligibility criteria have been met.  Note:  
If a patient’s screening florbetapir F18 PET scan result confirming eligibility for the study has not been received 
by the site by Day 63 of the scree ning period, then repeat the following laboratory tests:  blood hematology, 
chemistry , and serum pregnancy test (HCG) for women of childbearing potential (WOCBP).  Results of the 
repeated labs are to be reviewed by the investigator or qualified designee fo r assessment of the patient’s 
continued eligibility.  Repeat screening for MMSE, CBB, C -SSRS, ECG , dermatological and ophthalmological 
examinations , flortaucipir F18 PET, MRI, and laboratory testing for HBsAg, and HCV RNA PCR is not 
required.  V1 is not co nsidered complete until all screening procedures have been completed and results reviewed 
by the investigator or qualified designee to determine patient eligibility.
cA preliminary screening informed consent may be obtained to conduct initial screening to collect demographics 
data and administer the MMSE and CBB.  Patients who do not meet the  MMSE screening criteria are not to 
have any other screening procedures performed with the exception of the CBB.  The CBB should be 
administered to all patients at th e screening visit, regardless of the MMSE score.  They may be rescreened for the 
MMSE 8 weeks after the first screen.  Study partners are not required to complete the preliminary screening 
informed consent.
dPatients who meet the MMSE screening criteria may proceed to the remaining screening procedures once they 
have given signed/dated informed consent for the full study and their study partner has given signed/dated 
informed consented to participate as a study partner.
eA complete physical and neurological exam is to be performed at this visit.  Additional details are provided in 
Section 9.4.1.
fEye examinations must be conducted by an ophthalmologist or optometrist (where permitted by law).  Additional 
details are provi ded in Section 9.4.6.3.
gSkin examinations must be conducted by a dermatologist.  Additional details are provided in Section 9.4.6.4
fhSitting Bblood pressure and pulse will be m easured after 5 minutes in the sitting position only.  Temperature will 
be collected with sittingvital signs.
giHeight and weight will be measured with shoes removed.
hjECGs should be taken in triplicate at approximately 1 -minute intervals.  ECGs should be collected at 
approximately the same time of day, as much as possible, to minimize diurnal variation.
ikThe baseline version of the C -SSRS is to be administered at V1.  Patients at imminent risk of suicide (positive 
response to question 4 or 5 on the C -SSRS) will be excluded from participating in the study.
I5T-MC-AACG(d)Clinical Protocol Page 122
LY3002813jlThe Self-Harm Supplement form SHSFis completed after each C -SSRS administration to enter the number of 
discrete events of suicidal behavior identified.  If, based on administration of the C -SSRS, it is determined that 
suicide-related behaviors have occurred, then the Self Harm Follow -Up (SHFU)form will be used to collect 
additional information to allow for a more complete assessment of these behaviors.
kmFemales of childbearing potential are to have a serum pregnancy test (HCG) at V1 (if applicable).
lnFemales of child bearing potential are to have a urine pregnancy test (HCG) on the day  of flortaucipir F18 PET 
imaging before the flortaucipir F18 dose is administered.
moFemales of childbearing potential are to have a urine pregnancy test (HCG) on the day  of florbetapir F18PET 
imaging before the florbetapir F18 dose is administered.
npPatients with a past history of Hepatitis B are to have a serum HBsAg test at screening V1 and are excluded if the 
HBsAg test is positive.
oqPatients with a past history of Hepatitis C are to have a HCV RNA PCR test at screening V1 and are excluded if 
the HCV RNA PCR test is positive.
prA screening flortaucipir F18 PET scan will be performed as part of the study eligibility criteria at all sites to 
determine patient eligibility for participation in Study AACG (see Appendix 5 ).  With the exception of an MRI 
anda florbetapir F18 PET scan, ophthalmological, and dermatological exams, a patient should meet all other V1 
eligibility criteria before having a screening flortaucipir F18 PET scan.  The flortaucipir F18 PET scan will be 
submitted to a centralized PET imaging vendor designated by Lilly for an assessment of patient’s eligibility.  A 
historical flortaucipir F18 PET scan may be submitted to b e considered for eligibility if performed within 6 
months of V1.
qsA local screening MRI will be performed at V1 as part of the study eligibility criteria.  With the exception of the 
evidence of amyloid pathology by florbetapir F18 PET scan, and ophthalmo logical and dermatological exams, a 
patient should meet all other V1 eligibility criteria before having an MRI scan.  The MRI scans will be reviewed 
by the investigator or qualified designee for immediate patient management.  After the MRI scan is read loc ally, 
the scan is to be submitted to the centralized MRI vendor designated by Lilly for final determination of MRI 
eligibility.  Results of centrally read MRIs will be used for data analysis and report -writing purposes and patient 
safety and eligibility wi ll be reported back to sites.
rtA screening florbetapir F18 PET scan will be performed as part of the study eligibility criteria to determine 
patient eligibility for participation in Study AACG (see Appendix 6 ).  With the exception of an MRI and 
ophthalmo logical and dermatological exams , a patient should meet all other V1 eligibility criteria before having a 
screening florbetapir F18 PET scan.  The PET scan will be submitted to a centralized PET imaging vendor 
designated by Lilly for assessment of patient’s eligibility.  The florbetapir F18 PET screening criteria must be 
met (scan results consistent with the presence of amyloid pathology) in order for the patient to proceed to V2 and 
be randomized to trea tment assignment.
suAssessment is to include the audio voice recording of the rater’s questions and the patient and caregiver 
responses to assessment questions.
I5T-MC-AACG(d)Clinical Protocol Page 123
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 14 (Doubl e-Blind Period)
Period:
ProcedureRand
Visit No.: V2a,bV3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14
End of Week Relative to Study Medication Start0 4 8 12 16 20 24 28 32 36 40 44 48
Tolerance Interval for Visit (days) 0777777777777
Inclusion/exclusion review X X X X X X X X X X X X X
   Contact IWRS –dispensation of study medicatio n
   (LY3002813 and LY3202626 )XeX X X X X X X X X X X X
   Physical/neurological examinationefXfgXfgXfgXgh
   Ophthalmological examinationhi jkXhXhX
   Dermatological examinationij jkXiXi
   Previous/concomitant medications X X X X X X X X X X X X X
   Preexisting conditions/adverse eventsefX X X X X X X X X X X X X
   LY3002813 study medication administeredk  
Assess LY3202626 complianceX X X X X X X X X X X X X
   LY3202626 study medication administered at site tX X
   LY3002813 Study medication administered l X XXXXXXXXXXXX
Efficacy Measures
   ADAS-Cog 13l,ffm,jjX X X X
   ADCS-ADLl,ffm,jjX X X X
   CDR-SBl,ffm,jjX X X X
   MMSEl,ffm,jjX X X
Safety Assessment
   C-SSRS/SHSF /SHFUm,no   mnX X X X X X X X X X X X
I5T-MC-AACG(d)Clinical Protocol Page 124
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 14 (Double -Blind Period)
Period:
ProcedureRand
Visit No.: V2a,bV3 V4 V5 V6 V7 V8 V9 V10 V11 V12 V13 V14
End of Week Relative to Study Medication Start 0 4 8 12 16 20 24 28 32 36 40 44 48
Tolerance Interval for Visit (days) 0777777777777
Laboratory Specimensop
   Clinical chemistry, hematologypqX X X X X X
   High sensitivity C -reactive proteinpqX X X X X X
   UrinalysispqX
   Serum for anti -LY3002813 antibodypqX X X X X X X
   Serum LY3002813q,rr,sXqXrsXrsXqrXrsXqrXrs
   Plasma LY3202626t,u,vXt, uXvXvXt, uXvXv
   Blood for assessment of APOE genotypep,sq,wX
   Whole blood, plasma and serum for biomarker 
storagep,tq,xXX X X
   Blood for pharmacogenomicsp,t,uq,x,yX
Other Safety Measures
   Weight X X X X
   Vital signs and te mperaturev,wz,aaXwaaX X XwaaX X XwaaX X XwaaX X X
   ECG in triplicatexbbX X X X X X
   MRIycc zddX XaaeeX X X
Additional Efficacy Measures
  Flortaucipir F18 PET scanbb,ccff,gg zdd
  Florbetapir F18 PET scanbb,ddff,hh
zdd Xbb,ddff,
hh
I5T-MC-AACG(d)Clinical Protocol Page 125
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 15 through Visit 2122(Double-Blind Period) and Follow -Up
Period:
Procedure
Visit No.:V15 V16 V17 V18 V19 V20 V21 V22 EDcV801-
V804d,eeii
End of Week Relative to Study Medication Start 52 56 60 64 68 72 76 80 88-124
Tolerance Interval for Visit (days) 77777777 14
   Inclusion/exclusion review X X X X X X X
   Contact IWRS –dispensation of study medications
   (LY3002813 and LY3202626 )X X X X X X     
   Physical/neurological examination ef XfgXghXfgXgXfg
   Ophthalmological examinationh,jiX XXh
   Dermatological examinationi,jjX XXi
   Previous/concomitant medications X X X X X X X X X X
   Preexisting conditions/adverse events ef X X X X X X X X X X
   Assess LY3202626 compliance X XX X X XX X
   LY3002813 Sstudy medication administeredkl X X X X X X
Efficacy Measures
   ADAS-Cog 13l,ffm,jjX X X X
   ADCS-ADLl,ffm,jjX X X X
   CDR-SBl,ffm,jjX X X X
   MMSEl,ffm,jjX X X X
Safety Assessment
   C-SSRS/SHSF/SHFU m,no X X X X X X X X X X
I5T-MC-AACG(d)Clinical Protocol Page 126
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 15 through Visit 2122(Double-Blind Period) and Follow -Up
Period:
Procedure
Visit No.:V15 V16 V17 V18 V19 V20 V21 V22 EDcV801-
V804d,eeii
End of Week Relative to Study Medication 
Start52 56 60 64 68 72 76 80 88-124
Tolerance Interval for Visit (days)77 7 77777 14
Laboratory Specimensop
   Clinical chemistry, hematologypqX X X X X
   High sensitivity C -reactive proteinpqX X X X X
   UrinalysispqX X X X X
   Serum for anti -LY3002813 antibodypqX X X X
   Serum LY3002813p,q,rr,sXqrXrsXqrXrsXrsXrs
   Plasma LY3202626t,u,vXvXvXvXv
   Blood for assessment of APOE genotypep,sq,w
   Whole blood, plasma and serum for biomarker 
storagep,tq,x X X X X
   Blood for pharmacogenomicsp,t,uq,x,y
Other Safety Measures
   Weight X X X X X
   Vital signs and temperaturev,wz,aaXwaaX X XwaaX X XwaaXaaX XaaX 
   ECG in triplicatexbbX X X X X
   MRIyccX X X
Additional Efficacy Measures
   Flortaucipir F18 PET Scanbb,ccff,ggXbb,ccff,
ggXbb,ccff,
gg
   Florbetapir F18 PET scanbb,ddff,hhXbb,
ddff,h
hXbb,ddff,
hhXbb,ccff,
gg
I5T-MC-AACG(d)Clinical Protocol Page 127
LY3002813Schedule of Activities, Protocol I5T -MC-AACG, Visit 2 through Visit 2122(Double-Blind Period) and 
Follow-Up Abbreviations and Footnotes
Abbreviations:  APOE = aApolipoprotein subtype E; ARIA-E = amyloid related imaging abnormalities –
edema/effusions
aConfirm that the patient has met all V1 eligibility criteria before proceeding with V2 procedures.
bAt V2, appointments should be made for all remaining visits and should be scheduled as close as possible to the 
target date, relative to V2.  Procedures fo r some visits may take more than 1 day.
cIf a patient discontinues before the double -blind period endpoint (V 21V22at Week 7680), complete the Early 
Discontinuation CRFs.  The patient should be encouraged to return to the site beginning 12 weeks after the ED 
visit for an immunogenicity follow -up visit (V isit 801through V804 ).
dPatients are to return to the site for collection of blood samples and safety assessments for assessment of 
immunogenicity status at V isit 801 (Week 88).  Follow -up for patients experiencing clinically significant events 
associated with TEADA status is described in Sec tion 9.4.7.2.
ePatients are to take oral study medication (placebo or LY3202626) once per day in the morning.  The first dose 
should be taken the morning after the first dispensing of oral study medication at Visit 2.
efAny clinically  significant changes from baseline on follow -up physical/neurological examinations should be 
noted on the AE page.
fgA complete physical and neurological exam is to be performed at thi s visit.  Additional details are provided in 
Section 9.4.1.
ghA brief physical and neurological exam is to be performed at this visit.  Additional details are provided in Section 
9.4.1.
hEyeOphthalmological examinations will be performed only in patients who previously received LY3202626/oral 
placebo in this study.  The finalexamination for each patient will be the next scheduled op hthalmological 
examination after the final administration of LY3202626/oral p lacebo.  It will not be considered a protocol 
deviation if this examination is scheduled sooner than indicated above in order to accommodate patient and/or 
site preference.  Patients w ho received LY3202626/oral placebo after their V9 ophthalmological examination are 
to have an unscheduled ophthalmological examination at the next available opportunity.   TheseEye
examinations must be conducted by an ophthalmologist or optometrist (where permitted by law).  Additional 
details are provided in Sectio n 9.4.6.3.
iDermatological examinations will be performed only in patients who previously received LY3202626/oral 
placebo in this study.  The finalexamination for each patient will be the next scheduled dermatological 
evaluation after the final administration of LY3202626/oral placebo.  It will not be considered a protocol 
deviation if this examination is scheduled sooner than indicated above in order to accommodate patient and/or 
site preference.  Patients w ho received LY3202626/oral placebo after their V8 der matological examination are to 
have an unscheduled dermatological examination at the next available opportunity.   Theseexaminations must be 
conducted by a dermatologist.  Additional details are provided in Section 9.4.6.4.
jFor subjects randomized prior to amendment (d), the eyeophthalmological and skindermatological examination 
performed at screening will serve as the baseline eyeophthalmological and skindermatological examination.
klStudy drug will be administered by intravenous administration at i nvestigative study site.  Patients should be 
observed for approximately 2 hours following each infusion of LY3002813 for the first 6 infusions.  After the 
first six doses, a minimal post -infusion observation time of 60 minutes will be required for all subs equent 
infusions.  However, patients w ho have had dosing restarted after ARIA -E are required to be monitored for 
2hours following infusion for a minimum of 3 subsequent infusions, and a minimum of 60 minutes post -infusion 
observation thereafter.
lmWhen administered, cognitive and functional assessments (ADAS -Cog13, ADCS-ADL, CDR, and MMSE) 
should be performed first, before medical procedures that could be stressful for the patient (e.g., blood draws).
mnThe C-SSRS administered at screening will serve as the baseline C -SSRS.
I5T-MC-AACG(d)Clinical Protocol Page 128
LY3002813noThe ‘since last visit’ version of the C -SSRS will be administered at visits after V2 (Week 0) to the patient with 
the study partner/study informant present, after the cognitive and functional assessments.  The Self-Harm 
Supplement form (SHSF) is completed after each C -SSRS administration to enter the number of discrete events 
of suicidal behavior identified.  If, based on administration of the C -SSRS, it is determined that suicide -related 
behaviors have occurred, then the SHFU form will be used to collect additional information to allow for a more 
complete assessment of these behaviors
opUnscheduled laboratory tests may be performed at the discretion of the investigator.
pqLabs are to be collected prior to administration of the int ravenous study medication (LY3002813 or IV placebo).  
Record the date and times of sample collection on the Lab Requisition Form.
qrPre-dose(before beginning the infusion) samples for intravenous study medication (LY3002813) may be 
collected from the int ravenous site prior to beginning the infusion. Post-dose(within 30 minutes of completion 
of the infusion) samples for intravenous study medication (LY3002813) should be collected from the arm that 
did not receive the infusion at V2 (Week 0), V5 (Week 12) , V8 (Week 24), V15 (Week 52), and V20 (Week 72).
rsA single pre -dose LY3002813 sample should be collected before beginning the infusion at V3 (Week 4), V4 
(Week 8), V6 (Week 16), V11 (Week 36), and V18 (Week 64).  In addition, a single sample for serum 
LY3002813 should be collected at V21 (Week 76), or ED, and V801 (visits at which the patient may not receive 
a study drug infusion).  If LY3002813 infusion is permanently discontinued but the patient remains in the study, 
one PK sample should be collected at the soonest scheduled visit regardless if serum LY3002813 is on the 
Schedule of Activities at that visit.  Subsequent PK sample collection should follow the protocol Schedule of 
Activities for serum LY3002813 collection unless the scheduled visit exceed s 6 months since discontinuation of 
infusions.  No additional serum collection for LY3002813 is required once the patient exceeds 6 months since 
discontinuation of LY3002813 infusions.  Record the actual date and times of sample collection on the Lab 
Requisition Form.
tPrior to V3 (Week 4) and V6 (Week 16), a phone call should be made approximately 1 business day before the 
clinic visit to remind patients to hold the morning dose of oral study medication (LY3202626) on the day of the 
visit and to bring the dose to the clinic.
uPre-dose (before taking oral study medication) and post -dose (prior to the patient departing the site) samples for 
oral study medication (LY3202626) should be collected at V3 (Week 4) and V6 (Week 16).  Record the date and 
times of s ample collection on the Lab Requisition Form.  The actual time of LY3202626 dose administrations on 
the day of study visits will be recorded in the subject’s case report form (CRF).  In addition, the actual time of 
LY3202626 dose administration for the 2 d ays prior to each visit at which LY3202626 PK samples will be 
collected will be recorded in the subject’s CRF.
vA single LY3202626 sample should be collected at V4 (Week 8), V5 (Week 12), V8 (Week 24), V11 (Week 36), 
V15 (Week 52), V18 (Week 64), and V21 (Week 76) or ED.  Record the date and times of sample collection on 
the Lab Requisition Form.   The actual time of LY3202626 dose administrations on the day of study visits will be 
recorded in the subject’s CRF.  If LY3202626 is permanently discontinued but the patient remains in the study, a 
final sample should be collected, provided the last dose of LY3202626 is within 3 days of the visit.  No other PK 
samples for LY3202626 are required after the final sample.  In addition, the actual time of LY3202626 dos e 
administration for the 2 days prior to each visit at which LY3202626 PK samples will be collected will be 
recorded in the subject’s CRF.
swA blood sample will be collected to determine APOE genotype.  The APOE genotype sample may be collected at 
an alternative visit if it cannot be collected at V2.
txBlood for biomarker storage, and blood for pharmacogenomic samples are to be collected unless not allowed or 
unfeasible due to local regulations prohibiting sample transport outside of the country.
uyPharmacogenomic samples may be collected at an alternative visit if they cannot be collected at V2.  It will not 
be a protocol deviationviolation if a biomarker storage sample cannot be collected for technical reasons (e.g., if 
the site is unable to collect eno ugh blood via venipuncture).
vzSitting blood pressure and pulse will be measured after 5 minutes in the sitting position at allvisits.  Temperature 
will be collected with sitting vital signs.
I5T-MC-AACG(d)Clinical Protocol Page 129
LY3002813waaIn addition, orthostatic blood pressure and pulse will be measured at V2 (Week 0), V5 (Week 12), V8 
(Week24), V11 (Week 36), V15 (Week 52), V18 (Week 64), V21 (Week 76), V22 (Week 80) or ED, and at 
unscheduled visits after 5 minutes in the supine position and after 3 minutes standing.
xbbElectrocardiograms shou ld be taken in triplicate at approximately 1 -minute intervals.  ECGs should be collected 
at approximately the same time of day, as much as possible, to minimize diurnal variation.  ECGs are to be 
performed prior to the administration of intravenous study m edication (LY3002813 and IV placebo).
yccIf MRI is done on the same day as cognitive and functional assessments, then it should be done after cognitive 
and functional tests.  MRI may be done before other visit procedures, including cognitive and functional tests, 
but in that case must be done at least 1 day before other visit procedures.
zddThe screening flortaucipir F18 PET scan, MRI, and florbetapir F18 PET scan done at V1 serve as the baseline 
flortaucipir F18 PET scan, MRI and florbetapir F18 PET scan, respectively .
aaeeThe V5 MRI is to be performed 2 weeks prior to the V5 (Week 12) LY3002813 infusion to allow for 
receipt and review of the central vendor MRI report prior to a possible LY3002813 dose change at V5 (Week 
12).
bbffFemales of chi ldbearing potential are to have a urine pregnancy test (HCG) performed on the day of 
florbetapir F18 PET and flortaucipir F18 PET imaging before the florbetapir F18 dose or flortaucipir F18 dose is 
administered to confirm that they are not pregnant.
ccggAll patients will have a flortaucipir F18 PET scan done at V21 (Week 76) or ED (if ED occurs more than 
36 weeks after randomization) (se e Appendix 5 ).  Before the flortaucipir F18 PET scan, the investigator should 
review the patient’s medical history and concomitant medications to verify there is no risk factor for Ttorsades de 
Ppointes and review the most recent ECG. If clinically meaningful abnormalities are noted on the ECG, th e 
advisability of the flortaucipir scan should be considered by the investigator in consultation with the 
Lilly-designated medical monitor. Patients permanently discontinued from LY3202626 study treatment due to 
initiation of a pro hibited medication known to prolong the QT -interval should not have an ED flortaucipir scan 
unless the scan can be performed prior to initiation of the prohibited medication.   The study investigator and site 
clinical study team will not have access to the flortaucipir F18 follow-up scans, as the site clinical study team 
must remain blinded to any potential changes in tau deposition .
ddhhAll patients will have double -blind period florbetapir F18 PET scans done at V8 (Week 24), V15 (Week 
52), and V21 (Week 76) or ED (if ED occurs mo re than 8 weeks after a florbetapir F18 PET scan has been 
performed at a previous visit) (see Appendix 6 ).  The study investigator and site clinical study team will not have 
access to any florbetapir F18 follow -up scans, as the site clinical study team mus t remain blinded to any potential 
changes in amyloid deposition.
eeiiPatients are to return to the site for an immunogenicity and safety follow -up visit (V isit 801) at Week 88 (or 12 
weeks after the ED visit) for collection of blood samples for anti -drug antibody (ADA) measurements and 
assessment of adverse events and concomitant medications.  The need for additional study visits after V801 will 
be determined by results of the ADA sample taken at V801.  A patient will stop immunogenicity follow -up visits 
when they either complete 3 additional quarterly visits (Week 100, Week 112, and Week 124) or complete a visit 
at which their ADA returns to baseline (2 -fold titer from baseline), whichever occurs first.  See Section 5.1.3and 
Section 9.4.7.2for details.
ffjjAssessment is to include the audio voice recording of the rater’s questions and the patient and caregiver 
responses to assessment questions.
3.Introduction
3.1.Study Rationale
This study  evaluates use of two anti -amyloid therapies with different mechanisms of act ion 
targeting the amylo id cascade.   LY3002813 is an ant ibody directed at the py roglutamate 
modification of the third amino aci d of amyloid beta (N3pG Aβ) epitope that is present only in 
I5T-MC-AACG(d)Clinical Protocol Page 130
LY3002813brain amylo id plaques.  It is being studied for the t reatment of Alzheimer’s disease (AD).  The 
mechanism o f action of LY3002813 is considered to be the targeting and removal of exist ing 
amyloid plaque, which is a key  pathological hallmark of AD.  The clinical strategy  for 
LY3002813 targets the N3pG Aβ speci fic to amyloid plaque in the populat ion of early 
symptomatic AD patients with exist ing brain amyloid load, as measured using the amylo id 
plaque biomarker, florbetapi r F18 posi tron emissio n tomography (PET) imaging. This 
LY3202626 is a synt hetic small mo lecule, an inhibitor of β -site amyloid precursor protein 
(APP)-cleaving enzyme [BACE]1, being assessed for the treatment of AD in an ongoing phase 2 
study.  The mechanism  of action of LY3202626 is considered to be the reduction of Aβ 
monomer production throug h BACE 1 inhibit ion.  Combinat ion therapy rationale is based on the 
amyloid hypothesis of AD, which states that the production and deposition o f Aβ is an early  and 
necessary  event in the pathogenesis of AD (Selkoe 2000).  Clinical support for this hypothes is 
comes from the demonstration that parenchymal Aβ levels are elevated before the appearance of 
symptoms of AD, and supported by  genetic variants of AD that overproduce brain Aβ and 
genetic variants that protect against Aβ production (Jonsson et al. 2012; Fleisher et al. 2015).  
Furthermore, early  in the disease, the presence of brain amylo id appears to increase the risk of 
conversio n from mild cognit ive impairment (MCI) to AD dement ia (Doraiswamy et al. 2012).  
This suggests that enhanced clearance of Aβ will lead to sl owing of AD progression.
This study , I5T-MC-AACG (AACG), is evaluat ing LY3002813, alone or in combinat ion with 
LY3202626, compared with placebo.  There is evidence suggest ing that different forms of 
amyloid (monomeric, oligomeric and insol uble plaques) may all contribute to neurotoxicit y 
independent ly (Selkoe 2008).  Animal models suggest that treatment with a combinat ion of a 
BACE inhibitor and an ant i-plaque ant ibody will reduce sol uble forms of amylo id and contribute 
to a greater reduction of deposited plaques com pared with a plaque-specific ant ibody alone 
(Jacobsen et al. 2014).  This may also provide synergist ic effects on plaque removal co mpared to 
either drug given independent ly with more rapid and quanti tatively greater amylo id removal
(DeMattos 2016).  Increased and more rapid removal of amylo id plaque plus rem oval of soluble 
forms of amylo id by parallel administrati on of both LY3002813 and LY3202626 over time is 
therefore hy pothesized to have the potential for greater clinical efficac y than either drug given 
alone, with broader target engagement.  Combinat ion of therapeut ics has been standard of care in 
most disease clinical pract ices, such as oncology, cardio logy, and endocrino logy.  Of late there 
has been much discussio n of the need for combinatio n therapies in AD, as an ult imate path 
toward finding beneficial treatments for patients (Hendrix 2016).
Study I5T-MC-AACG (AACG) is a Phase 2, double -blind, placebo -controlled study  to evaluate 
the safety and efficacy of N3pG antibody  (LY3002813) alone or in combinat ion with BACE 
inhibitor (LY3202626) in patients with early symptomat ic AD (prodromal AD and mild 
dementia due to AD).  Study  AACG will assess whether removal of exist ing amylo id plaque 
alone or in combinat ion with lowering of A β production via BACE inhibit ioncan slow the 
progression of disease as assessed by clinical measures and bio markers of disease patho logy and 
neurodegenerat ion over up to 72 weeks of treatment 76 weeks of treatment.  No LY3202626 
monotherapy  arm is included in this proof of concept study .  Clinical tri als using LY3202626 
I5T-MC-AACG(d)Clinical Protocol Page 131
LY3002813and other BACE inhibitors as monotherapies are being conducted which may provide further 
understanding of the safet y and efficacy  data collected in thi s study.
Multiple biomarkers of disease pr ogress will also be evaluated.  The bio marker florbetapir F18 is 
a PET ligand that binds to fibrillar amylo id plaque.  This bio marker can provide a qualitat ive and 
quantitative measurement of brain plaque load in patients with prodromal AD ormild AD 
dementia.  The absence of significant florbetapir F18 signal on a visual read indicates that those 
patients clinically  manifesting cognit ive impairment have sparse to no amylo id plaques.  As 
such, implementation o f florbetapir F18 will  provide a screening tool for entry into the clinical 
trialsand provi de a confirmat ion of amylo id pathology .  Florbetapir F18 PET al so provides 
quantitative assessment of fibrillar amylo id plaque in the brain and can assess amylo id plaque 
reductions from the brain by LY3002813 andin combinat ion with BACE inhibit ion with 
LY3202626 .
3.2.Background
Alzheimer’s disease is an age -related neurodegenerative disorder characterized by progressive 
decline in cognit ive function and the abilit y to perform activities of daily living, ult imately 
resulting in dement ia, typically with fatal complications.  The amylo id hypothesis of AD 
postulates that the accum ulation of amylo id-β peptide (Aβ) i s an early and necessary  event in the 
pathogenesis of AD.  This hypothesis suggests that treatments that slow the accum ulation of Aβ 
plaque in the brain or increase clearance of Aβ may  be able to sl ow the progression of the AD 
clinical syndro me.  It is further postulated that combinat ion of treatments that target both 
removal of Aβ plaque in the brain and re duce production of Aβ mo nomers may have added 
benefit.  The other hallmark neuropathological lesion of AD, intraneuronal neurofibrillary 
tangles consist ing of tau proteins, is thought to be another marker for disease progression (Braak 
and Braak 1996).  Th e relationship between these 2 pathologies is st ill unclear, although the 
presence of both is necessary for the diagnosis of definite AD.
Amyloid βis part of the APP, which is a transmembrane protein widely expressed on the cell 
surface, particularly  in neurons.  The APP has been found to be cleaved through 2 cleavage 
pathways invo lving 3 secretase enzymes:  -secretase, γ -secretase, and -secretase (now called 
-site APP-cleaving enzyme [BACE]1).  Cleavage of APP by  -secretase precludes the 
formation of Aas the site is located within the A sequence.  In the second pathway, 
-secretase cleaves the APP mo lecule, generat ing membrane -associated C99 and releasing a 
larger secreted fragment called secreted APP (sAPP) .  γ-Secretase then cleaves C99 in a 
heterogeneous fashion wit hin the membrane releasing a variet y of Aspecies that aggregate in 
protofibrils, then fibrils, which seem to comprise the ma ss of Aplaques in AD brain t issue 
(Turner et al. 2003).  While both γ- and β-secretase inhibit ion represent effect ive means of 
precluding the form ation of A, -secretase inhibit ion may provide improved safet y and 
tolerability (Doody  et al. 2013).
3.2.2.LY3002813 Phase 1 Studies
I5T-MC-AACD (Study  AACD) i s an ongoing Pphase 1b single -and multiple-dose study  to 
assess the safet y, tolerability, PK, and PD of single and mult iple IV doses of LY3002813 in 
I5T-MC-AACG(d)Clinical Protocol Page 132
LY3002813patients with mild cognit ive impairment due to AD or mild to moderate Alzheimer’s dement ia.  
It is evaluatingcurrently enrolling, with up to 150 patients in 6sevendifferent dosing cohorts 
receiving single, every 2 weeks, or every  4 weeks dosing of eit her 10 mg/kg, 20 m g/kg or 40 
mg/kg of LY3002813.  Treatme nt durationsbeing assessed include single dose, six mo nth dosing 
every two weeks, or up to 72 weeks of every 4 week dosing.  Safet y, PK and PD data fro m this 
ongoing study  are used to inform further development of LY3002813.  See Section 3.3 and the 
IB for detailed safet y and PK informat ion regarding LY3002813.
3.2.3.LY3202626 Nonclinical Studies
[Section deleted]
3.2.4.LY3202626 Clinical Studies
[Section deleted]
3.2.5.LY3002813/LY3202626 Combination Therapy -Nonclinical 
Findings
[Section deleted]
3.3.Benefit/Risk Assessment
3.3.1.Benefit
There is a large unmet medical need for disease -modifying treatments for AD. Data from the 
completed Phase 1a Study  AACCAnimal models suggest that combinat ion of a BACE inhibitor 
with an anti-plaque antibody  will reduce so luble forms of amylo id and from the ongoing Phase 
1b Study AACD indicate a dramat iccontribute to reduction in cerebral amylo id (as assessed by 
florbetapir F18 PET imaging) in individuals who received repeated doses of at least 10 mg/kg 
(IB; Fleisherof insoluble plaques com pared to a plaque -specific ant ibody alone.  This may also 
provide synergist ic effects on plaque removal co mpared to either drug given independent ly with 
more rapid and quant itatively greater amylo id removal (DeMattos 2016; Hole et al. 2018).  
Along with2016).  Increased and more rapid removal of amylo id plaque plus rem oval of soluble 
forms of amylo id by parallel administrati on of both LY3002813 and LY3202626 over time is 
therefore hy pothesized to have greater clinical efficacy  than either drug given alo ne, with 
broader target engagement.
In addition to assessment of safet y and tolerability of LY3002813 single and combined therapies , 
this study will assess whether removal o f existing amylo id plaque alone or in conj unction with 
inhibition of Aproduction in the brain will show evidence of slowed clinical decline and 
change in bio markers of disease progression relative to placebo treatment.
Although there are currently no available disease -modifying agents for the treatment of AD, 
there are several medicat ions approved by  the Food and Drug Administration ( FDA)and Health 
Canada for the treatment of symptoms of AD; these include acet ylcholinesterase inhibitors (e.g., 
donepezil, galantamine, and rivast igmine) and the N methyl D aspartate receptor antagonist 
memantine.  Because these medicat ions are considered sta ndard of care for the treatment of AD, 
I5T-MC-AACG(d)Clinical Protocol Page 133
LY3002813participants in thi s trial will be permitted to take these medications during the course of the 
study, provided that they have been on a stable dose at the time of rando mization and rem ain on 
a stable dose throughout the study.
3.3.2.Risks
Potential risks (discussed below) for LY3002813 and LY3202626 given alone include, but are 
not limited to ,:  1) LY3002813 -formation of ant i-drug antibodies (ADA), hypersensit ivity 
(immediate and non -immediate, including infusio n-related reactions), and amyloid related 
imaging abnormalit ies (ARIA). ) and 2) LY3202626 -hepatic effects, QT prolongation wit h 
overdose, skin or hair hypopigmentation, rash, retinal changes, and potential interactions with 
other drugs.
LY3002813 –Anti-Drug Antibodies:   High incidences of treatment -emergent anti -drug 
antibodies (TEADAs) have been observed in clinical studies wit h LY3002813.  Although there 
were no serious adverse events (SAEs) related to the development of ADAs in Study  AACC, the 
incidence of TEADAs in LY3002813- exposed patients and subjects was >90 %; in Study  
AACD, the incidence of TEADAs to date (final protocol) in LY3002813 -exposed pati ents and 
subjects is approximately 75 %.  In AACD, on 10 mg/kg Q2WK dosing, one patient was 
observed wit h a highly elevated ADA titer of 1:163840 on Day  144 postbaseline, with no clinical 
consequences.  Ant i-drug antibodies levels may affect PD levels o f drug effect.  Infusion 
reactions and ADAs are potential risks commo n to all large mo lecules.  See the IB for details 
regarding TEADAs.
LY3002813 –Hypersensitivity (Immediate and Non- immediate ,), including infusion -related 
reactions )):  
LY3002813 -Amyloid-Related Imaging Abnormalities:   
LY3202626 -Hepatic effects :  In nonclinical studies, liver enzyme elevat ions were observed 
with LY3202626 in rats and dogs.  These changes in the 1 -month rat and dog studies occurred at 
exposures 245-fold the projected exposure at the high dose (12 mg) in the Phase 2 study.  In the 
6-month toxicology study in rats, mild alanine aminotransferase (ALT)/aspartate 
aminotransferase (AST) increases occurred in the high -dose group; these analy tes remained 
increased at similar levels at the end of the 1- month recovery  period, indicating lack of 
reversibilit y.  In the 6-month rat study , ALT/AST increases did not occur at the mid- dose, and 
AUC-based margins at the mid -dose no-observed-adverse-effect level (NOAEL) of 4.5 mg/kg 
are 23-and 6-fold relative to the Phase 2 doses of 3 and 12 mg, respectively.  No liver changes 
occurred in the 9- month toxicology study in dogs (AUC -based margin 39 -fold relative to 12-mg 
dose in the Phase 2 study).  Liver-related clinical chemistry  analytes will be monitored in the 
clinical trial.  In addit ion, the investigator may perform addit ional tests when clinically  indicated.  
Clinical manifestations of hepat ic injury may include fati gue, jaundice, steatosis, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, or pruritus.
LY3202626 -QT Prolongation:   Dose-dependent QT corre cted for heart rate (QTc) prolongation 
(10 to 25 msec)occurred fo llowing repeated administration in dogs, at plasma unbound 
I5T-MC-AACG(d)Clinical Protocol Page 134
LY3002813maximum observed drug concentration (C max) values approximately  3-fold of those projected for 
the highest planned Phase 2 clinical dose of 12 mg.  Specific study  exclusion criteria related to 
QTc are defined in the clinical protocol.  Electrocardiograms and vital signs will be carefully 
monitored during the clinical trial.  Cardiac signs and symptoms should be closely  monitored in 
thepresence o f overdose.
LY3202626 -Hypopigmentation :  Dose-dependent decreased pigmentation of the skin and 
haircoat of dogs has been observed in preclinical studies with LY3202626.  The lightening o f 
haircoat and mucocutaneous junction epit helium did not impact the well -being of the dogs and 
was reversible during the treatment -free recovery  period.  Scheduled skin examinat ions will be 
performed by a dermatol ogist in the clinical trial, and are defined in the clinical protocol.  If 
hypopigmentation is obser ved, patients may continue treatment.  The location of 
hypopigmentation, occurrence of any  associated cutaneous changes, and response after the 
treatment period should be monitored.
LY3202626 -Retinal effects:   Adverse retinal effects occurred in both the 1-month and 6-month 
toxicology studies with LY3202626 in rats, which included autofluorescent granule 
accumulat ion and hypertrophy  of the retinal pigmented epithelium wit h photoreceptor 
degeneration.  In the 6 -month rat study , these retinal  findings occur red only in the high -dose 
group (25 mg/kg) and did not reverse during the 1 -month, treatment-free period.  No retinal 
effects occurred at the NOAEL (4 mg/kg) in the 6- month rat toxico logy study, providing area 
under the drug plasma concentration versus t ime curve (AUC) -based MOS of 23- and 6-fold to 
the Phase2 doses of 3 and 12 mg.  No adverse retinal changes occurred in dogs.  Scheduled eye 
examinations by an ophthalmo logist or optom etrist (where permitted by  law) will be perform ed 
in the clinical trial, and are defined in the clinical protocol.  Patients who complain o f vision 
disturbance during the clinical trial should be referred to the ophthalmo logist or optom etrist 
(where permitted by  law) for unscheduled evaluat ion.
LY3202626 -Potential Drug Interactions:  LY3202626 has been shown to be a substrate of 
CYP3A and potentially a time -dependent inhibitor of CYP3A.  Co -administration wit h a strong 
CYP3A inhibitor led to an approximate 20% increase in LY3202626 exposure, whic h is not 
thought to be clinically significant.  The effect of LY3202626 on other CYP3A substrates is 
predicted to be modest.  Accordingly, clinically meaningful drug interactions are not anticipated 
with LY3202626 administration.  See the IB for a detail ed assessment of clinical and nonclinical 
data regarding the potential for drug interactions.
3.3.3.Benefit/Risk Assessment Summary
To mitigate the potential risks described in Sect ion 3.3.2, the current study  will include standard 
safety assessments; i.e ., reported AEs, clinical laboratory  tests, immunogenicit y assessments, 
vital sign and body  weight m easurements, 12 -lead electrocardi ograms (ECGs), and physical 
examinations.
Additional safety assessments will include neuro logical examinat ions (as part of each physical 
examination), comprehensive eye examinat ions by an ophthalmo logist or optom etrist (where 
permitted by  law), skin examinat ions by a dermatologist, MRI examinat ions, and suicidalit y 
I5T-MC-AACG(d)Clinical Protocol Page 135
LY3002813evaluations using the Columbia -Suicide Severi ty Rating Scale ( C SSRS).  The current study  will 
use an independent external Data Monitoring Committee (DMC) to monitor data on an ongoing 
basis to ensure the con tinuing safet y of patients enrolled in this study .
The current study  includes placebo s of both LY3002813 intra venously and LY3202626 orally as 
a comparator, and approximately  one-halfthirdof the patients will be rando mized to placebo.  In 
addition, all patients participating in the study  will have a designated study  partner who will have 
regular contact wi th the patient, accom pany the patient to study  visits, and liaise wi th the study  
staff between visits as needed (see Sect ion 6.1 for addit ional information about the role of the 
study partner).
In conclusio n, the available non -clinical and clinical data support t he intravenous administration 
of LY3002813 and the IV administration of LY3002813 in co mbination with the oral 
administration of LY3202626 to the intended study population according to the proposed clinical 
investigat ion plan and also provide a sufficient margin of safet y for the proposed design and 
doses.  There are currently  no disease-modifying treatments for AD.  The potential benefit s of 
LY3002813 and LY3002813 in co mbination with LY3202626 showing di sease-modifying 
properties in AD are considered to o utweigh the potential risks.
More informat ion about the known and expected benefits, risks, SAEs and reasonably 
anticipated AEs of LY3002813 and LY3202626 are to be found in the respective IB(s).
4.Objectives and Endpoints
Table AACG.4.1. Objectives and E ndpoints
Primary Objective Primary Endpoint
To test the hypothesis that LY3002813 alone 
and/or in combination with LY3202626
administered for up to 7276weeks will decrease 
the cognitive and/or functional decline in 
patients with early symptomatic ADChange in cognition and function as measured by the 
change in integrated Alzheimer’s Disease Rating Scale 
(iADRS) score from baseline to 18 months
Secondary Objectives Secondary Endpoints
To assess the effect of LY3002813 alone and in 
combination with LY 3202626 vs. placeboson 
clinical progression in patients with early 
symptomatic ADChange in cognition from baseline to 18 months as 
measured by:
the change in Alzheimer’s Disease Assessment 
Scale—Cognitive subscale (ADAS -Cog13) 
score
the change in Clinica l Dementia Rating Scale 
Sum of Boxes (CDR -SB) score
the change in Mini Mental State Examination 
(MMSE) score
the change in Alzheimer’s Disease Cooperative 
Study-instrumental Activities of Daily Living 
scale (ADCS -iADL) score 
I5T-MC-AACG(d)Clinical Protocol Page 136
LY3002813To assess the effect of LY3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain amyloid depositionChange in brain amyloid plaque deposition from 
baseline through 18 months as measured by florbetapir
F18 PET scan  
To assess the effect of L Y3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain tau depositionChange in brain tau deposition from baseline to 18 
months as measured by flortaucipir F18 PET scan  
To assess the effect of LY3002813 alone and in 
combination with LY3202626 vs. placebo on 
brain volume measuresChange in volumetric MRI measures from baseline to 
18 months.
To assess the effect of combination therapy with 
LY3002813 and LY3202626 vs LY3002813 
alone on clinical progression in patients with 
early symptomatic ADChange from baseline to 18 months in iADRS score, 
ADAS-Cog13score, CDR-SB score, MMSE score, 
ADCS-iADL score
Safety Objective Safety Endpoints
To evaluate safety and tolerability of 
LY3002813 alone and in combination with 
LY3202626Standard safety assessments:
ospontaneously reported adverse events 
(AEs)
oclinical laboratory tests
ovital sign and body weight 
measurements
o12-lead electrocardiograms ( ECGs)
ophysical and neurological 
examinations
MRI (ARIA and emergent radiological 
findings)
Skin examination
Eye examination
Columbia Suicide Severity Rating Scale
(C-SSRS)
Exploratory Objectives Exploratory Endpoints
To assess the effect of LY3002813 alone and in 
combination with LY3202626 vs. placebo s, as 
well as combination therapy with LY3002813 
and LY3202626 vs LY3002813 alone on 
clinical progression in patients with early 
symptomatic ADthe change in dependence level derived from 
ADCS-ADL scale scores
To assess peripheral PK and presence of 
anti-LY3002813 antibodies over 72in 
LY3002813 alone and in combination with 
LY3202626 over 76 weeksPlasma pharmacokinetics of LY3002813
Anti-drug-antibodies (ADA) against 
LY3002813 including treatment -emergent 
ADA and neutralizing antibodies.
To assess peripheral PK of LY3202626  in 
combination with LY3002813 over 76 weeksPlasma Pharmacokinetics of LY3202626 
To assess the effect of combination therapy with 
LY3002813 and LY3202626 vs LY3002813 
alone on brain amyloid depositionChange in brain amyloid p laque deposition 
from baseline through 18 months as measured 
by florbetapir F18 PET scan  
I5T-MC-AACG(d)Clinical Protocol Page 137
LY3002813To assess the effect of combination therapy with 
LY3002813 and LY3202626 vs LY3002813 
alone on brain tau depositionChange in brain tau deposition from baseline to 
18 months as measured by flortaucipir F18 
PET scan
5.Study Design
5.1.Overall Design
Study AACG is a m ulticenter, randomized, double- blind, placebo -controlled, Phase 2 study  of 
LY3002813 , alone and in combinat ion with LY3202626, in subjects with early symptomat ic AD.  
The 133124-week study  includes a screening period of up to 9 weeks, a treatment period of up to 
7276weeks with final evaluat ions occurring 4 weeks later at Week 76, and , a 484-week 
posttreatment fo llow-up, and a 4 4-week immunogenicit y and safet y follow-up period.  Subjects 
who meet entry  criteria will be rando mized in a 1:1 :1ratio to one of the fo llowing treatm ents:
•LY3002813 :monotherapy  (LY3002813- M):  IV LY3002813 (700 mg Q4WK for the 
first 3 doses, then 1400 mg Q4WK) forin combination with daily oral placebo up to 7276weeks,
•LY3002813 in co mbination wit h LY3202626 (LY3002813- C):  IV LY3002813 (700 mg 
Q4WK for the first 3 doses, then 1400 mg Q4WK) in co mbination with daily oral LY3202626 
(12 mg) up to 76 w eeks, or
•Placebo:  IV placebo Q4WK in combinat ion with daily oral placebofor up to 7276
weeks.
The primary  hypothesis being tested is that LY3002813 administered alone, or in combination 
with LY3202626, for up to 7276weeks will result in a significant slowing in 
cognitive/functional decline co mpared with placebo as measured by the change fro m baseline to 
the end of the double blind treatment period (Week 76) on the integrated Alzheimer’s Disease 
Rating Scale (iADRS), in subjects with early symptomat ic AD (where early symptomat ic AD 
refers to the combinat ion of 2 stages:  prodromal AD [MCI -AD] and mild AD dement ia; Alaka 
et al. 2015).
Under previous versio ns of this protocol, LY3002813 was administered in co mbination with 
LY3202626, an inhibitor of β sit e amyloid precursor protein cleaving enzyme (BACE)1.  
However, as of this amendment (d), the combinat ion therapy and the oral placebo have been 
discontinued fro m the study.
I5T-MC-AACG(d)Clinical Protocol Page 138
LY3002813[Old figure:]

I5T-MC-AACG(d)Clinical Protocol Page 139
LY3002813[Updated figure:]
Figure AACG.5.1. Illustration of study design for Clinical Protocol I5T -MC-AACG.
5.1.1.Screening Period (Visit 1)
Once the MMSE criteria are met, 63 days are allowed for completion o f Visit1 screening 
assessments, procedures, and evaluat ion of results fro m laboratory  tests, ECGs, phy sical and 
neurological examination, ophthalmo logical and derm atological exams, flortaucipir F18 PET, 
MRI, and florbetapir F18 PET.  Even though florbetapir F18 PET imaging may be the last 
screening procedure of the study , it is expected that the centrally  read florbetapir F18 PET resul ts 
will be available wit hin the timeframe of 63 days.  However, it will not be a protocol 
deviationviolationshould the screening florbetapir F18 PET results not be available until after 
63days.
Patients whose screening florbetapir F18 PET results are not available until after 63 days will 
remain eligible wit hin Visit 1 unt il these results become available.  Note:  If a patient’s screening 
florbetapir F18 PET resul ts confirming evidence of amylo id burden are received by the site after 
63 days, laboratory tests (blood hematol ogy, chemistry , and serum human chori onic 
gonadotropin [ HCG] for females of childbearing potential) are to be repeated for that patient.  
Results of the repeated labs are to be reviewed by the invest igator or qualified de signee for 
assessment of the patient’s continued eligibilit y.  Repeat screening for MMSE, CBB, C -SSRS, 

I5T-MC-AACG(d)Clinical Protocol Page 140
LY3002813ECG, ophthalmo logical and dermatological exams, flortaucipir F18 PET imaging, and MRI, and 
laboratory  testing for hepatitis B surface ant igen (HBsAg),and hepatitis C virus ( HCV)RNA 
polymerase chain react ion (PCR), is not requi red.
Patients in active screening prior to implementation of amendment (d) remain eligible wit hin 
Visit1 until all screening procedures are completed and results are available. This will not be a 
protocol deviation.  Patients who complete Visit 1 beyond63 days are to repeat laboratory  tests 
(blood hematology, chemistry , and serum HCG for females of childbearing potential) prior to 
being rando mized.  The results of these laborat ory tests are to be reviewed by  the invest igator or 
qualified designee for assessment of the patient’s continued eligibility.  Repeat screening for 
MMSE,CBB, C-SSRS,ECG,flortaucipir F18 PET imaging ,MRI,and laboratory testing for 
HBsAg and HCV RNA PCR is not required.
5.1.1.1. Screening Procedures
Screening entry  and administrative procedures, cognit ive assessments, safet y assessments ,(with 
the exception of ophthalmo logical and derm atological exams),and laboratory  assessments (see 
Schedule of Act ivities in Sect ion 2) are to be done at Visit 1 before the screening flortaucipir F18 
PET scan, MRI, and florbetapir F18 PET scan procedures.
5.1.1.1.1. Modified Hachinski Ischemic Scale (MHIS)
Patients who score ≥4 are more likely  to have a dement ia of vascular etio logy and are excluded 
from participating in the trial.
5.1.1.1.2. Mini-Mental State Examination (MMSE)
The MMSE is a brief instrument used to assess cognit ive function in elderlypatients (Folstein et 
al.
5.1.1.1.5. Screening Ophthalmological and Dermatological Examinations
[Section deleted]
5.1.1.1.6.5.1.1.1.5. Screening Positron Emission Tomography and Magnetic 
Resonance Imaging
With the exception o f ophthalmo logical and dermatological exams, aAll other screening criteria 
should be met in order for the patient to proceed wit h flortaucipir F18 PET scan, followed by 
MRI, and a florbetapir F18 PET scan procedure.
5.1.1.1.6.2.5.1.1.1.5.2. Screening MRI
A local screening MRI will be performed at Visit 1 as part of the study  eligibility criteria.  Wi th 
the exception of the evidence of amylo id pathology by florbetapir F18 PET scan, and 
ophthalmo logical and dermatological exams,a patient should meet all oth er Visit 1 eligibili ty 
criteria before having an MRI.  
5.1.1.1.6.3.5.1.1.1.5.3. Screening Florbetapir F18 PET Scan
I5T-MC-AACG(d)Clinical Protocol Page 141
LY3002813With the exception o f theMRIand ophthalmo logical and derm atological exams , a patient should 
meet all other Visit 1 eligibilit y criteria before having a scree ning florbetapir F18 PET scan. 
5.1.2.Double-Blind Period (Visit 2 through Visit 2122)
Patients who m eet entry criteria will be enro lled and randomized to receive up to 7276weeks of 
treatment with LY3002813- M, LY3002813- C, or placebo.
Patients are to take oral study  medication (oral placebo or LY3202626) once per day  in the 
morning.  The first dose should be taken the morning after the first dispensing of oral study  
medication at Visit 2.
A finalFinal endpo int measures and safety assessmentsvisit for the doubl e-blind period will be 
performed at Visi t 2122(Week 7680) 4 weeks fo llowing the patient’s last dose of study 
medication.  
5.1.3.Immunogenicity and Safety Follow -up Visits (Visit s801 through 804 )
Patients are to return to the s ite for an immunogenicit y and safety follow-up visits (Visit 801 
through Visit 804) beginning at Week 88 (or 12 weeks after their last dose of LY3002813 for 
collection of blood samples for anti -drug antibody [(ADA; ant i-LY3002813 ant ibody]) and PK 
measurem ent,andassessment of adverse events, C -SSRS, andconcomitant m edications, and 
vital signs.
5.2.Number of Participants
Approximately  266375participants will be randomized.
5.4.Scientific Rationale for Study Design
Continuing Standard of Care. During the double -blind treatment period (V2 to V21V22), 
changes in doses of available symptomat ic medications for MCI or AD will require reporting to 
the sponsor and these changes should occur only when necessary for the adequate overall care of 
the patient. The effect of LY3002813 treatment alone or in combinat ion with LY3202626 plus 
SOC will be co mpared with placebo plus SOC.
Dosing. As described more fully in Section 7.1, LY3002813 (700 mg or 1400 mg) will be 
administered every  4 weeks as an IV infusi on of approximately  140 mL over a minimum of 30 
minutes and LY3202626 (12 mg) will be administered orally once a day .
Design. Study AACG is a m ulticenter, randomized, double- blind, placebo -controlled study  of 
LY3002813 , alone and in combinat ion with LY3202626,in patients with early symptomat ic AD 
(where early symptomat ic AD refers to the combination of 2 stages:  prodromal AD [MCI AD] 
and mild AD dement ia) (Alaka et al. 2015).  The study  is intended to characterize the benefits 
and risks of treatment with LY3002813 alone or in combination wit h LY3202626 versus placebo 
in patients early symptomat ic AD.
.... The use of a placebo comparator in Study  AACG is needed to determine efficacy and safet y 
of LY3002813 monotherapy  and LY3002813 combinat iontherapy.
I5T-MC-AACG(d)Clinical Protocol Page 142
LY3002813The duration of the doubl e-blind period of the study is 7680weeks and includes up to 7276
weeks of treatment ,with endpoint measures and safety assessments at the end of the double -
blind treatment period (Week 76), to assess the safety , tolerability and effic acy of LY3002813 
alone or in combinat ion with LY3202626 versus placebo , as well as LY3002813 alo ne versus 
LY3002813 in co mbination wit h LY3202626, and safet y assessments at 80 weeks .
In addition to AE reporting, safet y measures such as laboratory  assessmen ts, immunogenici ty 
testing, vital signs and weight monitoring, ECG monitoring, physical examinat ions, neurological 
examinations dermatological examinations, ophthalm ological examinat ions,MRI assessments, 
and assessments of suicidal ideat ion and behavior a re included to facilitate a comprehensive 
safety evaluation.  For patients enrolled under previous versio ns of this protocol , which included 
a combinat ion arm of LY3002813 (N3pG) and LY3202626 (BACE inhibitor -IV), final 
dermatologicalexaminations by a der matologist and final comprehensive ophthalm ological
examinations by an ophthalmo logist or optom etrist (where permitted by  law) will be perform ed 
at the next visit occurring after the patient stopped receiving LY3202626/oral placebo.
5.5.Justification for Dose
....
The LY3202626 dose of 12 mg administered orally once a day  was selected based on current 
nonclinical pharmaco logy and toxicology data and clinical PK, PD and safety  data.  Doses of 
LY3202626 chosen for this study  were based on central and periphe ral PK/PD data from  healthy 
subjects collected in a previous single -and multiple-dose study  that were used to estimate the 
exposures necessary  to achieve the desired levels of CSF Aβ reduction.  These exposure targets 
were then used to select a daily  doseof 12 mg LY3202626 for this study .  This dose is l ess than 
the highest doses previously evaluated in healt hy subjects (45 mg as a single dose, or 26 mg once 
a day for 14 day s), which were found to be well tolerated.  As described in Sect ion 3.2.4, 
LY32026 26 appears to be well tolerated in an ongoing Phase 2 study  investigating the effect of 3 
mg and 12 mg LY3202626.  Together, these data suggest that a dose of 12 mg LY3202626 will 
be well tolerated in an AD populat ion and will allo w evaluat ion of near maxi mal inhibition of Aβ 
production.
6.Study Population
6.1.Inclusion Criteria
....
Patient/Subject Characteristics
[4]....  
A second study  partner m ay serve as backup.  The study  partner(s) i s/are requi red to 
accompany  the patient for signing consent.  One study  partner is requested to be present 
on all days the Columbia Suicide Severit y Rating Scale (C-SSRS)/Self-Harm Suppleme nt 
Form is administered and must be present on all days the andcognitive and funct ional 
scales are administered (i.e., Visits 1, 2, 5, 8, 11, 15, 18, and 21/ED) .  If a patient has a 
I5T-MC-AACG(d)Clinical Protocol Page 143
LY3002813second study  partner, i t is preferred that one study  partner be primarily  responsible for the 
CDR and ADCS -ADL assessments.  If a study  partner(s) i s not able to accompany the 
patient in person for visits other than those listed above , they must be available by 
telephone for the following assessments:
•AEs and conco mitant medications
•relevant porti ons of the C -SSRS/Self -Harm Supplement Form s
•CDR and ADCS -ADL (primary study  partner if possible)
6.2.Exclusion Criteria
Medical Conditions
[11]Current serious or unstable illnesses including retinal,cardiovascular, hepat ic, renal, 
gastroenterologic, respiratory , endocrino logic, neurologic (other than AD), psy chiatric, 
immunologic, or hematologic disease and other condit ions that, in the invest igator’s 
opinion, could interfere wi th the analyses in this study; or has a life e xpectancy of 
<24months.
[57][Note:  Cri terion #57 has been deleted.] Ocular patho logy that significantly limits abilit y 
to reliably evaluate visio n or the retina, or puts participant at undue risk for visio n loss 
during the study .
[18][Note:  Cri terion#18 has been deleted.] History of vit iligo and/or current evidence of 
post-inflammatory hypopigmentation.
Magnetic Resonance Imaging, Vital Signs, Electrocardiograms, Laboratory Tests, and 
Physical Examination
[54]Patients with past history  of Hepatitis C should have hepatitis C virus ( HCV)ribonucleic 
acid (RNA)polymerase chain react ion (PCR)testing at screening and are excluded if 
HCV RNA PCR is posit ive.
Prior/Concomitant Therapy
[32][Note:  Cri terion #32 has been deleted.] Current use of strong inducers of CYP3A (see 
the Manual of Operat ions for a list of excluded drugs).
[37][Note: Criterion #37 has been deleted.] Have known allergies to LY3202626, related 
compounds, or any  components of the formulat ion.
Prior/Concurrent Clinical Trial Experience
[47][Note: Criterion #47 has been replaced by criteri ona #55 and #56.]
[56][Note: Criterion #56 has been deleted.] Have previously had LY3202626 treatment 
discontinued due to treatment- related adverse event.
6.2.1.Rationale for Exclusion of Certain Study Candidates
I5T-MC-AACG(d)Clinical Protocol Page 144
LY3002813The use of LY3002813 and LY3202626 in older patients is ant icipated; thus this study  will 
specifically examine the efficacy and safet y in an elderly  population.  Criterion [2] defines the 
population age range for the purposes of thi s study.  Therefore, patients not meet ing the age 
criterion are excluded.
6.3.Lifestyle Restrictions
2.Patients shoul d avoid use of tanning beds and self -tanning products.
3.Patients shoul d wear a hat and appropriate clothing when exposed to sunlight; u se a 
sunscreen with a skin protection factor (SPF) of at least 15; and protect their lips with a 
lip balm containing sunblock.
7.Treatments
7.1.Treatments Administered
This study  involves a comparison of LY3002813 administered as an IV infusion o f 
approximately  140 mL over a minimum of 30 minutes compared with LY3002813 in 
combination with LY3202626 administered orally once a day , andplacebo.  In the doubl e-blind 
period, the treatment groups will be given eitheran IV infusio n of LY3002813 monotherapy  
(LY3002813 -M), LY3002813 combinat ion therapy (LY3002813-C), or Placebo for up to 7276
weeks.
....
The LY3202626 dose will remain 12 mg throughout the double -blind treatment period.  Table 
AACG.7.1 shows the 23treatment regimens during the double -blind period.
Table AACG.7.1. Treatment Regimens, Double -Blind Period
RegimenDose
Visit 2 (Week 0) through Visit 21 (Week 76)
LY3002813 -MLY3002813 (700 mg intravenous infusion every 4 weeks x 3 doses, then 1400 mg 
intravenous infusion every 4 weeks for up to 72 weeks) in combination with 
orally dosed placebo tablet once per day in the morning x 76 weeks
LY3002813 -CLY3002813 (700 mg intravenous infusion every 4 weeks x 3 doses, then 1400 mg 
intravenous infusion every 4 weeks for up to72 weeks) in combination with 
LY3202626 ( 12 mg tablet orally once a day in the morning for 76 weeks)
PlaceboIntravenously dosed placebo infusion ever y 4 weeks for up to 72 weeks in 
combination with orally dosed placebo tablet once per day in the morning x 76 
weeks
Abbreviat ions:  C = combinat ion therapy; M = monotherapy .
I5T-MC-AACG(d)Clinical Protocol Page 145
LY30028137.1.1.2. LY3202626 Packaging and Labelling
LY3202626 will be supplied as 12 -mg tablets.  The study drug and placebo will be i dentical in 
appearance and will be packaged in blister packs.
7.2.Method of Treatment Assignment
Patients will be randomized to LY3002813 -M, LY3002813 -C,or Placebo in a 1:1 :1ratio.
7.2.1.Selection and Timing of Doses
Assessment of LY3002813 and LY3202626 safety and tolerabilit y is a central  objective; 
therefore, monitoring 100 patients on LY3002813 -Mover 7276weeks in parallel wit h 
approximately  100 patients on LY3002813 -C over 76 weeks of exposure provides data to as sess 
safety for further clinical development.
The actual  time of bothLY3002813 and LY3202626 dose administrations on the day  of study 
visits will be recorded in the subject’s case report form (CRF).  In addition, the actual time o f 
LY3202626 dose administ ration for the 2 day s prior to each visit at which LY3202626 PK 
samples will be co llected will be recorded in the subject’s CRF.
7.2.1.1. LY3002813:  Selection and Timing of Doses
.... Intravenous study  medication given at a dosing interval o f less than 21 days at any  time 
during the study  will be considered a protocol deviationviolation.  
7.2.1.2. LY3202626:  Selection and Timing of Doses
[Section deleted]
7.3.Blinding
This is a double -blind study , with design to m aintain blinding to treatmentboth LY3002813 and 
LY3202626 treatments .  
7.4.Dosage Modification
7.4.1.LY3002813 Dosage Modification for ARIA -E
7.4.1.1. LY3002813 Dosage Modification for ARIA-E
Patients will continue LY3202626 at 12 mg per day.
7.4.1.2. 7.4.2LY3002813 Dosage Modification for ARIA -H
Patients will continue LY3202626 at 12 mg per day.
Patients perm anently discontinued from LY3002813 are to continue taking LY3202626 unless 
they are perm anently discont inued from LY3202626 treatment or from the trial.
7.4.2.LY3202626 Dosage Modification
I5T-MC-AACG(d)Clinical Protocol Page 146
LY3002813[Section deleted]
7.6.2.LY3202626 Treatment Compliance
[Section deleted]
7.7.Concomitant Therapy
Allowed Medications.   Use of approved or standard of care treatments for AD is permitted during 
the study, provided that such m edications dose has been unchanged for 2 months before Visit 2.  
Doses of these medicat ions should remain constant throughout the double -blind period (Visit 2 
to Visit 2122).
Prior to V21V22, before a patient starts, stops, or changes doses of AChEIs and/or memantine 
or other treatments for their AD, the Sponsor or designee must be contacted to determine 
whether or not the patient should continue in the study and whether or not clinical outcome 
measures should be performed.  Failure to notify Lilly or its designee regarding starting, 
stopping or changing doses of AChEIs and/or memantine or other treatments for their AD 
prior to V21V22will be considered a protocol deviation violation.
If unforeseen starting, stopping, or changing of stable doses of drugs affect ing CNS function 
occurs pri or to V21V22of the study , Lilly or i ts designee must be contacted to determine 
whether or not the patient should cont inue in the study  and whether or n ot outcome measures 
should be perform ed.  Failure to notify Lilly or its designee regarding starting, stopping or 
changing doses of CNS medications prior to V21V22of the study will be considered a protocol 
deviation violation.
Excluded Medications.
Concomitant therapies that are prohibited during treatment with LY3002813:   IgG therapy 
(also known as gamma glo bulin or intravenous immunoglobulin [IVIG]) is not allowed during 
the study.
Concomitant therapies that are prohibited during treatment with LY3202626:
Use of depigment ing agents, such as, hydroquinone
Current use of strong inducers of CYP3A (See the Manual o f Operations for a list of 
excluded drugs)
Current use of drugs known to significant ly prolong the QT interval (See the Manual o f 
Operations for a l ist of excluded drugs)
Use of any  drug of abuse, including but not limited to cannabis, illicit amphetamine, 
cocaine, illicit opiates, propoxy phene, methadone, methaqualo ne, phencyclidine, or illicit 
barbiturate
7.8.Treatment after the End of the Study
7.8.1.Treatment after Study Completion
I5T-MC-AACG(d)Clinical Protocol Page 147
LY3002813There is no planned open l abel extension at this time, or plan to otherwise make LY3002813 or 
LY3202626 available to patients after conclusio n of the study .
8.Discontinuation Criteria
8.1.Discontinuation from Study Treatment
•Treatment with LY3002813 will also be permanently discont inued in pat ients with:
oAdverse event or clinically significant laboratory  value, ECG resul t, physical 
examination finding,(including eye or skin examinat ion), MRI finding (such as 
symptomatic ischemic stroke), C -SSRS result, or vital sign measurement of such 
severity that, in the opinion o f the investigator or Lilly -designated medical mo nitor, 
continued treatment is not in the best interest of the patient.
Patients permanently discontinued from  one treatment may continue to receive the other 
treatment and continue in the trial.  Patients may also permanent ly discont inue study 
treatmentboth treatments and remain in the trial.
If LY3202626 oral dose is permanent ly discont inued but the patient remains in the study , a final 
sample should be co llected, provided the last dose of LY3202626 is within 3 days o f the visit.  
Dosing dates and t imes should be collected.  No other PK samples for LY3202626 are required 
after the final sample.
8.1.1.Temporary Discontinuation from Study Treatment
8.1.1.1. Temporary Discontinuation from LY3002813 Study Treatment Due to 
ARIA-E
8.1.1.1.1. Temporary Discontinuation from LY3002813 Study  Treatment Due to ARIA -E
8.1.1.2. Temporary Discontinuation from LY3202 626 Study Treatment
[Section deleted]
8.2.Discontinuation from the Study
Subjects discont inuing fro m the study prematurely for any  reason must com plete AE and other 
safety follow-up per Secti on 2 (Schedule of Activit ies), Section 9.2 (Adverse Events), and 
Section 9.4 (Safet y) of this protocol .  In addition, subjects discontinui ng from the study  
prematurely should be encouraged to return to the site beginning 12 weeks after their ED visit for 
animmunogenicit y and safety assessments (Visitsassessment visit (Visit 801 through 804, as 
described in Section 5.1.3 ).
9.Study Assessments and Procedures
9.1.Efficacy Assessments
Note that the ADAS -Cog and MMSE shouldmustbe administered by  a different rater than the 
ADCS-ADL and CDR.  
I5T-MC-AACG(d)Clinical Protocol Page 148
LY30028139.1.2.Secondary Efficacy Assessments
9.1.2.4. Mini-Mental State Examination (MMSE)
The MMSE is a brief instrument used to assess cognit ive function in elderlypatients (Folstein et 
al. 1975).
9.1.3.Biomarker Efficacy Measures (Double -Blind Period)
Florbetapir F18PET scan. Change in amylo id burden (as assessed by florbetapir F18 PET 
signal) will be com pared in LY3002813- , LY3002813/LY3202626 -and placebo -treated pati ents 
for those pati ents who undergo florbetapir F18 PET scans at baseline, Week 52 [Visit 15], and 
Week 76 [Visit 21] or early discont inuation [ED]) as described in the Sche dule of Activities 
(Section 2).
Flortaucipir F18 PET scan.   Change in tau burden (as assessed by flortaucipir F18 PET signal) 
will be co mpared in LY3002813- , LY3002813/LY3202626 -and placebo -treated patients for 
those patients who undergo both baseline and endpoint (Visit 21 [Week 76] or ED) flortaucipir 
F18 scans as described in the Schedule o f Activities (Section 2).
Volumetric MRI.  Magnetic resonance imaging of the brain will be performed according to the 
Schedule of Act ivities (Section 2).  LY3002813 -,LY3002813/LY3202626- and placebo -
treatment effects on volumetric MRI will be assessed and compared to evaluate the loss of brain 
volume that occurs in AD pat ients.
9.2.1.2. Adverse Events of Special Interest
Specific safet y topics of interest for this stu dy include, but are not limited to, the fo llowing:
•QT prolongation
•Adverse eye effects
•Adverse skin effects including rash and hypopigmentation
•Liver toxi city
9.3.Treatment of Overdose
9.3.1.Treatment of LY3002813 Overdose
There is no known antidote to LY3002813.  In case of overdose, use appropriate monitoring and 
supportive therapy .
9.3.2.Treatment of LY3202626 Overdose
There is no known ant idote to LY3202626.  In the case of known or suspected overdose, 
monitoring of cardiac, hepat ic, andhematological effects i s essential, and appropri ate supporti ve 
therapy should be initiated, as appropriate.  Refer to the LY3202626 IB.
9.4.Safety
I5T-MC-AACG(d)Clinical Protocol Page 149
LY30028139.4.1 Physical and Neurological Examinations
Complete physical  examinat ions will be performed at screening, baseline, and Weeks 12, 24, 52, 
76, 80,and ED as indicated in the Schedule of Activit ies (Section 2).  
9.4.6 Other Tests
9.4.6.3. Ophthalmological Examination
While the BACE inhibitor LY3202626 is no longer being administ ered in this study  (see Secti on 
5.1), ophthalmo logical examinat ions in patients who previously received LY3202626 or oral 
placebo will  be perform ed at the next scheduled examinat ion time po intafter their finaldose of 
oral study medication (see the Schedule o f Activities [Section 2]).  Patients who received 
LY3202626/oral placebo after their Visit 9 ophthalmo logicalexamination are to have an 
unscheduled ophthalmo logical examinat ion at the next available opportunit y.  Patients screened 
or randomized under the current amendment are not required to undergo any  ophthalm ological
examinations at baseline or any  other study  visits.
AllPatients who previously  received LY3202626 or oral placebo will undergo comprehensive 
ophthalmo logical examinations performed by an ophthalmo logist or optom etrist (where 
permitted by  law) to assess visual function and mo rphology.  Schedul ed examinat ions will 
include the fo llowing:  visual acuit y, intraocular pressure, dilated funduscopic exam (dilat ion 
only performed in patients without contraindicat ion to mydriat ics), slit lamp exam , color 
photography  of the retina, and optical coherence tomography  (OCT) or equivalent; examinat ions 
will also include co lor vision assessment.  Assessments will preferably be perform ed at times 
shown in the Schedule of Act ivities (Section 2), preferably by the same ophthalmo logist or 
optometrist for each patient’s visit.  Patients who complain o f vision disturbance, such as change 
in field of visio n, color, acuity or anything potenti ally localizable to the retina, during the clinical 
trial should be referred to the ophthalmo logist or optom etrist (where permitted by  law) for 
unscheduled evaluat ion.
Data from the eyeophthalm ologicalexamination visit s will be provided from the local 
ophthalmo logist or optom etrist to the invest igator.  Based on the morpho logical and funct ional 
results, the investi gator will include or exclude the patient in consultation wit h the performing 
eye examiner,.     
The local ophthalm ologist or optom etrist will review the color photography  and OCT to ai d in 
the investigator’s assessment of study eligibilit y and for immediate patient management.  
Additionally, the color photography  of retina and OCT will be analyzed by a central reader.
9.4.6.4. Dermatological Examination
While the BACE inhibitor LY3202626 is no longer being administered in this study , Acomplete 
dermatological examinations in patients who previously received LY3202626 or oral placebo 
willskin exami nation willbe perform ed at the next scheduled examinat ion time po intafter their 
finaldose of oral  study medication (seetimes shown in the Schedule of Act ivities ([Section 2]).  
Patients who received LY3202626/oral placebo after their Visit 8 dermatolog ical examinat ion 
I5T-MC-AACG(d)Clinical Protocol Page 150
LY3002813are to have an unscheduled dermatological examinati on at the next available opportunit y.  
Patients screened or randomized under the current amendment are not required to undergo any  
skin exams at baseline or any  other study  visits.
This examination will ), preferably be performed by the same dermatologist for each pat ient’s 
visit.  All skindermatologicalexaminations must be perform ed by a derm atologist who will 
inspect the patient’s unclothed full body  using an ultravio let (UV) light.  The initial examination 
will include Fitzpatrick skin -type classification scale.
9.4.7.Safety Monitoring
The Lilly clinical research physician or scient ist will, as appropriate, consult with the 
functionally independent Gl obal Patient Safety therapeutic area physician or clinical scient ist, 
and periodically review:
•AEs including mo nitoring of hypersensit ivity and infusio n reactions, AEs associated with 
anti-LY3002813 ant ibodies (immunogenicit y), ARIA -H, ARIA-E-E, eye and skin, ECG 
findings, neuro logical findings, hemorrhagic stroke, microhemorrhage (cerebral 
microhemorrhage, cerebellar microhemorrhage, brain stem microhemorrhage) as ident ified 
by investigator, and suicide -related thoughts and behaviors.
9.4.7.1.2. Management of Infusion Reactions
Additional data shoul d also be collected via the CRF/electronic data entry . Pplease see the 
Operations Manual  for more detail.
9.4.7.2. LY3002813 Immunogenicity
In order to preserve the blind, patients will need to complete Visits 801 throughto804 until all 
patients in the trial have reached Visit 21 22and datalock for the treatm ent period has been 
achieved.
In the event of a finding of hypersensit ivity, the investigator is to complete the CRF regarding 
the presence or absence of symptoms relat ed to the hy persensitivity.
9.4.7.4. Amyloid -Related Imaging Abnormalities (ARIA- E and ARIA -H)
In the event of a finding of ARIA E on MRI, the investigator is to complete the CRF regarding 
the presence or absence of symptoms related to the ARIA -E.  
If theabove mentioned symptoms are reported, and ARIA E is suspected, then the abnormalit y is 
best detected by  fluid attenuat ion inversion recovery  (FLAIR) sequences on magnetic resonance 
imaging ( MRI)and ARIA H is best detected with the T2* gradient recalled echo on MRI.
9.4.8.Appropriateness of Safety Assessments
The clinical safet y measurements (AE reporting, physical examinat ions, neurological 
examinations, ophthalmological examinat ions, dermatological examinat ions,vital signs, ECGs, 
and clinical safet y laboratory tests [including immunogenicit y]; Section 9.2 and Section 9.4) are 
I5T-MC-AACG(d)Clinical Protocol Page 151
LY3002813well-established methods in drug development research and are standard procedures for clinical 
trials.
Performance of ophthalmo logical anddermatological examinat ions isareindicated in subjects 
who were previously treated with LY3202626, based on the potential for the occurrence of 
adverse retinal effects and hypopigmentation, respectively, during treatment with LY3202626.  
While LY3202626 is no longer being administered in this study , dermatological and 
ophthalmological examinations in subjects who previously received this therapy  or oral placebo 
will be performed at the next scheduled examinat ion time po intafter their finaldose of oral  study 
medication, in accordance wit h the Schedule of Activities(Section 2).  Patients who received 
LY3202626/oral placebo after their Visit 8 or 9 dermatological or ophthalmo logical examinat ion 
are to have an unscheduled examinat ion at the next available o pportunity.  Patients screened or 
randomized under the current amendment are not required to undergo any dermatologicalor 
ophthalmo logicalexaminations at baseline or any  other study  visits.
9.5.Pharmacokinetics
At the visits and times specified in the S chedule of Act ivities (Section 2), venous blood samples 
of approximately  4 mL each will  be collected to determine the serum concentrations of 
LY3002813 and venous blood samples of approximately 2 mL each will be co llected to 
determine plasma concentrations of LY3202626.  Instructi ons for the collection and handling o f 
blood sam ples will be provided by the sponsor.  The actual date and time (24- hour clock time) of 
each sampling will be recorded.
If LY3202626 oral dose is permanent ly discont inued but the pati ent remains in the study , a final 
sample should be co llected, provided the last dose of LY3202626 is within 3 days o f the visit.  
Dosing dates and t imes should be collected.  No other PK samples for LY3202626 are required 
after the final sample.
9.7.Pharmacogenomics [OR] Genetics
9.7.1.Apolipoprotein E Genotyping
Blood sampling for APOE genoty ping will be perform ed as shown in the in theSchedule o f 
Activities (Section 2).  
10.Statistical Considerations
10.1.Sample Size Determination
Approximately  250375subjects will be enro lled and rando mized in a 1:1 :1ratio to the 2three
treatment arms (placebo , LY3002813- M,and LY3002813 -C).  It is expected that approximately 
200300subjects will co mplete the double -blind treatment period of the study  (approximate ly 100 
per treatment arm).  This sample size will provide approximately 8486% power to dem onstrate 
that theat least oneactive treatment arm has a ≥ 0.6 posterior probabilit y of slowing down 
iADRS progression over placebo by at least 3 points.  The assumpt ion for power calculat ion is 
that mean progression levels in theplacebo, LY3002813-M and LY3002813 -Carms are 
approxim ately 12, 8 (33% sl owing),and 6 points (50% slowing) over 18 months, respectively, 
I5T-MC-AACG(d)Clinical Protocol Page 152
LY3002813with common standard deviat ion of 17.  If thebothactive treatment arm isarms areplacebo-like 
with no efficacy , the probabili ty of passing the efficacy  criterion specified above (i.e., false 
positive) is approximately 611%.  The simulat ion for the power calculation and sample size 
determinat ion was carried out in FACTS Version 6.05.5.
10.2.Populations for Analyses
For purposes of analysis, in general the fo llowing popul ations are defined unless otherwise 
specified:
For efficacy  analysis, the Full Analysis Set will group patients according to randomized 
treatment assignment (LY3002813 or placebo) , even if the patient does not take the assigned 
treatment, does not receive the correct treatment, or otherwise does not follow the protocol.  
When change fro m baseline is assessed, patients will be included in the analysis only if both a 
baseline and at least 1 valid post- baseline measure are available.
For safety analysis, all pati ents who received at least 1 dose of randomized study  treatment 
(LY3002813 , LY3202626 or placebo) will be included in the safet y analysis set.  In safet y data 
presentations, erroneously  treated pati ents (e.g., th ose randomized to “Treatment A” but actually
given “Treatment B”) will be accounted for in their actual treatment groups.
There were approximately 48 patients randomized before the removal o f LY3202626 treatment 
in protocol amendment (d) (about 16 each in the LY3002813 and LY3202626 combinat ion 
therapy arm, LY3002813 m onotherapy  arm, and placebo arm ). Patients already rando mized to 
the former LY3002813 m onotherapy  arm and placebo arm  will be pooled with patients 
randomized after protocol amendment (d) to form the Full Analysis Set and safet y analysis set 
specified above.  Data from patients randomized to the LY3002813 and LY3202626 
combination therapy arm will be summarized separately  and will not be included in treatment 
comparisons on efficacy  and safet y endpoints. The total number of patients to be randomized in 
the study is approximately  266.
10.3.2. Treatment Group Comparability
10.3.2.2. Subject Characteristics
The patient’s age, gender, race, height, body  weight, BMI (wei ght (kg) / [height (m)]2), tobacco 
use, alcohol use, caffeine use, y ears of education, work status, time since onset of first AD 
symptoms, time since diagnosis, baseline MMSE, CBB score at Visit 1, apolipoprotein E 
(APOE) genoty pe (E4 carrier vs. non -carrier), having 1 or m ore first degree relat ives with AD, 
and AChEI and/or memant ine use at baseline will be recorded.
10.3.3. Efficacy Analyses
10.3.3.1. Primary Analyses
The primary  objective of this study is to test the hypothesis that IV infusio n of LY3002813 alone 
or in combination wit h LY3202626   will slow the cognit ive and/or functional decline of AD as 
I5T-MC-AACG(d)Clinical Protocol Page 153
LY3002813measured by the composite measure iADRS compared with placebo in patients with early 
symptomatic AD.  This will be assessed using an MMRM analysis.
The primary  time point for treatment comparison will be at Week 76.  The treatment group 
contrast in least -squares mean progression and its associated p -value and 95% CI will be 
calculated for the treatment comparisonsof LY3002813 -Mvs. placebo and LY3002813 -C vs.   
placebo,using the MMRM model specified above.  In addit ion, Bayesian posterior probabilit y of 
the active treatment arm being superior to placebo by at least a margin o f interest (25% s lowing 
of placebo progression) will also be calculated assuming a non -informative prior.
10.3.4. Safety Analyses
10.3.4.5. ARIA-E and ARIA -H
The incidence of ARIA -E will be summarized.  Change in ARIA -E status from  baseline, to each 
subsequent MRI (in the event of unscheduled MRIs), and to double -blind period endpoint (Visit 
2122) will be compared between treatment groups using Fisher’s exact test.
10.3.5. Pharmacokinetic/Pharmacodynamic Analyses
Compartmental modeling of LY3002813 and LY3202626 PK data using nonlinear mixed effects 
modeling or other appropriate software may  be explored, and populat ion estimates for clearance 
and central  volume of distribution may  be reported.  Depending on the model selected, other PK 
parameters may also be repo rted.  Exploratory graphical analyses of the effect of dose level or 
demographic factors on PK parameters may  be conducted.  If appropriate, data from other 
studies of LY3002813 or LY3202626 may in beused in thi s analysis.
Concentrations of LY3202626 were collected under the original versi on of this protocol , as well 
as amendments (a -c).  These data will be summarized in the final study  report and m ay be 
analyzed graphically.  If appropriate, exploratory  analyses may  be conducted to evaluate 
potential relationships between LY3202626 concentrations and LY3002813 concentration.
The PK/PD relat ionships between plasma LY3002813 concentration and SUVr, cognit ive 
endpoints, ARIA incidence rate or other markers of PD act ivity may be explored graphically.  
The relationship between the presence of ant ibodies to LY3002813 and PK, PD, safet y and/or 
efficacy may be assessed graphically.  The effect of LY3202626 exposure on SUVr, cognit ive 
endpoints, or other markers of PD activit y may also be explored graphically.  Grap hical and/or 
descriptive analyses may be explored to evaluate potential interact ions between LY3002813 and 
LY3202626 for PK.  If warranted, addit ional analysis m ay be expl ored to evaluate potential 
interactions for ADA, PD and other endpoints (PET scan, AR IA-E, etc.).
10.3.6. Interim Analyses
There will be periodic alsafety data reviews during the study  and the external DMC is authorized 
to evaluate results fro m unblinded safet y data reviews.  
I5T-MC-AACG(d)Clinical Protocol Page 154
LY300281311.References
DeMattos R, May  P, Racke M, Hol e J, Tzaferis J, Liu F, DeLong C, Day  T, Yang Z, Boggs L, 
Monk S, Mergott D, Tang Y, Lu J, Hutton M, Nordstedt C, Anderson W, Iverson P. 
Combinat ion therapy with a plaque-specific abeta ant ibody and bace inhibitor results in dramat ic 
plaque lowering in aged pdapp transgeni c mice. Alzheimer’s Dement. 2016;12(7):P149.
Doody RS, Ram an R, Farl ow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, 
Thomas RG, Aisen PS; Alzheimer’s Disease Cooperative Study  Steering Committee, Siemers E, 
Sethuram an G, Mohs R; Semagacestat S tudy Group. A phase 3 trial o f semagacestat for 
treatment of Alzheimer’s disease. N Engl J Med. 2013;369(4):341-350.
Fleisher AS, Lowe SL, Liu P, Shcherbinin S, Li L, Chua L, Nakano M, Hawdon A, Willis BA, 
Schwarz AJ, DeMattos RB, Mintun MA, Irizarry  MC. Significant and sustained florbetapir F18 
uptake reduction in patients with symptomat ic Alzheimer’s disease with LY3002813, a β 
amyloid plaque-specific ant ibody. Presented at the Alzheimer’s Associat ion International 
Conference 2018, July 22, 2018, Chicago, IL.
Hendrix JA, Bateman RJ, Brashear HR, Duggan C, Carrillo MC, Bain LJ, DeMattos R, Katz RG, 
Ostrowitzki S, Siemers E, Sperling R, Vitolo OV. Challenges, solut ions, and recommendations 
for Alzheimer’s disease combinat ion therapy. Alzheimers Dement. 2016; 12(5):623 -630.
Hole JT, Racke MM, Tzaferis JA, Liu F, Oluoch H, Ahmed Z, Fisher A, Anderson W, Iversent 
P, Gonzales C, Yang Z, Boggs LN, Monk SA, Mergott DJ, Yang YYT, Lu J, Irizarry MC, Sims 
JR, May PC, Hutton M, Nordstedt C, DeMattos RB. Combination ther apy with a plaque-specific 
abeta antibody and a bace inhibitor results in dramatic plaque reduction in a dose -dependent 
manner in aged pdapp transgenic mice. Alzheimers Dement. 2016;12(7):P -1191 (Abstract).
Jacobsen H, Ozmen L, Caruso A, Narquizian R, Hilp ert H, Jacobsen B, Terwel D, Tanghe A, 
Bohrmann B. Combined treatment with a BACE inhibitor and anti -Aβ antibody gantenerumab 
enhances amylo id reduction in APP London mice. J Neurosci. 2014 27;34(35):11621 -11630.
Selkoe DJ. Sol uble oligo mers of the amylo idbeta-protein impair synapt ic plasticity and 
behavior. Behav Brain Res. 2008;192:106 -13.
Turner PR, O’Connor K, Tate WP, Abraham WC. Roles of amylo id precursor protein and its 
fragments in regulating neural act ivity, plasticity and mem ory. Prog Neurobi ol. 2003;70(1):1 32.
Appendix 5. Flortaucipir F18 Tau PET Imaging
Inclusion Criteria for Flortaucipir F18 PET Scans
With the exception o f theophthalmological and derm atological examinat ions, MRI and 
florbetapir F18 PET scan, a pati ent should meet all other Vi sit 1 eligibili ty criteria before having 
a flortaucipir F18 PET scan.
PET Scan -Specific Information
PET Scan Procedures
I5T-MC-AACG(d)Clinical Protocol Page 155
LY3002813Scan Safety
The primary  risk related to flortaucipir F18 PET is F18’s radiat ion exposure. 
....
•flortaucipir F18 PET scans should tobe performed at least 16 hours apart from the 
florbetapir F18 PET scans due to the half -life of fluorine 18.
With respect to other compound -related risks, flortaucipirAV-1451 was positive in the in vitro 
hERG assay .  
Nonperformance of postbaseline florta ucipir F18 PET scans in pat ients taking a medicat ion 
known to prolong QT interval will not be considered a protocol deviationviolation.
Appendix 6. Florbetapir F18 A myloid PET Imaging
Inclusion Criteria for Florbetapir F18 PET Scans
With the exception o f theMRI, ophthalmo logical and dermatol ogical exams,a patient should 
meet all other Visit 1 eligibilit y criteria before having a florbetapir F18 PET scan.
PET Scan -Specific Information
PET Scan Procedures
PET Scan Safety
•florbetapir F18 PET scans should tobe performed at least 16 hours apart from the 18F
flortaucipir F18PET scan due to the half -life of fluorine 18.
Leo Document ID = 29a7b9e3-12e0-407a-97a6-57f6cc8de831
Approver: 
Approval Date & Time: 09-Oct-2018 12:54:09 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 09-Oct-2018 13:11:13 GMT
Signature meaning: Approved
PPD
PPD